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A genetic recoding event termed −1 frameshifting is often used by retroelements (retroviruses 
and retrotransposons) including HIV-1 to produce two different sized proteins from a single 
mRNA. This mechanism appeared to be ideal for a drug target against HIV-1 because 
successful viral replication is absolutely dependent on this rare translational event, and yet the 
mechanism was not apparently used in humans or indeed any organisms in the animal 
kingdom. Now, two human genes, Paternally Expressed Gene 10 (PEG10) and C-C 
chemokine receptor 5 (CCR5) (confirmed only in 2014) have been documented to use −1 
frameshifting for their expression, challenging whether the mechanism is a suitable drug 
target in HIV-1. To further evaluate feasibility of such a strategy, my study focused on 
PEG10, identified in 2001. The PEG10 frameshift mechanism was investigated and compared 
with that of HIV-1. The expression of PEG10 was also analysed in mouse and rat tissue 
samples by qPCR, immunoblotting and mass spectrometry to determine where rodent Peg10 
protein was being synthesised and whether the frameshift mechanism was being used. 
The PEG10 frameshift element has a slippery sequence (G GGA AAC) and a 
pseudoknot secondary structural element that together promote frameshifting, and these are 
different from the sequences and structures found in HIV-1. Immediately downstream of the 
slippery sequence is a UCC ‘intercodon’. Substitution of the UCC with a UGA stop codon 
reduced −1 frameshifting 4-fold in PEG10, suggesting a decoding mechanism was 
responsible. Frameshifting did not decrease further however, when the stop codon decoding 
factor, eRF1, was overexpressed. This was in contrast to the effect found with the HIV-1 
frameshift element when the intercodon was substituted with UGA. However, the alternative 
decoding molecule, opal (UGA) suppressor tRNA, increased −1 frameshift efficiency, but the 
non-cognate amber (UAG) suppressor tRNA unexpectedly also modestly affected −1 
frameshifting compared with the parental serine tRNA from which the suppressor tRNAs 
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were derived. Mass spectrometry analysis of the frameshift peptides produced as a result of 
ribosome translation through the PEG10 element showed the shift from the 0 frame to the −1 
frame largely, but not exclusively, occurred before the intercodon, consistent with the 
equivocal evidence that the 0 frame intercodon was being decoded before frameshifting.   
Peg10 mRNA was detected in most tissues at a low level and in a small number of 
tissues at a significantly increased level, for example, in endocrine organs particularly 
placenta and hypothalamus. By contrast, Peg10 protein was expressed in only a small number 
of tissues (embryo and extra-embryonic) as previously documented, and it was also detected 
in lactating rat hypothalamus for the first time. Although there was no definitive evidence that 
−1 frameshifting occurred in the hypothalamus, as only Peg10 ORF1 peptides were identified 
by mass spectrometry in protein extracts from this tissue, it was deduced from an immunoblot 
analysis and mass spectrometry that a product of identical size produced in placenta was an 
ORF1-ORF2 fragment. Nevertheless, frameshifting has been confirmed definitively only in 
placenta, amniotic membrane and embryonic tissues. 
The outcome of −1 frameshifting in the virus HIV-1 and the human gene PEG10 are 
identical regarding the translation of a second open reading frame as a fusion protein (gag-pol 
for HIV-1 and ORF1–2 for PEG10). Despite this, the results of this study, together with 
concurrent studies in the laboratory, indicated that there are differences in the frameshift 
mechanisms between HIV-1 and PEG10. Considering these findings, −1 frameshifting in 
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Paternally Expressed Gene 10 (PEG10) is an unusual mammalian gene. It shows high 
homology to a retroelement, the sushi-ichi Ty3/Gypsy retrotransposon. As discussed in detail 
in section 1.3, the striking similarity of PEG10 to this retrotransposon suggests PEG10 may 
have evolved as an essential mammalian gene following a retroelement insertion into a 
genome through a process termed ‘molecular domestication’, and this likely occurred after 
divergence of therian and prototherian lineages (Butler et al., 2001; Ono et al., 2001; Suzuki 
et al., 2007). Compared to its proposed ancestral retrotransposon, PEG10 has lost the 
characteristic long terminal repeats and has accumulated a number of mutations that have 
inactivated various enzymes necessary for retrotransposition. However, PEG10 has retained 
structural elements required for a rare translational mechanism, backward (−1) frameshifting. 
The second open reading frame (ORF2) can be expressed as a fusion protein with the first 
open reading frame (ORF1) in a fraction of translational events (Clark et al., 2007). PEG10 
has been documented to have a function in placental development (Ono et al., 2006) but it is 
unknown whether there are other functions in specific cell types or tissues for either the ORF1 
or ORF1–2 protein. Expression of PEG10 has been reported, however, in various cancers 
(Okabe et al., 2003; Kainz et al., 2007). 
 PEG10 is the first human gene documented to use −1 frameshifting, previously 
thought to occur only in viruses. The discovery of PEG10 gene expression complicates the 
targeting of −1 frameshifting for development of antiviral drugs. Understanding PEG10 
expression is critical for development of an antiviral strategy targeting this mechanism in 
HIV-1. 
 Only a limited number of studies have investigated PEG10 expression in normal cells 
or tissues and most studies have focused simply on the abundance of the transcript. Our group 
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previously reported the preliminary analysis of murine Peg10 protein expression, and found it 
was largely restricted to embryonic tissues, such as amniotic membranes, the placenta, and the 
developing embryo. Frameshifting of PEG10 to produce the ORF1–2 protein was also 
confirmed to occur in these tissues (Clark et al., 2007). Prior to the discovery of PEG10, the 
backward frameshifting mechanism was thought to be restricted in eukaryotes to their viruses 
and retroelements and therefore an ideal therapeutic target for the debilitating virus, HIV-1. 
With the frameshifting mechanism now documented as being used for PEG10 expression, it 
was important to establish the expression profile of this essential gene in mammals. 
Therefore, this project focused on investigation of Peg10 expression at both the 
transcriptional and translational levels in mammalian tissues, and in particular to the brain. 




1.1 Programmed ribosomal frameshifting 
 
 
Translational events require high fidelity to produce functional proteins. For this, a fixed 
reading frame needs to be maintained throughout the process and each codon is read triplet by 
triplet by appropriate decoding molecules, firstly tRNAs and finally release factors. A small 
number of mRNAs contain additional recoding signals within the coding region that subverts 
how the mRNA is translated (Gesteland et al., 1992). Genetic recoding is the process by 
which mRNA is translated at a particular site by a noncanonical mechanism outside the 
constraints of the genetic code. One example of genetic recoding is termed programmed 
ribosomal frameshifting (PRF) where the translating ribosome slips its reading frame either 
forward (+1) or backward (−1) following slowing of, during a brief pause in, translation or 
destabilisation of the two pairs of codon/anticodon interaction. Translation is then resumed in 
the new reading frame until a stop codon is encountered in the new frame. In this way, two 
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different protein products can be synthesised from a single mRNA, depending on whether 
canonical events or the frameshifting event occurs during translation over the recoding site 
(Marquez et al., 2004; Poole et al., 2004). The frequency of the noncanonical event can 
facilitate precise regulation. PRF is most commonly utilised among retroelements 
(retroviruses and retrotransposons) such as HIV-1, Rous sarcoma virus, and Ty 
retrotransposons in yeast (Jacks and Varmus, 1985; Jacks et al., 1988b; Belcourt and 
Farabaugh, 1990). Ebola virus, the causative agent of the serious outbreak of infectious 
disease in West Africa in 2014/2015, is also thought to use −1 PRF to express a functional 
nucleocapsid protein (Taylor and Ramanathan, 1995; Ramanathan and Taylor, 1997). Other 
organisms such as bacteria and eukaryotes also employ forward (+1) PRF to express their 
genes (Craigen et al., 1985; Tsuchihashi and Kornberg, 1990; Matsufuji et al., 1995) and, 
indeed, the first example of this mechanism of translation was discovered in bacteria in the 
prfB gene encoding translational release factor-2 (UGA, UAA) (Craigen et al., 1985). In this 
case the recoding site allows tight feedback regulation of expression of the protein as there is 
a UGA stop codon in the original frame at the recoding site (Marquez et al., 2004; Poole et 
al., 2004). Frameshifting allows the ribosome to avoid the stop codon.  
In 2001, the first example of backward (−1) PRF in a eukaryotic organism was 
reported (Shigemoto et al., 2001). Recent studies have reported new examples of both 
forward and backward PRF that is related to regulation of gene expression in both prokaryotes 
and eukaryotes (Advani et al., 2013; Belew et al., 2014; Sharma et al., 2014; Ramsay et al., 
2015). For +1 PRF, the components of the signals are diverse. In −1 PRF, there are two 
structural elements embedded in RNAs that are essential, and one is a heptanucleotide 
slippery sequence (X XXY YYZ in the 0 frame) where translating ribosomes falter in 
maintaining the reading frame – relevant to my study of PEG10 (Table 1.1). This sequence 
alone is capable of promoting significant frameshifting (Stahl et al., 2002), but to enhance 
efficiency, an RNA secondary structure is located several nucleotides downstream of the 
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slippery sequence. A pseudoknot is most frequently associated with −1 PRF, but some viruses 
such as HIV-1 instead have an extended stem-loop (Giedroc and Cornish, 2009). It has been 
considered that an RNA secondary structure indirectly contributes to −1 PRF by slowing 
down or pausing the translating ribosomes at the slippery sequence, or perhaps distorting the 
decoding site. To better understand the role of an RNA structure in −1 PRF, several studies 
have now been conducted using optical tweezers to investigate the correlation between 
mechanical stability of the pseudoknot structure and frameshift efficiency. These studies, 
however, disagree on their conclusions (Hansen et al., 2007; Green et al., 2008; Chen et al., 
2009; White et al., 2011). The contradictory outcomes most likely originate from the fact that 
each study each analysed a single viral pseudoknot (infectious bronchitis virus or beet western 
yellow virus) and compared it with derivatives of that same structure carrying destabilising 
mutations. To obtain more conclusive evidence, multiple viral pseudoknots associated with 
varying frameshift efficiencies were analysed by Ritchie et al. (2012). This more 
comprehensive study found a positive correlation between the tendency of an RNA 
pseudoknot to form alternative structures, and the frameshift efficiency. This finding suggests 
a more active involvement of the RNA pseudoknot in −1 PRF than had been previously 
thought, although the conclusions are still equivocal. What seems clear is that an individual 
pseudoknot might convey unique characteristics to the mechanism of −1 PRF for its particular 




Table 1.1: Frameshift element comparison between HIV-1 and PEG10. 
Frameshift elements of HIV-1 and PEG10 are presented together with generic forms of each secondary structure. 










1.1.1 Frameshifting in HIV-1 
 
 
The slippery sequence in HIV-1 is U UUU UUA (spaces indicate the distinction between 
codons in the 0-frame) and the stem-loop RNA secondary structure is 3´ to the slippery 
sequence. Although many retroviruses have an alternative pseudoknot, only the O group of 
HIV-1 has this structure, and most strains of HIV-1 (for example the common M group) 
contain a unique stem-loop that has two stems interrupted by three bases (Dulude et al., 2002; 
Baril et al., 2003). NMR studies confirmed this conformation. Recent studies have proposed 
that the HIV-1 sequence has the potential to form dynamic pseudoknot structures based on a 
larger nucleotide sequence than was previously defined (Gaudin et al., 2005; Staple and 
Butcher, 2005; Huang et al., 2014; Low et al., 2014). Although a short sequence of HIV-1 
including the slippery sequence is alone capable of stimulating −1 frameshifting significantly, 
the extended stem-loop enhances −1 frameshift efficiency to in vivo levels, within the range 
of 5–10% depending on the assay systems (Wilson et al., 1988; Plant and Dinman, 2006; 
Cardno et al., 2009). In addition to these cis-acting elements, sequences further upstream and 
downstream of the slippery sequence can also modulate frameshift efficiency (Kim et al., 
2001). Recently, some trans-acting factors in mammalian cells such as an RNA helicase 
DDX17, and as well viral proteins were found to promote −1 frameshifting (Lorgeoux et al., 
2013; Li et al., 2014). It is proposed that some of these elements improve frameshift 
efficiency through a decrease in translation initiation rate (Gendron et al., 2008; Charbonneau 
et al., 2012). Nevertheless, it should be re-emphasised that the frameshifting efficiency 
obtained in vitro in cultured cells with the slippery sequence and the stem-loop alone inserted 
between two reporters reflects that found in vivo (5–10%) (Mathew et al., 2015). Despite high 
mutation rates in the nucleic acid sequence of viruses generally, the frameshift elements, by 
contrast, are highly conserved among a large number of clinical isolates, which emphasises 
the importance of frameshifting and its efficiency for biology of HIV-1 (Telenti et al., 2002; 
Biswas et al., 2004). Analysis of the HIV-1 sequences also showed that the triplet in the 0 
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frame between the slippery sequence and stem-loop that our group has termed the 
‘intercodon’ (Mathew et al., 2015) is as highly conserved as the slippery sequence although 
the third position of the intercodon does vary in a minor fraction (~5%) of isolates (Figure 1.1 
B, Mathew et al. 2015). Most variants have GGA instead of GGG, but this codon would still 
be decoded by the same isoaccepting species of tRNAGly. Indeed, HIV-1 uses −1 
frameshifting not only to simply express pol genes but also to ensure there is a precise ratio of 
Gag to Gag-Pol polyproteins. This ratio is critical for successful replication of infectious 
viruses as even a small disturbance results in markedly reduced virus infectivity (Shehu-




Figure 1.1: Intercodon conservation in HIV-1 sequences. 
HIV-1 sequences (3534 out of 4675) deposited in the Los Alamos National Laboratory 
(http://www.hiv.lanl.gov/) were analysed for sequence conservation in HIV-1. Sequence conservation around the 
intercodon is shown as logo representation, and the intercodon is underlined (A). The identity and frequency of 
codons at the intercodon position are shown in B. These figures were modified from Mathew et al. (2015) under 
the terms of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). 
 
 
1.1.2 Frameshifting in PEG10 
 
 
Within the same generic structural features, there are significant differences between the 
frameshift elements of HIV-1 and PEG10 (see Table 1.1). The X XXY YYZ slippery 
sequence for PEG10 is G GGA AAC while that of HIV-1 is U UUU UUA and the 






chemical probing analysis (Shigemoto et al., 2001; Manktelow et al., 2005). The PEG10 
slippery sequence satisfies the consensus sequence structure, and like HIV-1 it is also 
conserved. The second codon in the 0 frame (AAC) is the codon for a tRNAAsn but in the new 
frame it is for a tRNALys (AAA). AAA is apparently recognised by the Asn tRNA in what 
may be a ‘distorted’ site. For PEG10, the secondary structural element might be more 
important than that in the HIV-1 element. As PEG10 contains the more common pseudoknot 
structure rather than a stem-loop like that of HIV-1, an antiviral strategy against −1 PRF in 
HIV-1 focusing on the stem-loop might not affect expression through −1 PRF in PEG10. 
Nucleotide sequences of both frameshift elements (the slippery sequence and an RNA 
pseudoknot structure) are highly conserved in PEG10 among different mammalian species, 
and −1 frameshifting was confirmed to occur in vivo in mouse and human tissues (Clark et 
al., 2007). PEG10 frameshift efficiency has been measured to be ~20–30% in translation 
systems in vitro or cultured cells (Janicke, 2005). However, the frameshift efficiency appears 
to be much higher in a specialised tissue in vivo, for example in placenta, it is 60–70% 
(Manktelow et al., 2005; Clark et al., 2007). While this level of frameshift efficiency of 
PEG10 is ~10-fold higher than that of HIV-1, the biological significance remains unknown as 
functions of the ORF1 and ORF2 products of PEG10 within this now functional mammalian 
gene have not yet been defined. By contrast, the situation in HIV-1 is clear; ORF1 encodes 
structural proteins of the virus and the ORF2 in the −1 frame encodes three enzymes — 
reverse transcriptase, protease and integrase. A 10–20:1 ratio of structural to enzyme proteins 
is critical for correct assembly and replication in HIV-1 (Shehu-Xhilaga et al., 2001). 
 
 
1.2 Mechanism of −1 frameshifting 
 
 
Over 20 years of intensive research has expanded knowledge of −1 frameshifting, including 
the frameshift signals and molecules that modulate frameshift efficiency in vivo, but the 
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precise mechanism of −1 frameshifting still remains somewhat controversial. At least five 
major models have been proposed to elucidate how and in which steps during translation −1 
frameshifting occurs.  
The first model proposed was a ‘simultaneous slippage model’ and it predicted that 
two tRNAs in the P- and A-site slip one nucleotide backwards at the time of tRNA 
accommodation into the A-site and the next step peptidyl transfer (Jacks et al., 1988a). This 
model explained the importance of the slippery sequence but failed to explain what caused the 
frameshift to occur. The time window for −1 frameshifting to occur in this model also raised a 
paradoxical issue because peptidyl transfer is relatively fast and tightly coupled to tRNA 
accommodation in the A-site, which is relatively slow. Hence frameshifting would likely 
occur before or after peptide bond formation but not while the accommodated tRNA is 
undergoing peptidyl transfer (Brierley et al., 2010). 
The ‘integrated model’ is similar to the simultaneous slippage model in its 
fundamental concepts in that −1 frameshifting is thought to occur before peptidyl transfer 
(Harger et al., 2002). This model is based upon genetic and pharmacological studies where 
inhibition of or a slower reaction rate of peptidyl transfer stimulated −1 frameshifting 
(Dinman et al., 1997; Meskauskas et al., 2003). Although the ‘integrated model’ does not 
offer the driving force of −1 frameshifting, a third ‘9Å model’ complements this model and 
provides a mechanical explanation for −1 frameshifting (Plant et al., 2003). The ‘9Å model’ 
explains that the driving force of −1 frameshifting is the local tension generated by a 9Å 
movement of the mRNA towards the 5´ end at the accommodation of a tRNA into the A-site, 
and the resistance created by the downstream RNA secondary structure blocking the 
ribosomal entrance channel. To relieve the mechanical stress, the ribosome and two tRNAs in 
the P- and A-sites need to shift in the −1 frame or the RNA secondary structure must be 
unwound. Although the ‘integrated’ and ‘9Å model’ both appeared to be convincing at the 
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time of their proposal, eukaryotic elongation factor 2 (eEF2) has been reported to modulate 
−1 frameshifting, in apparent conflict with the elements of these models (Ortiz et al., 2006). 
Two models postulate that −1 frameshifting occurs before or during the translocation 
of the small ribosomal subunit (the ‘dynamic model’ and the ‘mechanical model’, 
respectively). The dynamic model is built upon the simultaneous slippage model with a 
modification (Weiss et al., 1989; Farabaugh, 1996). This model explains that −1 
frameshifting occurs when the tRNA-mRNA interaction is weakened in the hybrid state (post-
translocation of the large subunit but with the small subunit of the ribosome still in a pre-
translocated state). Although several studies supported the idea that the codon-anticodon 
interactions become weaker in the hybrid state, this model also does not specify what drives 
−1 frameshifting (McGarry et al., 2005; Spiegel et al., 2007). In contrast, the ‘mechanical 
model’ does provide a possible reason for the driving force of −1 frameshifting. In this model, 
tension builds up prior to the completion of translocation with the opposing forces of the 
small subunit translocation mediated by the elongation factor and resistance of a pseudoknot 
being unwound by the helicase activity at the mRNA entrance channel of the ribosome. The 
tension is then released either by −1 frameshifting or unwinding of a pseudoknot (Namy et 
al., 2006). In support of these models, recent studies suggested that a downstream RNA 
secondary structure can disrupt the small ribosomal subunit translocation, providing an 
opportunity for −1 frameshifting to occur (Mouzakis et al., 2013; Caliskan et al., 2014; Kim 
et al., 2014a).  
The ‘three tRNA model’ is based on experimental evidence where a triplet nucleotide 
5´ to the slippery sequence affected the frameshift efficiency (Leger et al., 2007). In this 
model, the two nucleotides preceding and the first four nucleotides of the slippery sequence 
are decoded in the P- and A-site and the two tRNAs are shifted to the E- and P-site however 
they are in an aberrant position compared with the canonical state due to the completed 
elongation cycle but without proper completion of translocation. Accommodation of a new 
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tRNA into the A-site forces those tRNAs to slide one nucleotide backwards, allowing all three 
tRNAs to be properly accommodated in the ribosome. However, it is unclear whether or not 




Figure 1.2: A new proposed model of −1 frameshifting in HIV-1. 
The diagram presented above explains a new model of −1 frameshifting in HIV-1. A, the translating ribosome 
decodes the codon including the first nucleotide of the slippery sequence, and the intercodon is placed in the +13 
position; B, the more stable upper stem-loop is positioned near the entry channel of the ribosome, resisting 
unwinding that causes the tension to build up. This tension may allow −1 frameshifting to occur at the A- and P-
sites; C, tRNAGly binds to the intercodon possibly in a distorted state; D, the intercodon is decoded by the 
tRNAGly and the translation continues in 0 frame; or E, the intercodon is not decoded by the tRNAGly and −1 
frameshifting occurs to relieve the tension. The slippery sequence is indicated in blue and the intercodon is in 
orange. The figure was adapted from Mathew et al. (2015) under the terms of the Creative Commons Attribution 
(CC BY) license (http://creativecommons.org/licenses/by/4.0/). 
 
 
Most of these models have one shared feature in that −1 frameshifting occurs when 
tRNAs occupy the P- and A-sites of the ribosome with a single-molecule fluorescence study 
supporting this idea (Chen et al., 2013). According to the above models, the intercodon 
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(Mathew et al., 2015), nucleotides that reside between the slippery sequence and the 
downstream RNA secondary structure should not have any influence over −1 frameshift 
efficiency. However, our group initially collected data with bacterial ribosomes suggesting 
that this intercodon did indeed have an effect (Horsfield et al., 1995). In that study, the 
intercodon of HIV-1 was changed from GGG to a stop codon(s). These mutations caused a 
significant reduction in −1 frameshift efficiency in a prokaryotic expression system that could 
be modulated by the decoding molecule, release factor 2, in a dose-dependent manner. None 
of the existing models included the intercodon within their proposed mechanisms and our 
group therefore proposed the novel model of −1 frameshifting named ‘P-E site post-
translocation slippage’. In this model, −1 frameshifting is postulated to occur when tRNAs 
occupy the E- and P-sites while the intercodon is positioned for decoding in the A-site. The 
effect of the intercodon in the context of the HIV-1 frameshift site using a dual luciferase 
reporter system in mammalian cells has now been further explored by our group (Mathew et 
al., 2015). A large decrease in −1 frameshift efficiency (approximately 75% reduction) 
observed with the stop intercodon was consistent with the idea that the intercodon is decoded 
before the frameshifting event in a significant proportion of ribosome passages where 
frameshifting occurs. The decoding release factor, eRF1, and cognate suppressor tRNA 
modulated frameshift efficiency (Mathew et al., 2015). This is also consistent with a previous 
study where only 20–30% of −1 frameshifting in HIV-1 was claimed to occur before this 
intercodon reached the A-site of the ribosome (Liao et al., 2011). To accommodate a role of 
the intercodon in −1 frameshifting, our group proposed a modified model for −1 frameshifting 
based on the new experimental data (Figure 1.2, Mathew, et al. 2015). In this new model, −1 
frameshifting can occur at two distinct steps during the elongation step. A proportion of the 
ribosomes undergo −1 frameshifting when tRNAs occupy the P- and A-sites prior to 
translocation as proposed by the dynamic model (Figure 1.2 B). However, as supported by 
our data of the effect of the intercodon on −1 frameshift efficiency, a significant proportion of 
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−1 frameshift events occur when the intercodon is in the A-site, as proposed in the P-E site 
post-translocation slippage model (Figure 1.2 C). Interestingly, it has been reported in a mass 
spectrometric analysis of in vitro translated dnaX-derived mRNA, that frameshifting can 
occur at multiple sites with a range of slip sizes (Yan et al., 2015). 
 
 
1.3 Paternally Expressed Gene 10 
 
 
The human genome encodes a significant number of retrotransposons (~45% of human 
genome) and these elements have a profound impact on genomic evolution. They not only 
simply accumulate mutations but also provide a template for innovation to create new genes 
(Cordaux and Batzer, 2009). Among many families of retrotransposons, one family, 
Ty3/Gypsy, is distributed in a wide variety of organisms including plants, fungi and 
vertebrates, suggesting there has been horizontal transfer or infection as a mode of 
transmission from one family or organism to another (Miller et al., 1999; Butler et al., 2001; 
Llorens et al., 2009). In therian organisms (such as mammals and marsupials), this type of 
retrotransposon has often been ‘domesticated’ or ‘exapted’ by the hosts through evolution to 
eventually become an essential gene for development in the host organism. PEG10 is such an 
example. PEG10 is considered to originate from a retrotransposon because its sequence is 
most closely related to the sushi-ichi element in the V-clade of Ty3/Gypsy retrotransposons, 
first identified in Fugu rubripes (Poulter and Butler, 1998; Butler et al., 2001; Youngson et 
al., 2005; Llorens et al., 2009). Genomic analyses and comparisons among mammals 
confirmed PEG10 exists only in therian mammals but is absent in platypus, indicating that 
insertion and domestication of an ancestral retrotransposon occurred after the split of the 
monotremes from therian mammals approximately 200 million years ago (Figure 1.3). These 
studies also provided evidence for development of defense mechanisms against 
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retrotransposons like genomic imprinting (Brandt et al., 2005; Suzuki et al., 2007; Pask et al., 




Figure 1.3: Insertion and domestication of an ancestral retroelement of PEG10. 
This phylogenetic tree shows the divergence of mammalian groups together with the evolution of unique 
features associated with each group. PEG10 gene has been found only in therian mammals (red box). This figure 
was modified from Hore et al. (2007). 
 
 
PEG10 is located on chromosome 7q21 adjacent to sarcoglycan ε in a head-to-head 
orientation. PEG10 is transcribed into a ~6.6 kb mRNA from two exons separated by a ~6.8 
kb intron, and PEG10 mRNA includes a long 3´ untranslated region (UTR) making up 4 kb of 
the mRNA (Figure 1.4). The first exon encodes a 5´ UTR whereas the two open reading 
frames (ORF1 and ORF2) and the 3´ UTR are encoded by the second exon. The two ORFs 
are partially overlapping and ORF2 is situated in the −1 frame relative to the ORF1. This 
genetic arrangement implies that the ORF2 expression depends on an −1 PRF event, and if 
that occurs, two different proteins (ORF1 and ORF1–2 fusion) can be synthesised from the 
same mRNA (Ono et al., 2001; Lux et al., 2010). A partial mouse Peg10 was first isolated 
from a cDNA library prepared using young mouse brain and described as myelin expression 
factor-3 (Steplewski et al., 1998). The full-length sequence was successfully isolated first 
from an embryonic carcinoma cDNA library in 2001 (Shigemoto et al., 2001). Similar to the 
mouse Peg10, the human homologue of this gene was first identified through analysis of 
cDNA clones from human adult brain (Kikuno et al., 1999), followed by cloning of the full-
length human PEG10 in 2001 (Ono et al., 2001). Although the PEG10 in human and mouse 
large imprinted gene clusters in marsupials and
monotremes – the Prader-Willi–Angelman syndrome
domain (PWS–AS) and the Callipyge locus (CLPG) –
now provide crucial insight into the evolutio of imprinted
domains and lead to an alternative model of a gradual and
rather haphazard evolution of imprinting in mammals.
Evolution of the Prader-Willi–Angelman syndrome
imprinted domain
Two phenotypically distinct neurological disorders,
Prader-Willi and Angelman syndromes (PWS and AS;
reviewed in Ref. [13]), are associated with deletions in
the same region of human chromosome 15q11–13. The
observation that indistinguishable defects caused ASwhen
maternally inherited, but PWS when paternally inherited,
suggested that imprinted genes were involved in these
diseases.
Further characterization of the 2.3 Mb PWS–AS
domain divided it into two parts, each responsible for
one disorder. The smaller AS subdomain contains two
imprinted genes, UBE3A (which has a crucial role in
AS) andATP10A. The genes are bothmaternally expressed
(paternally silenced) in neuronal tissue [14,15]. Proximal
to the AS subdomain is the larger PWS subdomain, com-
prising five protein-coding genes, three of which (MKRN3,
MAGEL2 and NDN) are intronless (reviewed in Ref. [13]).
The other two protein coding genes (SNURF and SNRPN)
are located adjacent to each other and form a bicistronic
transcript [16]. All five genes are paternally expressed
(maternally silenced). The PWS subdomain also includes
two clusters of small nucleolar RNAs (snoRNAs), also
paternally expressed. These are of the C/D box family of
snoRNAs, whose members mostly function to guide 2-O-
methylation and pseudouridylation of rRNA, but at the
PWS–AS loci, snoRNA HBII-52 (which is present as 50
tandem repeats) regulates alternative splicing of the ser-
otonin receptor, possibly contributing to the PWS pheno-
type [17].
Regulation of thePWS–ASdomainhas been explored in
detail. A differentially methylated ICR located upstream
of SNURF and SNRPN controls imprinted expression
throughout the entire domain (reviewed in Ref. [18]).
Through interaction with the ICR, a second differentially
methylated cis element is set up closer to SNRPN. When
unmethylated (as it is on the paternally derived allele),
this cis element is thought to function as a bidirectional
enhancer, activating expression of MKRN3, MAGEL2,
NDN and SNURF–SNRPN. A large alternatively spliced
non-coding transcript, initiating upstream of SNURF–
SNRPN, is responsible for expression of the downstream
snoRNAs [19] and extends into the AS sub-domain to
produce a transcript antisense to UBE3A (UBE3A-as)
[19,20]. Although the mechanism is currently debated,
the expression of this antisense transcript is thought to
provide the regulatory link between the ICR and UBE3A
[21–23].
The expression and location of orthologues of genes
within the PWS–AS locus were explored in marsupials
Figure 1. Reproductive strategy and imprinting status differs between various vertebrate groups. The evolution of lactation, viviparity and complex placentation can be
dated against a phylogeny (asterisks, left) and correlates with changes in the nature of genomic imprinting and X-chromosome inactivation (right).
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shows significant sequence conservation, the mouse Peg10 contains large insertions in both 




Figure 1.4: Chromosomal organisation of PEG10 gene and its transcript. 
PEG10 gene consists of two exons separated by a large intron. The exon 1 encodes a 5´ UTR (untranslated 
region) whereas the exon 2 contains both ORF1 and ORF2 (coding sequence, CDS) and a long 3´ UTR. The size 
of each region is annotated based on the data deposited in the NCBI RefseqGene (NG_011340.1). bp, base pair 
and nt, nucleotide. 
 
 
There are several retrotransposon recognisable motifs conserved in PEG10 such as the 
major homology region (MHR, Figure 1.5) and a CCHC-type zinc finger motif (ZF) in the 
ORF1, and a DSG catalytic triad of an aspartyl protease domain (PR). There is a proline-rich 
domain (Pro) in the ORF2 (Figure 1.5). Despite these conserved regions, PEG10 has also 
accumulated mutations in the active sites and the sequences of other enzymes. There is a 
vestigial reverse transcriptase and little evidence of RNase H or integrase domains that are 
typically found in retroviruses and retrotransposons. The retention of a protease active site 
implies it has importance in the ‘domesticated’ function of the gene (Butler et al., 2001; Ono 





















Figure 1.5: Structural comparison of PEG10 to other retroelements. 
A, PEG10; B, a typical chromovirus closely related to PEG10 and C, a simple retrovirus. Figure not to scale. 
Gag, group specific antigen; Pol, polyprotein; MHR, major homology region; ZF, zinc finger motif; PR, aspartyl 
protease; RT, reverse transcriptase; RH, RNase H; IN, integrase; Pro, proline-rich domain; CD, chromodomain 
and LTR, long terminal repeats. Asterisks (*) indicate −1 frameshift elements. 
 
 
1.3.1 Function of PEG10 
 
 
PEG10 has been investigated for its physiological function in vivo using a Peg10 knockout 
mouse (Ono et al., 2006). Germline deletion of Peg10 resulted in early embryonic death. 
More detailed analyses of embryonic tissues (amniotic membrane, embryo and placenta) 
revealed that the placenta of the knockout mouse lacked spongiotrophoblast cells and the 
labyrinth layer that is in direct contact with maternal-fetal interface. This abnormal placental 
development resulted in embryonic growth restriction and lethality between day 9 and 10 post 
coitus. Consistent with this, Clark et al. (2007) showed expression of Peg10 was induced in 
mice at day 9, and increased significantly by day 10. In support of the knockout mouse study, 
both Peg10 mRNA and protein expression were detected in cells located in the labyrinth layer 
(Henke et al., 2013). The expression level of PEG10 has been shown to be altered in two 
clinical conditions (preeclampsia and intrauterine growth restriction), further emphasising the 
importance of PEG10 in normal placental development and function (Diplas et al., 2009; 
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because three patients suffering from myoclonus-dystonia had a large deletion of paternal 
chromosome 7 that included PEG10 (Asmus et al., 2007). 
Perhaps as an explanation of its function in placental development, PEG10 promotes 
cellular proliferation, apoptotic resistance and adipocyte differentiation through induction of 
transcription factors (Tsou et al., 2003; Lux et al., 2005; Hishida et al., 2007). The anti-
apoptotic property of PEG10 has been investigated intensively in cancer cells and aberrant 
PEG10 expression has been detected repeatedly in various cancers including hepatocellular 
carcinoma, endometrial cancer, gallbladder adenocarcinoma and leukemia (Okabe et al., 
2003; Tsou et al., 2003; Ip et al., 2007; Kainz et al., 2007; Tsuji et al., 2010; Liu et al., 2011; 
van der Horst et al., 2012; Xiong et al., 2012). Consistent with its anti-apoptotic linkage, 
PEG10 has been shown to interact with two proteins SIAH1 and SIAH2 that are involved in 




1.4 Genomic imprinting 
 
 
1.4.1 Evolution of imprinting 
 
 
The name PEG10 implies the gene is silenced in the maternal allele. This phenomenon is 
known as genomic imprinting. Genomic imprinting generates hemizygosity at particular loci 
in a diploid organism. Although genomic imprinting is potentially risky for organisms due to 
an increased vulnerability to deleterious mutations, it must provide much greater benefit since 
it has been conserved during mammalian evolution (Renfree et al., 2009; Bartolomei and 
Ferguson-Smith, 2011). A number of hypotheses have been proposed to explain how and why 
genomic imprinting evolved. These include two widely supported theories, ‘conflict 
hypothesis’ and ‘coadaption theory’ (Hall, 1990; Moore and Haig, 1991; Barlow, 1993; 
Varmuza and Mann, 1994; Kaneko-Ishino et al., 2003; Curley et al., 2004; Kaneko-Ishino et 
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al., 2006). The conflict hypothesis proposes that genomic imprinting has evolved to mediate 
the difference in interest of paternal and maternal genes, and the conflict of interest mainly 
lies in resource allocation. Paternal interest is to maximise resource allocation to offspring 
regardless of maternal cost while mothers attempt to restrict resource allocation to the fetuses 
to minimise cost to them and to protect their future offspring (Moore and Haig, 1991). This 
hypothesis is supported by the findings that many paternally and maternally expressed genes 
have conflicting growth-promoting and growth-limiting functions, respectively (Coan et al., 
2005; Fowden et al., 2011). In contrast, the other major theory called the coadaptation theory 
focuses on the maternal-offspring relationship, and it predicts that genomic imprinting has 
developed to coordinate relationships between maternal and fetal hypothalamus and placenta 
through hormones. The hormonally synchronised physiological changes in these regions have 
significant contribution to successful reproduction (Curley et al., 2004). Despite the limited 
experimental evidence, understanding the function of Paternally expressed gene 3 (Peg3) has 
provided a key example for this theory. Peg3 encodes a zinc finger protein and it acts as a 
mediator in a p53 apoptotic pathway (Relaix et al., 1996; Deng and Wu, 2000; Relaix et al., 
2000). Functional studies of Peg3 found various deficits with ablation of the gene in both 
adult and embryonic knockout mice. Of the observed phenotypes, a lack of maternal care (pup 
retrieval, milk ejection and nest building) was particularly interesting, and it provided an 
important clue in consideration of genomic imprinting evolution. Intriguingly, this deficit was 
observed not only in mothers carrying Peg3 mutations but also with wild-type mothers who 












Genomic imprinting is a unique epigenetic regulation of gene expression in mammals where 
genes are silenced in a parent-of-origin manner. Although it was not the first evidence, one of 
the most important observations in the discovery of genomic imprinting was inviability of 
androgenotes and gynogenotes (Mann and Lovell-Badge, 1984; McGrath and Solter, 1984; 
Surani et al., 1984). These studies suggested that both paternal and maternal chromosomes are 
required for successful development of embryos because they differ in their functionality and 
contribute unique sets of gene expression. With numerous supporting data (Cattanach and 
Kirk, 1985; Reik, 1989; Reik et al., 1990), three genes (one paternally expressed and two 
maternally expressed) identified in 1991 provided more direct evidence for the existence of 
genomic imprinting. Following the studies of parthenogenetic embryos, a distal region of 
chromosome 7 was identified using genetic complementation as responsible for the lethal 
phenotype (Searle and Beechey, 1990). Investigation of mice carrying a partial duplication of 
chromosome 7 resulted in identification of Igf2 as a causative gene for the lethal phenotype. 
This study also showed a paternal expression and maternal repression of Igf2 (Ferguson-
Smith et al., 1991). An independent study involving an Igf2 knockout mouse, confirmed a 
paternal expression of Igf2 based on the manifestation of a growth deficient phenotype by the 
mutant allele transmitted paternally but not maternally (DeChiara et al., 1991). The Igf2r 
(receptor) gene was found to reside within the region deleted in chromosome 17 that causes 
the Hairpin-tail phenotype in mice. As this phenotype was known to transmit maternally, the 
expression pattern of the Igf2r gene was determined and expression confirmed to derive from 
the maternal chromosome (Barlow et al., 1991). The H19 gene encodes a 2.5 kb long non-
coding RNA that is mapped close to the Igf2 gene. H19 expression determined by an RNase 
protection assay indicated maternal expression of the H19 gene. This finding was interesting 
because two imprinted genes (Igf2 and H19) are in close proximity, yet their imprinting status 
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is opposite to each other (Bartolomei et al., 1991). The H19 gene was later found to locate 90 
kb downstream of Igf2, suggesting that imprinted genes may exist in clusters rather than being 
dispersed throughout the genome (Zemel et al., 1992). The number of imprinted genes in 
humans has now increased to 80 and in mice there are over 120 genes most of which are 




1.4.3 Mechanisms of genomic imprinting 
 
 
There are three key aspects for mechanisms of genomic imprinting: imprinting marks (i) must 
be present on one, but not on both chromosomes, (ii) must be sufficiently stable for mitotic 
inheritance, and (iii) must be erasable prior to reproduction. The two parental chromosomes 
usually differ at multiple loci with single nucleotide polymorphisims. However, mouse strains 
used in research are often highly inbred so that the genetic variations are reduced, and as a 
consequence, the offspring inherits nearly identical chromosomes from each parent. Despite 
the high sequence similarity, however, genomic imprinting is still observed in these inbred 
mice. This implies that imprinting should be established when gametes (sperm and oocytes) 
are still separated because it is impossible to distinguish genetically identical chromosomes 
after fertilisation (Barlow and Bartolomei, 2014). Indeed, studies of germ cells confirmed 
acquisition of DNA methylation in the gametes, and these studies also made an interesting 
finding that the timing of DNA methylation differs between sexes. In a male germ line, 
progressive DNA methylation occurs in prospermatogonia in developing embryos and this 
process is completed by the time of birth (Li et al., 2004; Kato et al., 2007). In contrast, DNA 
methylation in oocytes occurs in a size-dependent manner at later stages of development 
(Hiura et al., 2006). 
 Epigenetic modifications through imprinting must be sufficiently stable to be retained 
through development and adulthood. There are two likely candidate mechanisms that fulfil 
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this requirement. Histone proteins, around which DNA wraps for compact packaging to 
eventually form compact chromosomes, can carry various modifications including 
methylation, acetylation and phosphorylation (Barlow and Bartolomei, 2014). DNA 
methylation occurs at CpG dinucleotides by addition of a covalent methyl group to the 
cytosine residue. This reaction is mediated de novo by DNA methyltransferase (Dnmt) 3a and 
3b, together with an activator, Dnmt3L, and this methylation status is maintained by Dnmt1 
(Kato et al., 2007). Mutation studies have been carried out to determine whether histone 
modifications and/or DNA modification play a major role in genomic imprinting. These 
studies surprisingly showed that histone modification plays only a minor role but DNA 
methylation has a large effect in genomic imprinting (Mager et al., 2003; Kaneda et al., 2004; 
Nagano et al., 2008). Consistent with this finding, a recent study of chromatin-associated 
proteins showed that binding of these proteins depended on methylation status of DNA 
segments that overlap with several known imprinting control regions (Kernohan et al., 2014). 
The experimental evidence therefore suggests that DNA methylation and particular chromatin 
structure(s) are the key factors in genomic imprinting. 
 Another important property of genomic imprinting is the potential for reversibility of 
the imprinting marks. After an embryo becomes diploid upon fertilisation, imprinting marks 
are maintained on the specific chromosomes mainly by the activity of the maintenance DNA 
methyltransferase Dnmt1 (Spada et al., 2007; Hirasawa et al., 2008; Li and Zhang, 2014). 
However, the erasure of those imprinting marks occurs in the embryonic gonad. This process 
may occur by passive demethylation (DNA replication without a maintenance 
methyltransferase activity) and/or be mediated by demethylase enzymes. The demethylation 
in the embryonic gonad allows re-establishment of new imprinting marks according to the sex 
of an embryo (Barlow and Bartolomei, 2014). 
 To date, two major silencing mechanisms are known for genomic imprinting. The first 
mechanism was identified in the Igf2/H19 cluster and it involves an insulator protein CTCF (a 
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zinc finger protein) in the silencing of target genes (Hark et al., 2000). In this cluster, an 
unmethylated maternal allele allows the interaction of H19 with a downstream enhancer, 
resulting in its expression. A CTCF protein binds only to an unmethylated maternal allele and 
its binding prevents upstream genes like Igf2 from interacting with the enhancer, thereby 
silencing expression of the gene from the maternal allele. In contrast, H19 expression is 
repressed from a paternal allele due to DNA methylation. The DNA methylation on a paternal 
allele inhibits CTCF binding, and it allows expression of other genes through interaction of 
these genes with the enhancer. Following the initial discovery of a CTCF binding site in the 
Igf2 cluster, it has also been found in other imprinted clusters, suggesting that this may be a 
common mechanism for many clusters (Hikichi et al., 2003; Mukhopadhyay et al., 2004; 
Yoon et al., 2005; Essien et al., 2009). Another mechanism involving a long non-coding RNA 
(lncRNA) was later discovered in the Igf2r cluster (Sleutels et al., 2002). In this mechanism, a 
lncRNA is considered to silence expression of nearby genes by sequestering a binding site of 
transcription machinery that would target other genes (Latos et al., 2012). This mechanism 
has been speculated also to work in various imprinted clusters because non-coding RNA 
molecules are frequently found in such regions (O'Neill, 2005; Heard and Disteche, 2006). 
Although experimental evidence from the well-studied imprinted clusters suggests these two 
mechanisms (insulator model and lncRNA model) are predominant as a gene silencing 
mechanism, other regulating mechanisms also exist in other clusters. For example, alternative 
polyadenylation sites are used in an allele-specific manner for the H13 gene (Wood et al., 
2008). This finding implies the possibility that distinct mechanisms may govern some specific 
clusters. 
 What mechanism might regulate PEG10 imprinting status? Methylation occurs on the 
maternal chromosome approximately 60 bp downstream of tammar wallaby Peg10 
transcription start site (Suzuki et al., 2007) and it is not unusual for an internal regulatory 
element to control transcription of retrotransposons (Christy and Huang, 1988; Minakami et 
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al., 1992). Although it is probable that methylation at this position is responsible for 
transcriptional silencing of the maternal copy of PEG10 as PEG10 is derived from a 
retrotransposon, further studies are needed to determine unequivocally the mechanism of 
imprinting in PEG10. 
 
 
1.4.4 Imprinted genes and placental development 
 
 
The placenta is a special organ unique to eutherians and it plays a vital role in fetal 
development facilitating nutrient supply, waste and gas exchange. The placenta also acts as a 
physical barrier against the maternal immune system and produces hormones to coordinate 
maternal physiology and fetal growth (Cross et al., 2003; Rawn and Cross, 2008). As proper 
development and functioning of the placenta are the key for reproductive success, the placenta 
is thought to be the site where genomic imprinting acts most strongly (Wood and Oakey, 
2006; Frost and Moore, 2010). Indeed, of the imprinted genes identified so far, a significant 
proportion of them is expressed in the placenta and PEG10 is one of those genes (Coan et al., 
2005; Bressan et al., 2009). Five novel imprinted genes were recently identified in the mouse 
placenta using mRNA sequencing (Wang et al., 2011). 
 Inactivation of imprinted genes is associated with various phenotypes in humans and 
mice because these genes regulate both placental development and function. Peg10 and 
Mash2 are reciprocally imprinted but mutations in both cause early embryonic lethality. Mice 
that inherited a mutated Peg10 gene from the paternal allele died at early gestation due to 
placental developmental failure caused by lack of spongiotrophoblast cells (Ono et al., 2006). 
Mash2 is a maternally expressed gene and it encodes a basic helix-loop-helix transcription 
factor. Similarly to Peg10, the Mash2 mutant placenta also lacked spongiotrophoblast cells 
and their precursor cells, resulting in early embryonic lethality (Guillemot et al., 1994; 
Guillemot et al., 1995). Additionally, another retrotransposon-derived gene, Rtl1, plays an 
important role in fetal capillary maintenance at later stages of gestation. A mutated Rtl1 
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placenta showed reduced passive permeability for nutrients due to clogging and phagocytic 
reaction to the capillary cells, resulting in growth retardation and late fetal lethality (Sekita et 
al., 2008). In contrast to those essential genes, other better known imprinted genes such as 
Igf2 cause milder phenotypes. Deletion of Igf2 transcribed from a placental specific promoter 
P0 (Igf2 P0) caused a reduction in placental size followed by fetal growth retardation at late 
gestation stages due to a reduced permeability for nutrients (Constancia et al., 2002). 
Histological analyses of the Igf2 P0 null placenta showed that a reduced surface area and an 
increased thickness of the exchange barrier were responsible for a reduced nutrient supply 
(Sibley et al., 2004). A further study investigated a late onset of fetal growth retardation and 
found that the Igf2 P0 upregulated active transporters in response to fetal demand, 




1.4.5 Imprinted genes and neural development 
 
 
While many imprinted genes like PEG10 have important functions in placental development 
and fetal growth as exemplified by Peg10 and Igf2 (Constancia et al., 2002; Ono et al., 2006), 
imprinted genes are not exclusively expressed in the placenta, and a significantly large 
proportion of imprinted genes are now known to be expressed in the brain (Wilkinson et al., 
2007). Two studies played a pivotal role in the discovery that imprinted genes are involved in 
brain development (Allen et al., 1995; Keverne et al., 1996). In these studies, normal 
embryonic cells (N) were added to androgenetic (AG) or parthenogenetic (PG) embryos to 
generate AG-N and PG-N chimeric embryos, respectively. Use of these chimeric mice 
allowed the detailed analysis of how the uniparental cells behaved during neural development. 
These two types of chimeric mice showed distinctive and reciprocal distributions of AG and 
PG cells in the mouse brain. AG cells were found in the hypothalamus at a high level but 
were absent in the cortex or striatum where PG cells predominated. Surprisingly, the specific 
 24 
distribution of AG and PG cells was observed as early as day 10.5 and this pattern persisted 
into adulthood. Both studies therefore demonstrated that imprinted genes have a significant 
contribution to brain development and provided the first supportive evidence that paternal and 
maternal genomes and imprinted genes like PEG10 might have differential influences on the 
distinctive brain regions (for example, hypothalamus and cortex, respectively). Following 
these chimera studies, using knockout mice it was shown two paternally expressed genes 
(Peg1 and Peg3) controlled maternal behaviour. Mutation in these genes caused very similar 
phenotypes including latency in pup retrieval and nest building (Lefebvre et al., 1998; Li et 
al., 1999). Histological analyses confirmed a reduced number of oxytocin-positive neurons in 
the hypothalamus in the Peg3 mutant females compared with the wild-type females. Since 
oxytocin is known to induce maternal behaviour, it was probable that a deficient level of 
oxytocin in the mutant females caused the observed impairment of maternal care (Li et al., 
1999). These studies suggested that imprinted genes play a major role in proper development 
of specific neural cell types and these genes have the potential to control various behaviours. 
Another line of evidence that imprinted genes have important functions in brain 
development came from studies of human genetic disorders such as the Prader-Willi 
syndrome (PWS) and Angelman syndrome (AS). Both disorders are caused by a genetic 
disruption (deletion, uniparental disomy or loss of imprinting) of human chromosome 15q11–
13 containing multiple imprinted genes. Although these disorders result from a genetic 
disruption of the same region, the PWS is caused by a loss of paternal expression whereas AS 
results from a lack of maternal expression. Both disorders cause a wide range of symptoms 
including mental retardation and impaired cognition (Cassidy and Driscoll, 2009; Van 
Buggenhout and Fryns, 2009). Intensive searches of the causative gene(s) within this region 
have identified likely candidates, namely the paternally expressed HBII-85 cluster for PWS 
and the maternally expressed UBE3A gene for AS (Kishino et al., 1997; Matsuura et al., 
1997; Sahoo et al., 2008). It is also interesting to note that these disorders have somewhat 
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reciprocal behaviours, ‘stubbornness and temper tantrum’ in the PWS patients and ‘frequent 
laughter’ in the AS patients (Cassidy and Driscoll, 2009; Van Buggenhout and Fryns, 2009). 
As the loss of expression in these imprinted genes is thought to be the cause of these 
phenotypes, it is possible to speculate that the two genes regulate social behaviours by 
opposing each other, so that the paternally expressed gene (HBII-85 cluster) improves 
sociability with positive attitudes, whereas the maternally expressed gene (UBE3A) counters 
it, adding ‘negative’ features (Wilkinson et al., 2007). 
Imprinted genes identified so far seem to have a relatively large effect in neural 
development, and studies have shown variable expression of imprinted genes depending on 
developmental stages and cell types (Wilkinson et al., 2007). It was of interest to my project 
to investigate whether PEG10 might play an important role also. The general finding is 
particularly noticeable in the brain because some imprinted genes showed differential 
expression in discrete areas of the brain (Albrecht et al., 1997; Rougeulle et al., 1997). 
Although nearly 100 imprinted genes have been discovered, such dynamic regulation of them 
implies that molecular genetic approaches may have failed to identify a number of other 
candidate imprinted genes. To obtain an overview of imprinted gene expression in the brain, 
RNA from embryonic mouse (E15) brain and two adult brain regions (cortex and 
hypothalamus) was analysed by RNA sequencing (Gregg et al., 2010). Remarkably, this study 
identified over 1300 imprinted loci and 800 genes. Of those potentially imprinted genes 
identified in this study, the majority (>90%) were expressed in one brain region, with a small 
fraction (<10%) expressed in more than one brain regions, suggesting a complex 
spatiotemporal regulation of imprinted gene expression in the brain. In contrast to the 
chimeric mice studies that showed a distinctive localisation of AG and PG cells in 
hypothalamus and cortex respectively, this study determined preferential expression of 
maternally expressed genes in the developing brain and paternally expressed genes in both the 
adult cortex and hypothalamus. Therefore, this finding indicated that differential interests of 
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parental genomes are expressed in distinctive developmental stages rather than simply in 
distinctive regions of the brain. 
 
 
1.4.6 Coordination of hypothalamus and placenta 
 
 
The functions of both the hypothalamus and the placenta must be coordinated properly by 
balancing the supply and demand of nutrients to ensure successful reproduction. The placenta 
produces hormones that act on the maternal neuroendocrine system to modify maternal 
behaviours to achieve this goal. The molecular mechanism underlying this process is poorly 
understood but it is possible that this mechanism, at least partially, is governed by a subset of 
imprinted genes expressed in these organs (Keverne, 2013; Keverne, 2014). PEG10 could be 
one of those imprinted genes. Of those imprinted genes, the Zac1 gene is particularly 
important in this context. Zac1 is a paternally expressed gene and it encodes for a zinc finger 
transcription factor that regulates apoptosis and cell cycle arrest (Spengler et al., 1997; 
Varrault et al., 1998; Kamiya et al., 2000; Piras et al., 2000). Zac1 is expressed in neural 
cells, somites and placenta (Valente et al., 2005; Varrault et al., 2006). An in silico analysis of 
116 mouse microarray datasets identified a surprisingly large network of imprinted genes 
including Zac1. Since Zac1 is a transcription factor, it was hypothesised to regulate 
expression of multiple imprinted genes in the network (Varrault et al., 2006). Indeed, 
overexpression of Zac1 in cultured cells and Zac1 knockout mice confirmed that some 
imprinted genes in the network were regulated by Zac1, indicating that the Zac1 gene is one 
of the key regulators in the imprinted gene network (Varrault et al., 2006). Importantly, this 
network has recently been found to operate in humans and its dysregulation caused 
intrauterine growth restriction (Iglesias-Platas et al., 2014). 
 There are several other imprinted genes expressed in both the brain (especially the 
hypothalamus) and the placenta. These genes are discussed here in relation to their expression 
patterns and functions. Delta-like homologue 1 (Dlk1) encodes for a transmembrane protein 
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containing six repeats of epidermal growth factor (EGF)-like domains (Smas and Sul, 1993). 
The Dlk1 protein is processed by a tumour necrosis factor α converting enzyme (TACE) to 
produce its soluble, biologically active form (Wang and Sul, 2006). Dlk1 protein inhibits 
Notch signaling by interacting with Notch receptor through its EGF-like domains (Sanchez-
Solana et al., 2011). This functional role of the Dlk1 protein has been suggested to coordinate 
proliferation and differentiation for appropriate fetal development (Falix et al., 2013). The 
Dlk1 gene is expressed from a paternal allele and its mRNA has been detected in a range of 
tissues during embryonic development but largely restricted to pituitary and adrenal gland 
postnatally (Smas and Sul, 1993; Kobayashi et al., 2000; Schmidt et al., 2000; Falix et al., 
2013). The mice with Dlk1 deletion showed a number of abnormal phenotypes such as growth 
retardation and increased fat mass (Moon et al., 2002). Although Dlk1 function in the 
placenta remains to be determined, the Dlk1 gene may play a role in fetal development 
through nutrient transfer because Dlk1 protein was detected specifically in the fetal 
endothelial cells located around the maternal-fetal interface (Yevtodiyenko and Schmidt, 
2006). By contrast, Dlk1 has been studied extensively as a negative regulator in adipogenesis 
(Kim et al., 2007; Wang and Sul, 2009). Dlk1 protein activates the MEK/ERK pathway that 
induces Sox9 expression, and this suppresses expression of adipogenesis regulators, C/EBPβ 
and C/EBPδ. In addition to adipogenesis, Dlk1 studies have focused on its expression in the 
brain especially in the hypothalamus and pituitary gland. These studies showed that Dlk1 
protein was localised in neurons that produce a variety of hormones (Puertas-Avendano et al., 
2011; Villanueva et al., 2012; Meister et al., 2013; Persson-Augner et al., 2014). A level of 
Notch signaling is the key determinant of the fate of neural progenitor cells (proliferation or 
differentiation), and it is regulated by an inhibitory function of Dlk1 (Zhu et al., 2006; 
Surmacz et al., 2012). Together with the observed expression of Dlk1 in the developing 
pituitary gland, it is possible that Dlk1 functions in collaboration with Notch signaling for 
development of hormone-producing neurons in the pituitary gland. 
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Another imprinted gene is Ndn, a paternally expressed gene, and it is located in the 
region where it is often deleted in the PWS patients. The Ndn gene is highly expressed in 
brain and placenta (MacDonald and Wevrick, 1997). Function of the Ndn gene has been 
extensively studied in the brain in relation to PWS using Ndn knockout mice. The Ndn-
deficient mice showed some of the abnormalities observed in the PWS patients including 
neonatal lethality (Gerard et al., 1999; Muscatelli et al., 2000). These mutant mice also had a 
reduced number of specific neurons in the hypothalamus producing oxytocin and 
gonadotropin-releasing hormone (GnRH) (Muscatelli et al., 2000). The observed reduction in 
the population of specific neuronal types could be attributed to lower neural growth factor 
signaling that is important for neural survival, growth and maintenance in which Ndn protein 
has a positive function (Andrieu et al., 2003; Kuwako et al., 2005). It could also be possible 
that neural migration and differentiation might have been impaired due to Ndn mutation 
(Kuwajima et al., 2006; Kuwajima et al., 2010). The Ndn gene was more recently found to 
regulate expression of hormones in neurons. The Ndn protein binds to an Msx repressor 
protein to allow a GnRH expression (Miller et al., 2009). The Ndn protein also inhibits 
neuropeptide expression (Agouti-related peptide and neuropeptide Y) and thyrotropin-
releasing hormone production (Hasegawa et al., 2012). Although as with Dlk1 the function of 
the Ndn gene has yet to be determined in the placenta, it is plausible that the Ndn gene plays a 
critical role because it is known to regulate activities of transcription factors (Taniura et al., 
1998; Taniura et al., 1999). Among those transcription factors, hypoxia-inducible factor (Hif) 
and aryl hydrocarbon nuclear translocator are particularly interesting with respect to the 
potential function of the Ndn gene. These proteins are expressed in the developing placenta 
and regulate cell differentiation (Kozak et al., 1997; Jain et al., 1998; Adelman et al., 2000; 
Cowden Dahl et al., 2005). Therefore, it is possible that the Ndn protein mediates proper 
placental development as it interacts with these transcription factors and represses their 
activities (Moon et al., 2005; Friedman and Fan, 2007). 
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A third imprinted gene, Growth factor receptor-bound protein 10 (Grb10), that is 
located on human chromosome 7q11.2–12, functions as a growth inhibitor by suppressing 
activities of receptor tyrosine kinases (O'Neill et al., 1996; Morrione et al., 1997; Miyoshi et 
al., 1998). The imprinting status of the Grb10 gene is conserved between humans and mice 
where it is paternally expressed in the brain but maternally expressed in other mouse tissues. 
A maternal specific expression of Grb10 is restricted to trophoblasts in humans (Arnaud et 
al., 2003; Monk et al., 2009). The maternal Grb10-deficient mice showed both fetal and 
placental overgrowth (Charalambous et al., 2003). More detailed analysis of these mice 
demonstrated that the Grb10 gene not only reduced placental size and its nutrient transfer 
efficiency, but also influenced reproductive strategy producing a smaller litter of large 
offspring (Charalambous et al., 2010). These unusual mice also showed an altered body 
composition (muscle to fat ratio) and recently it was shown to be regulated by a coordinated 
expression of the Grb10 gene in the mother and offspring (Smith et al., 2007; Cowley et al., 
2014). A study of Grb10 gene function in the brain found an interesting phenotype in mice 
(Garfield et al., 2011). Mice carrying a paternal deletion of the Grb10 gene showed increased 
social dominance. Here, the imprinted gene controls social behaviours in contrast to 
reproductive behaviours. 
Another imprinted gene, Cdkn1c (cyclin-dependent kinase inhibitor), was identified in 
1995, and its expression has been detected in tissues such as brain, muscle and placenta 
(Matsuoka et al., 1995). The Cdkn1c gene is a maternally expressed gene and this imprinting 
status is conserved between humans and mice (Hatada and Mukai, 1995; Matsuoka et al., 
1996). Zac1 is involved in both activation and silencing of the Cdkn1c gene. Zac1 up-
regulates the Cdkn1c gene through the activation of another transcription factor, Tcf4 
(Schmidt-Edelkraut et al., 2014). Zac1 transcriptionally activates the Lit1 non-coding gene 
exclusively from the paternal allele, which supresses the Cdkn1c gene (Arima et al., 2005; 
Murakami et al., 2007). Deletion of the maternal Cdkn1c gene in mice caused severe 
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developmental abnormalities and a high degree of neonatal lethality (Yan et al., 1997; 
Takahashi and Nakayama, 2000). The Cdkn1c gene is widely expressed in the brain including 
hypothalamus, and it has been shown that the Cdkn1c protein regulates cell cycle exit of 
proliferating pituitary progenitor cells to prepare them for differentiation. Interestingly, 
Cdkn1c deficiency resulted in apoptosis at later stages of gestation (Bilodeau et al., 2009; Ye 
et al., 2009). Similar to the pituitary progenitor cells, Cdkn1c deletion caused extensive 
apoptosis of progenitor cells in cerebellum. This phenomenon was attributed to p53-
dependent apoptosis upregulated by over-activation of E2F1 (Matsumoto et al., 2011). In 
addition to the functions of the Cdkn1c gene in the brain, the Cdkn1c deletion caused 
defective placental formation in the labyrinth zone (Zhang et al., 1998). A significant 
reduction in glycogen stores in the mutant placenta suggested that the Cdkn1c gene was 
involved in maturation of glycogen cells (Tunster et al., 2011). 
 While this is a complex evolving research area, it seems clear the brain (and 
hypothalamus in particular) and the placenta have a unique connection and imprinted genes 
play a significant role in this connection. Although as yet there is limited understanding of 
PEG10 function, it has been reported to possess an anti-apoptotic property (Okabe et al., 
2003; Tsou et al., 2003). As imprinted genes are frequently involved in cell survival and/or 
differentiation as discussed above, it is therefore possible that PEG10 may have, in addition to 











1.5 A recently reported human gene in 




Until recently, PEG10 has been the only well documented and experimentally validated gene 
that has been shown to use −1 frameshifting to produce two proteins in vivo (Clark et al., 
2007). Unlike PEG10, −1 frameshifting for Paraneoplastic Ma3 (PNMA3) gene expression 
has been demonstrated only in assays and cultured cells but not yet in vivo (Wills et al., 
2006). This gene is normally expressed in brain, testis and a few other tissues. An abnormal 
expression of this gene in cancer cells causes an autoimmune response, resulting in 
paraneoplastic syndrome. PNMA3 protein is inferred to play a role in apoptosis based on 
amino acid sequence similarity to one of the same family members, PNMA4, which was 
identified as a Bax-associating protein (Schuller et al., 2005). Both the use and possible 
function of −1 frameshifting in the PNMA3 gene in vivo currently remain uncertain because 
of the limited number of studies undertaken to date. 
As the current study was being resolved, however, the C-C chemokine receptor 5 gene 
(CCR5), a human gene that in yeast had previously exhibited −1 frameshifting (Hammell et 
al., 1999), was shown to use this mechanism in human cells also (Belew et al., 2014). In the 
case of CCR5, −1 frameshifting was shown to regulate expression levels of both mRNA and 
protein, and thus differs significantly from its mechanistic function for viruses where it 
facilitates production of two distinct functional proteins. CCR5 mRNA contains a slippery 
sequence of U UUA AAA and a downstream RNA pseudoknot, giving 6–10% frameshift 
efficiency in cultured cells. Interestingly, the frameshift efficiency of CCR5 was modulated 
by two miRNAs, probably through stabilisation of the RNA pseudoknot. Although the 
frameshift mechanism of CCR5 was only recently documented, the gene has been extensively 
studied previously in relation to HIV-1 infection, because the CCR5 protein was found to play 
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a key role in HIV-1 entry into CD4+ immune cells at early stages of infection (Choe et al., 
1996; Dragic et al., 1996; Raport et al., 1996; Samson et al., 1996; Bleul et al., 1997). A 
homozygous deletion of 32 bp in the CCR5 gene conferred resistance to HIV-1 infection, 
reinforcing the importance of this gene for HIV-1 infectivity (Liu et al., 1996). 
 
 
1.6 Therapy against HIV-1 
 
 
1.6.1 HIV-1 antiretroviral drug targets 
 
 
There are several key steps in the life cycle of HIV-1, beginning with entry of the virions into 
the human host cell. This process is mediated by a specific interaction between viral 
glycoprotein (gp) 120 with cellular CD4, and then with co-receptors (CCR5 or CXCR4). 
These interactions expose another viral protein (gp41) that inserts itself into the host cell 
membrane. Following the fusion of a virion and a host cell, viral RNA is released into the 
cytoplasm where it is converted into DNA by the activity of incoming viral reverse 
transcriptase (RT). Following protein synthesis, the viral integrase (IN) then inserts the viral 
DNA into the host genome, creating a provirus that can be transcribed by the host cellular 
machinery in association with a viral regulatory protein, Tat. Two viral polyproteins 
translated from these transcripts are gag (structural proteins), and gag-pol polyprotein (now 
including the enzymatic proteins), and these proteins together with two copies of viral RNA 
are assembled into the virion at the host cell surface before budding out from the cell. The 
released virion becomes fully infectious upon cleavage of the gag and gag-pol viral 
polyprotein (Mehellou and De Clercq, 2010; Arts and Hazuda, 2012). 
 With advances in understanding of the HIV-1 life cycle, antiretroviral drugs have been 
developed to target different specific viral proteins involved in distinct stages of the viral life 




1.6.1.1 Reverse transcriptase inhibitors 
 
 
For example, nucleoside reverse transcriptase inhibitors (NRTIs) were the first type of drugs 
developed against HIV-1 (Mitsuya et al., 1985). These compounds inhibit the activity of the 
HIV-1 RT by acting as a terminator of a growing chain of DNA after incorporation due to the 
lack of a 3´-hydroxyl group (Arts and Hazuda, 2012). However, three consecutive 
phosphorylation reactions are required for NRTIs to become effective inhibitors, and the first 
phosphorylation reaction is very inefficient (De Clercq, 2002). To bypass this rate-limiting 
step, monophosphate derivatives of NRTIs were developed and these were found to have 
greater efficacy against HIV-1 in vitro (McGuigan et al., 1993). Despite the improved 
activities of these compounds, none of the monophosphate prodrugs are yet currently 
approved for clinical use.  
Nucleotide reverse transcriptase inhibitors (NtRTIs) exert their effect by the same 
mechanism as NRTIs, and they include a phosphate group similar to monophosphate 
derivatives of NRTIs. Although as yet there is only one approved NtRTI, inclusion of this 
NtRTI in a treatment regimen was found to be more beneficial than NRTI inclusion 
(Mehellou and De Clercq, 2010).  
Long-term use of these drugs as a monotherapy inevitably accelerated the emergence 
of resistance in HIV-1. HIV-1 becomes resistant to these types of drugs through two different 
mechanisms where the viral RT either has evolved to (a) facilitate removal of the incorporated 
nucleoside/nucleotide analogues (pyrophosphorolysis) or, (b) exhibit greater specificity 
towards native nucleotide substrates (Quan et al., 1996; Arion et al., 1998).  
In contrast to the competitive inhibitors of the HIV-1 RT (NRTIs and NtRTIs), non-
nucleoside reverse transcriptase inhibitors (NNRTIs) are non-competitive in that they bind to 
the allosteric site on the RT (Kohlstaedt et al., 1992). This class of inhibitors was first 
developed in 1989 and there are several agents currently in clinical trials (Baba et al., 1989; 
Arts and Hazuda, 2012). Use of early inhibitors of this class as a monotherapy resulted in 
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rapid development of resistance as a result of mutations affecting amino acids at the allosteric 
site. This was not surprising as these mutations maintained replication efficiency of the virus, 
and other lentiviruses contained such substituted amino acids at the same positions (Dykes et 
al., 2001; Tebit et al., 2010). To overcome this problem, the drug developmental strategy for 
new drug analogues was changed to target the backbone of the amino acids instead of their R-
group side chains. This approach was highly successful and has led to the development of the 
most recently approved anti HIV-1 agent and of others still in clinical trials (Ludovici et al., 




Figure 1.6: Crystal structure of the HIV-1 protease complexed with a protease inhibitor. 
A protease inhibitor (Atazanavir, shown in sticks) binds to the catalytic site located in the interface of the HIV-1 
protease dimer (each monomer is represented in blue and red). This structure was obtained from Protein Data 
Bank (3EKY) deposited by King et al. (2012). 
 
 
1.6.1.2  Viral protease inhibitors 
 
 
The HIV-1 protease is an enzyme that catalyses maturation of gag and gag-pol polyprotein 
precursors (De Clercq, 2005). Most approved protease inhibitors (PIs) have similar structures 
and they act as competitive inhibitors of the viral protease (Mehellou and De Clercq, 2010; 
Arts and Hazuda, 2012). Figure 1.6 shows a crystal structure of the HIV-1 protease with a PI, 
Atazanavir, bound to its catalytic site. Cross-resistance in HIV-1 to more than one inhibitor is 
often observed due to their structural similarity. Although mutations that confer resistance to 
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PIs are usually accompanied with reduced fitness of the virus itself, HIV-1 is adept at 




1.6.1.3 Integrase inhibitors 
 
 
Integrase inhibitors (INIs) are the most recently approved class of antiretroviral drugs 
(Mehellou and De Clercq, 2010; Arts and Hazuda, 2012). The HIV-1 IN catalyses a strand 
transfer reaction for integration of the viral DNA into the human genome (Figure 1.7), and 
INIs inhibit this reaction by interacting with a specific complex consisting of IN and the viral 
DNA (Grobler et al., 2002). Drug resistance against INIs in HIV-1 is known to arise in three 
distinct genetic pathways and the molecular mechanism of drug resistance conferred by these 
mutations was largely elucidated using the crystal structure of IN from the prototype foamy 





Figure 1.7: Integration process of HIV-1 into the human genome. 
A, the HIV-1 IN removes two nucleotides from the 3´ end after the synthesis of proviral DNA (red). B, 3´-OH 
groups attack the phosphodiester backbone of the host human DNA (black). Integration sites are indicated by the 
yellow stars. INIs interfere with this step of the integration process (green). C, 5´ nucleotides of the proviral 




A: 3´-processing B: 3´-OH group attacks host DNA















1.6.1.4 Entry inhibitors 
 
 
Unlike other classes of antiretroviral drugs that inhibit enzymatic activities, entry inhibitors 
(fusion inhibitors, FIs and co-receptor inhibitors, CRIs) target receptor proteins involved in 
viral entry during infection. For fusion of the viral envelope and the host cell membrane, two 
homologous regions (HR1 and HR2) of the gp41 form a helical bundle structure upon binding 
of gp120 and CD4 (De Clercq, 2002). Two synthetic peptides, DP-107 and DP-178 
corresponding to the N- and C-terminus of the gp41, respectively, showed good antiretroviral 
activity (Wild et al., 1992; Wild et al., 1994). DP-178 was later developed into the first, and 
so far the only, approved FI. A fourteen-day treatment regimen with this peptidomimetic 
agent successfully inhibited viral entry in vivo (Kilby et al., 1998). Monotherapy of patients 
with DP-178 generated a resistant strain of HIV-1 containing mutations in the HR1 although 
these mutations reduced viral fitness due to lower fusion efficiency (Wei et al., 2002; Reeves 
et al., 2005). In addition to CD4, HIV-1 requires one of the two co-receptors (CXCR4 and 
CCR5) for the fusion process (De Clercq, 2005). Although a selective inhibitor of CXCR4 
showed antiretroviral activity in vitro, it failed to replicate this effect in vivo (Schols et al., 
1997; Donzella et al., 1998; Hendrix et al., 2004). By contrast, small molecule CCR5 
antagonists, especially the one approved drug, showed great potency against HIV-1 infection 
both in vitro and in vivo (Baba et al., 1999; Dorr et al., 2005; Fatkenheuer et al., 2005; Wood 
and Armour, 2005; Imamura et al., 2006; Seto et al., 2006). Since these CCR5 antagonists 
bind to the transmembrane region of CCR5, drug resistance was suggested to arise either by a 
tropism switch or by recognition of inhibitor-bound CCR5 (Dragic et al., 2000; Tsamis et al., 
2003; Kondru et al., 2008; Arts and Hazuda, 2012). Analysis of the resistant HIV-1 strain 
indeed showed that use of inhibitor-bound CCR5 for viral entry was the predominant escape 
pathway instead of using an alternative co-receptor, CXCR4 (Trkola et al., 2002; Westby et 




1.6.2 New antiretroviral drug targets 
 
 
Continuous efforts to elucidate the replication cycle of HIV-1 in detail have resulted in 
development of antiretroviral drugs that revolutionised medical treatment of HIV-1 infection. 
Studies of how HIV-1 develops resistance have also brought valuable information for new 
drug design. HIV-1 infected patients are currently treated with a cocktail of three 
antiretroviral drugs targeting more than two viral proteins. In addition to improving the 
efficacy of treatment as found with monotherapy, it is recommended as a preventive measure 
for the development of drug resistance in HIV-1 (Mehellou and De Clercq, 2010; Arts and 
Hazuda, 2012). Although this has appeared to be effective over the last 20 years, there are 
now groups of multidrug resistant patients suggesting that this strategy is eroding. Therefore, 
it is important to continue searching for new drug targets and to design different types of 
treatment strategies.  
Several approaches have recently been proposed as a potential therapy for HIV-1 such 
as development of a vaccine against HIV-1 using broard spectrum, highly potent neutralising 
antibodies and genome editing (Klein et al., 2013; Gu, 2015). The guanine quadruplex 
structure in the HIV-1 promoter region has been suggested as a new target due to its high 
conservation and importance in gene regulation (Amrane et al., 2014). In addition to such 
new approaches for HIV-1 treatment, frameshifting has been studied as a potential drug target 
since 1998 (Hung et al., 1998). The first screening study of chemical compounds altering 
frameshift efficiency was performed using an in vitro translation system and modified 
luciferase mRNA containing the HIV-1 frameshift site. A frameshift enhancer, RG501, was 
found to have little effect on normal translation but it increased frameshift efficiency by two-
fold. Although mechanical understanding of how RG501 stimulated frameshifting remained 
unresolved, a recent NMR study showed an interaction of RG501 with the RNA stem-loop, 
stablising the structure to promote frameshifting. However, the structure of RG501 also 
suggested it had a capability to interact with other RNA molecules longer than 9 base pairs 
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non-specifically, suggesting it would not be suitable as a therapeutic agent (Marcheschi et al., 
2011).  
To search compounds with higher specificity against the frameshift elements, a dual 
reporter system was developed using Renilla and firefly luciferases (Grentzmann et al., 1998; 
McKinney, 2001; Harger and Dinman, 2003). This assay system was further modified by 
substituting the luciferase genes with green and red fluorescent proteins to be more amenable 
for high-throughput drug screening (Dulude et al., 2008; Cardno et al., 2009; Rakauskaite et 
al., 2011). Screening of a large compound library identified that doxorubicin tightly bound to 
the HIV-1 stem-loop and decreased frameshift efficiency in vitro (Marcheschi et al., 2009). 
Despite its lack of specificity, similar to RG501, it provided a platform to demonstrate that a 
novel antiretroviral drug can be developed with modifications. Similar high-throughput 
screens using a resin-bound dynamic combinatorial library, identified a molecule with a low 
dissociation constant (McNaughton et al., 2007). Analysis of each moiety of that compound 
led to substitution of a disulphide bond with a carbon-carbon double bond, resulting in 
increased stability inside the cell and reduced cytotoxicity (Palde et al., 2010). Further 
modifications of the molecule generated a highly specific agent against the HIV-1 stem-loop 
with good binding kinetics. These derivatives promoted a >50% higher level of −1 
frameshifting without obvious cytotoxicity, and they caused a significant decrease in viral 
infectivity (Ofori et al., 2014).  
Compared to the high-throughput studies discussed above, computational modeling 
provides an alternative approach for the discovery of lead compounds. Indeed, molecules that 
target the HIV-1 transactivation response element were identified through in silico screening 
of a large collection of compounds (Filikov et al., 2000; Lind et al., 2002). A library of 
approximately 80 000 compounds was screened using this method in search of SARS-
coronavirus (SARS-coV) RNA pseudoknot ligands that interfere with −1 frameshifting. Of 
the 58 molecules highlighted, a potent −1 frameshift inhibitor was identified through both in 
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vitro and in vivo assays. This compound was also highly specific to the RNA pseudoknot of 
the SARS-coV (Park et al., 2011). A recent study using optical tweezers investigated how this 
compound reduced −1 frameshifting and found that its binding to the RNA pseudoknot 
reduced the flexibility of the pseudoknot eliminating the formation of alternative 
conformations (Ritchie et al., 2014). 
 Our group has performed high-throughput screening of a compound library containing 
114 000 members using both dual luciferase and dual fluorophore reporter systems (Cardno et 
al., 2015). The primary screening selected 1024 compounds and 167 of those consistently 
modulated −1 frameshifting in the two independent assays. Following a series of counter 
screens, three enhancers belonging to two different chemical classes were identified. 
Commercially available analogues of these compound classes were analysed for their 
activities against −1 frameshifting. Two analogues of one class (Compound A2 and A3) 
increased −1 frameshifting, while none of the second class analogues had a significant effect. 
Importantly, Compound A2 stimulated frameshifting by 300% at 10 µM, marking it as worthy 
of further development as a therapeutic agent against HIV-1. This study has also contributed 
significantly to the development of new drugs since this compound represents a novel 
structural class with properties that modulate frameshifting and shares no structural similarity 
to any previously described molecules. 
 Frameshifting appears to be an ideal target for therapeutic intervention since 
successful viral replication and infectivity depends on a strictly controlled level of 
frameshifting (Shehu-Xhilaga et al., 2001; Dulude et al., 2006). Now that we know at least 
two human genes use −1 frameshifting, these examples need to be studied in depth to avoid 
serious side effects from an anti HIV-1 strategy targeting frameshifting (Clark et al., 2007; 
Belew et al., 2014). Not only should compounds targeting frameshifting be tested against the 
expression of these genes but also it is important to understand their functions and their 
expression patterns in human tissues. 
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1.6.3 Expression of PEG10 
 
 
Gene expression can be regulated at many different levels from DNA to protein. At the 
transcriptional level this can be through transcription factors and accessory proteins 
interacting with specific loci, allowing or preventing expression of the downstream genes 
(Mitchell and Parker, 2014; Woringer et al., 2014). Alternatively, it can be through 
hypermethylation of CpG islands in the promoter region. A recent study demonstrated that 
initiation of transcription of PEG10 occurs mainly at 24–30 bp downstream of TATA-box in 
the PEG10 promoter region (Lux et al., 2010). In search for transcription factors regulating 
PEG10 expression, a consensus binding sequence was identified for E2F in the promoter 
region and for the c-MYC transcription factor in the first intron. Both of these transcription 
factors were shown experimentally to up-regulate PEG10 expression (Li et al., 2006; Wang et 
al., 2008). Additionally, estrogen receptor β has been found to modulate PEG10 expression 
(Zhao et al., 2009).  
Gene expression can be regulated post-transcriptionally through binding of 
microRNA(s) to the 3´ UTR of mRNAs to prevent production of the protein. To test if this 
was occurring, the 3´ UTR of PEG10 was analysed in our group for microRNA binding sites 
using TargetScan 5.0 (Crowe-McAuliffe, 2009). Although putative binding sites for many 
microRNAs were identified, two microRNAs (miR-34a and miR-182) were selected for 
further study based on seed sequence and sequence conservation across mammalian species. 
Both microRNA-34a and miR-182 were shown to repress PEG10 expression using a 
luciferase reporter assay in cultured cells (Saurat, 2009). 
PEG10 expression at the RNA level has been studied in both embryonic and adult 
tissues by Northern blotting and reverse transcription PCR. A high level of PEG10 expression 
was detected in brain, testis, ovary and placenta. However, it was controversial across several 
studies whether or not PEG10 was expressed in other tissues such as kidney and spleen (Ono 
et al., 2001; Okabe et al., 2003; Smallwood et al., 2003; Brandt et al., 2005; Lux et al., 2005). 
 
 41 
Despite the reported expression of PEG10 RNA in various tissues, PEG10 protein expression 
was found only in embryo and tissues surrounding the embryo (Clark et al., 2007). Recently, 
two groups established databases for the human proteome independently that were based on 
mass spectrometric analyses of proteins expressed in various human tissues. One, ‘The 
Human Proteome Map’, contains information on PEG10 protein expression based on peptides 
from PEG10 ORF1 (Kim et al., 2014b). The highest PEG10 expression was detected in 
adrenal gland and some other fetal and adult tissues including placenta were scored as 
positive for PEG10 protein. In contrast, another, the Proteomics DB, included peptides 
derived from both ORF1 and ORF2 (Wilhelm et al., 2014). Despite discrepancies in the 
expression levels and expression patterns among the tissues tested in these databases, there 
was consensus that PEG10 protein is expressed in adrenal gland, brain, ovary, placenta and 
testis. Additionally, a recent RNA sequencing and immunohistochemistry study analysed 32 
tissue types representing all major tissues in humans with all data integrated into the Human 
Protein Atlas (Uhlen et al., 2015). In this study, PEG10 protein was found in four tissues 
(high in placenta, medium in adrenal gland, and low in bronchus and testis) consistent with 
the other two databases. While the Human Proteome Map and the Human Protein Atlas lack 
information about −1 frameshifting in PEG10 because peptides from and antibodies against 
only PEG10 ORF1 were used for detection, respectively, the Proteomics DB provided 
evidence of −1 frameshifting by detecting peptides from ORF2, although it was unclear in 
which tissue or tissues these were found. 
 
 
1.7 Aims of investigation 
 
 
Several classes of antiretroviral drugs have been developed to fight the debilitating effects of 
HIV-1 infection. With the emergence of strains of HIV-1 resistant to one or two of the drug 
classes in a combination therapy, novel drug targets are needed to expand the portfolio of 
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treatment options. The rare translational mechanism of −1 frameshifting has gathered 
significant attention as a potential drug target due to its critical involvement in viral 
replication and infectivity. For 10 years it looked to be an ideal drug target as no human gene 
was known to use the mechanism. However, the discoveries of human genes that also use −1 
frameshifting posed an important caution as to whether such a mechanism can be successfully 
used as a therapeutic target. Little is known about the importance of frameshifting for the 
function of these genes especially for PEG10, the first human example to be discovered (Ono 
et al., 2006), or CCR5, rigorously documented as my study was near completion (Belew et 
al., 2014). Frameshift mechanisms used by viruses and different genes could be so similar 
that targeting a viral mechanism would be difficult. On the other hand, the frameshift 
mechanism of human genes could have features that differ from their viral counterparts 
allowing specific drug development targeting the viral mechanism. Better understanding of 
PEG10 (and now CCR5) and the role of frameshifting in its expression and function are 
critical for this development.  
The aims of this project were to increase understanding of PEG10 expression, and its 
function in mammalian tissues: 
1. To investigate −1 frameshifting in PEG10 and in particular the role of the intercodon 
in the mechanism as a comparison to its role in HIV-1. 
2. To determine the expression profile of Peg10 mRNA in mammalian tissues utilising 
qPCR. 
3. To determine the expression profile of Peg10 protein in mammalian tissues, using an 
antibody specific to mPeg10 ORF1 protein. 
4. To evaluate whether the pattern of PEG10 tissue expression and the occurrence and 
mechanism of frameshifting in PEG10 is likely to compromise the development of 









Work involving the production of genetically modified E. coli was conducted with approval 
from the Environmental Risk Management Authority (ERMA, currently Environmental 
Protection Agency, EPA, GMO99/UO006, GMO00/UO049), and all work was done under 
PC1 conditions. All cell culture work was performed under PC2 conditions, and transient 
transfection of mammalian cells was done with approval from the EPA (GMO05/UO006). 
 All procedures were performed at room temperature unless specified. A complete list 






2.1.1 Plasmid isolation 
 
 
All bacterial cultures contained the appropriate antibiotic for retention of the plasmid. Plasmid 
DNA was extracted from either a 5 mL culture of E. coli DH5α grown in LB medium 
overnight at 37 °C, using a QIAprep® Spin Miniprep Kit (Qiagen), or a 100 mL culture, using 
a QIAGEN® Plasmid Maxi Kit (Qiagen) according to the kit instructions. Essentially, the 
bacteria were first isolated by centrifuging at ≥ 6 000 × g for 10 min, and the cells lysed at 
alkaline pH (supplied kit buffer P1 and P2). Cellular proteins as well as chromosomal DNA 
were then precipitated from the lysate in high salt buffer (supplied kit buffer N3), leaving the 
plasmid DNA in solution. This solution was then applied to the supplied column, and it was 
washed sequentially with the supplied buffer PB and PE. The plasmid DNA was finally eluted 




2.1.2 DNA quantitation 
 
 
Amounts of DNA in both plasmid DNA preparations and PCR products were quantitated 
using a NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies). The absorbance 
spectra (240–300 nm) were used to assess the purity of the samples, and to ensure the absence 
of impurities such as ethanol. 
 
 
2.1.3 Polymerase chain reaction (PCR) 
 
 
2.1.3.1 Generation of inserts for cloning 
 
 
The polymerase chain reaction (PCR) was used to amplify DNA sequences prior to cloning. 
Primers were designed to introduce restriction enzyme sites at both ends of the amplified 
products. The annealing specificity of the sequences of each primer was assessed using the 
Amplify 3.1 software (Engels, University of Wisconsin). The reaction included 10 ng of 
template DNA, 1× supplied PCR buffer, 1 µM of each primer, 200 µM dNTPs, 2 mM 
MgSO4, 1 U of Platinum® Taq DNA Polymerase (Life Technologies), and ddH2O for a 
reaction volume of 50 µL. All primers were purchased from Life Technologies (Table 2.1). A 
negative control (no DNA template) was included in every experiment. In a PTC-200 Peltier 
Thermal Cycler (MJ Research Inc.), the template DNAs were denatured at 95 °C for 5 min, 
then the reactions were given 30 cycles of denaturation (95 °C for 30 s), annealing (54 °C for 
30 s), and extension (68 °C for 80 s). Reactions were then heated to 72 °C for 5 min before 
cooling to 4 °C. The amplified DNA fragments were analysed by agarose gel electrophoresis. 
 
 
2.1.3.2 Touchdown PCR 
 
 
Touchdown PCR was performed to amplify the various types of frameshift elements for 
cloning because there were large differences between the melting temperatures of the forward 
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and reverse primers (Table 2.1). The reactions were prepared identically as for conventional 
PCR, but subjected to different conditions for the thermal cycles. The DNA was initially 
denatured at 94 °C for 3 min, reactions subjected to 18 cycles for the first amplification 
process involving denaturation (94 °C for 1 min), annealing (starting at 72 °C in the first cycle 
for 30 s), and extension (72 °C for 1 min). During these cycles, the annealing temperature was 
reduced by 1 °C per cycle. A second amplification step further amplified the DNA of interest 
with an additional 12 cycles, denaturation (94 °C for 1 min), annealing (54 °C for 30 s), and 
extension (72 °C for 1 min). The reactions were heated to 72 °C for 10 min and then cooled to 
4 °C. The PCR products were then fractionated on an agarose gel for analysis. 
 
 
Table 2.1: List of PCR primers 
Primer name Sequence (5´ to 3´) Tm (°C) 
mPeg10ORF1F cgcGGATCCgaacgcagacacgatgag 61 
mPeg10ORF1R1 attCTCGAGactacagcggggccggggagtttc 64 
mPeg10ORF1R2 cccAAGCTTactacagcggggccggggagtttc 61 
WildTypeF ataGAATTCtcaaagtcttcgccggcgggaaactcc 62 
FullF ataGAATTCtcaaagtcttcgccggcgttaatctccccggccccgctg 69 
NestedF ccggccccgctgttgagggaccttcag 64 
StopF ataGAATTCtcaaagtcttcgccggcgggaaactgaccggccccgctg 70 
−1 frameR atatatCCGCGGgggaccttattatttctgg 57 
0 frameR tatCCGCGGggggaccttgttctttctg 59 
Restriction sites are shown in capital letters and nucleotides that introduce mutations are shown in red. 
 
 
2.1.3.3 PCR for screening of transformant colonies 
 
 
PCR screening of transformant colonies was performed using the primer pairs and the thermal 
cycle programme that had been used to generate the inserts. Each colony was sampled using a 
pipette tip, touched to a new agar plate to create a master plate, and then a portion of the 
original colony was suspended in 6 µL LB. Half of the LB suspension was transferred to 10 
µL 0.5 % Tween® 20 solution, and the resulting solution was used for template DNA. The 
reaction contained 1 µL of template DNA, 1× PCR buffer without MgCl2, 200 nM of each 
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primer, 200 µM dNTPs, 2mM MgCl2, 0.5 U of Expand Taq polymerase (Roche Applied 
Science), and ddH2O to make the reaction volume to 10 µL. Once the programme was 
completed, the total reaction was analysed by agarose gel electrophoresis. 
 
 
2.1.4 Restriction endonuclease digestion for cloning 
 
 
PCR products and plasmids were digested with the same restriction enzyme(s) to create 
compatible ends for ligation. The reaction was prepared with 1 µg of DNA, 1× supplied 
buffer, and 1 U of restriction enzyme (Roche Applied Science) in a final volume of 10 µL, 
and digestion was ≥ 2 h at 37 °C. A digest with two restriction enzymes was carried out 
simultaneously when the same buffer was optimal for the activity of both enzymes. The 
digested DNA was then purified as described in Section 2.1.5.  
 
 




DNA fragments were purified using QIAquick® PCR Purification Kit (Qiagen) after either 
PCR or restriction digestion, essentially as described in the kit but with a minor modification. 
DNA samples in 30–50 µL were mixed with five volumes of the supplied buffer PB, applied 
to the column, washed with the supplied buffer PE, and the DNA was eluted with ddH2O (30 
µL). Columns had been pre-equilibrated with ddH2O for 10 min before elution began. 
 
 
2.1.6 Dephosphorylation of plasmid 
 
 
Where plasmids had been cut with two restriction endonucleases but still gave a high 
background with ligase alone implying only one site had been cut efficiently, they were 
dephosphorylated to prevent self-ligation in the absence of an insert. Linearised plasmid (0.5 
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µg) was mixed with 1× supplied buffer, 0.25 U of alkaline phosphatase (New England 
Biolabs), and ddH2O to a volume of 10 µL. The reaction was allowed to occur at 37 °C for 1 
h, and the plasmid was re-purified as described in Section 2.1.5. 
 
 
2.1.7 Agarose gel electrophoresis 
 
 
DNA samples were mixed with 1× agarose gel loading buffer containing dye and loaded onto 
1–3% (w/v) agarose gel in 0.5× TBE buffer containing 0.5 µg/mL ethidium bromide. 
Electrophoresis was at 90 V using a Bio-Rad Powerpac 300 (Bio-Rad laboratories Inc.) for 
40–90 min, or until the dye front travelled at least two thirds of the length of the gel. The 
DNA fragments were illuminated under UV light and gel images were taken using a GelDoc 
Imager (Bio-Rad Laboratories Inc.). 
 
 
2.1.8 Ligation of inserts into plasmid vectors 
 
 
The expression vectors and inserts (Table 2.2) were ligated using 1 U of T4 ligase DNA 
ligase (Roche Applied Science) with 1× supplied buffer in a total volume of 20 µL. Each 
reaction contained 20 ng of linearised plasmid with a plasmid to insert molar ratio of 1:5. 
Controls were included in each experiment and were set up as follows: (i) undigested plasmid 
alone to check the transformation efficiency of the competent cells, (ii) digested plasmid 
alone to test the amount of residual undigested plasmid in the digested sample, and (iii) 
digested plasmid with ligase to analyse the extent of ‘single-cut only’ molecules in the double 
digested sample. Reactions were incubated at 16 °C overnight and then transformed into E. 







Table 2.2: Plasmids and constructs 
Plasmid name Description and source 
pSP64T-Edr Edr (mPeg10) cDNA clone (Manktelow et al., 2005) 
pcDNA™3.1(+)-hPEG10 hPEG10 cDNA clone (Clark et al., 2007) 
pGEX-6P-3 Bacterial expression vector, N-terminal GST-tag (GE Healthcare) 
pMAL-c2 Bacterial expression vector, N-terminal MBP-tag (New England Biolabs) 
pGEX-ORF1 Edr ORF1 cloned into pGEX-6P-3 
pMAL-ORF1 Edr ORF1 cloned into pMAL-c2 
pGL3s-hRLuc Dual luciferase reporter (Mathew, 2008) 
pGL3s-hRLuc-WT Dual luciferase with wild-type frameshift elements 
pGL3s-hRLuc-Null Dual luciferase with mutated frameshift elements 
pGL3s-hRLuc-RT Dual luciferase with mutated frameshift elements in 0-frame 
pGL3s-hRLuc-Stop Dual luciferase with stop codon at intercodon position 
pcDNA™3.1(+) Mammalian expression vector (Life Technologies) 
pcDNA™3.1(+)-eRF1 eRF1 overexpression vector (Mathew, 2008) 
ptRNAser tRNASer expression (Le Goff et al., 1997) 
ptRNAam, op Suppressor tRNA expression (Le Goff et al., 1997) 
All plasmids had am ampicillin resistance marker for selection. 
 
 
2.1.9 Preparation of competent E. coli cells 
 
 
Ultra competent E. coli DH5α cells (Table 2.3) were prepared for transformation of the 
ligated plasmid DNA. To prepare a starting culture, a colony was inoculated into 3 mL LB, 
and grown at 37 °C with 200 rpm shaking overnight. The starter culture was then transferred 
to 300 mL LB the next day, and incubated at 18 °C with shaking until the OD600 reached 0.6. 
The culture was chilled on ice for 10 min and then centrifuged at 6 000 × g at 4 °C for 10 min. 
Cells were washed in 24 mL of sterile, ice-cold TB and centrifuged again to pellet the cells. 
After resuspending the pellet in an equal volume of TB, 1.8 mL of chilled DMSO was added 
drop-wise, and after mixing the cells were then chilled on ice for 10 min. Cells were 
aliquoted, snap-frozen on dry ice, and then stored at −80 °C. 
 For competent E. coli Rosetta 2 (DE3) cells (Table 2.3), a single colony was picked 
from an agar plate, inoculated into 1 mL LB broth containing 30 µg/mL chloramphenicol and 
incubated at 37 °C with shaking overnight. The starter culture was then seeded into 100 mL 
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LB with chloramphenicol and grown at 37 °C with shaking until the OD600 reached 0.6. After 
cooling on ice for 15 min, the culture was centrifuged at 6 000 × g at 4 °C for 10 min. Cells 
were washed in 10 mL of cold 100 mM CaCl2, and then chilled on ice for 15 min before being 
centrifuged as before. Cells were resuspended in 3.75 mL of a mixed solution (2.5 mL of 100 
mM CaCl2 and 1.25 mL of sterile 60% (v/v) glycerol). The cell suspension was then split into 
aliquots, snap-frozen on dry ice, and stored at −80 °C. 
 
 
Table 2.3: E. coli strains 
Name Genotype 
DH5α F
-, ϕ80lacZΔM15, Δ(lacZYA-argF), U169, endA1, recA1, hsdR17(rκ-mκ+), deoR, thi-
1, phoA, supE44, λ-, gyrA96, relA1 
Rosetta 2 (DE3) F-, ompT, hdsBB(rB-mB-), gal, dcm (DE3), pRARE (CmR) 
 
 
2.1.10 Transformation of E. coli 
 
 
A sample of competent E. coli cells was slowly thawed on ice and split into 100 µL aliquots. 
The total ligation reaction, or 30 ng of plasmid alone, was added to the cells and chilled on ice 
for 15 min. The mixture was then heat-shocked at 42 °C for 45 s in a water bath and chilled 
on ice for at least 1 min, before plating onto an agar plate with the appropriate selective 
antibiotic. The agar plate was incubated at 37 °C overnight and then kept at 4 °C. 
 
 
2.1.11 DNA sequencing 
 
 
The cloned DNA was sent to the Department of Anatomy, University of Otago for 
sequencing. Reactions contained 150 ng of DNA with 3.2 pmol of either forward or reverse 
sequencing primer (Table 2.4) in 5 µL. Each cloned DNA was sequenced from both directions 
to ascertain the integrity of the cloned DNA. High quality sequences were manually selected 
in the 4Peaks software (Nucleobytes Inc.) and compared against the reference sequence using 
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Table 2.4: List of vector-specific sequencing primers 
Primer name Sequence (5´ to 3´) 
pGEX-6P-3 Seq F gggctggcaagccacgtttggtg 
pGEX-6P-3 Seq R ccgggagctgcatgtgtcagagg 
pMAL-c2 Seq F tgcgtactgcggtgatcaac 
pMAL-c2 Seq R caagctgccattcgccattc 
pGL3s-hRLuc Seq ggacgctccagatgaaatgggtaag 






All the equipment and reagents used were RNase-free as RNA is very sensitive to 
degradation. RNase-free water was prepared by treating ddH2O with 0.01% (v/v) of 
diethylpyrocarbonate (DEPC) for at least 1 h, then autoclaved at 121 °C for 20 min at 15 psi. 
Disposable plasticware used, including pipette tips, were certified to be nuclease-free by the 
supplier, or treated with 0.5 M NaOH for 10 min and rinsed four times with DEPC-treated 
ddH2O. Glassware was wrapped with tinfoil and baked at 200 °C for 4 h. Separate stocks of 
chemicals were kept specifically for RNA, and solutions were prepared using DEPC-treated 
ddH2O and baked glassware. 
 
 
2.2.1 Isolation of RNA 
 
 
To extract high quality RNA from an animal tissue, it is important to disrupt the tissue 
without thawing. To do this, animal tissues were ground in liquid nitrogen using a baked 
mortar and pestle. Typically tissues were ground for 5 min with frequent topping up of the 
liquid nitrogen. There were two different methods employed in this study. One of which 
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(Section 2.2.1.1) was simpler and better suited for isolation of large sized RNA, and the other 




2.2.1.1 Total RNA extraction using the TRIzol® Reagent 
 
 
After grinding a tissue under liquid nitrogen to a fine powder, TRIzol® Reagent (1 mL per 
100 mg of tissue) was added, and transferred to a 1.5 mL microcentrifuge tube. The mixture 
was thoroughly homogenised by passing it at least 10 times through a 21G × 1½ thin wall 
needle (BD) attached to a 3 mL syringe (Covidien). After 5 min incubation, chloroform (0.2 
mL per 1 mL of TRIzol®) was added, and the mixture was shaken vigorously by hand for 
approximately 15 s. The mixture was incubated for 3 min, and then centrifuged at 12 000 × g 
at 4 °C for 15 min. The aqueous phase was transferred to a new microcentrifuge tube and 
mixed with isopropanol (0.5 mL per 1 mL of TRIzol®) by inversion. RNA was allowed to 
precipitate for 10 min and then centrifuged to pellet at 12 000 × g at 4 °C for 10 min. The 
RNA pellet was washed with 75% ethanol (1 mL per 1 mL of TRIzol®) by brief vortexing, 
and centrifuged at 7 500 × g at 4 °C for 5 min. The RNA pellet was carefully dried and 
resuspended in 50 µL DEPC-treated ddH2O. To aid complete dissolution, the RNA solution 
was incubated at 55 °C for 10 min. Purity of the extracted RNA was assessed using a RNA-40 
mode in a NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies). The RNA was 
split into 10 µL aliquots (to minimise RNA degradation during freeze/thaw cycles) before 
storing at −80 °C. 
 
 




To preserve tissue samples for protein extraction (Section 2.4.4), most tissue powder was 
quickly transferred to a 15 mL conical tube following tissue grinding and stored at −80 °C 
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until required. The remaining samples were used for RNA isolation using TRIzol® Reagent 
similar to Section 2.2.1.1. After the separation of three phases, the aqueous phase was 
carefully transferred to a new microcentrifuge tube without disturbing other phases to avoid 
contamination, and mixed with equal volume of 70% ethanol. Total RNA, including small 
RNA species, was isolated from the mixture using the Total RNA purification kit (Norgen 
Biotek Corp.). The mixture was applied to a column and centrifuged at 14 000 × g for 1 min. 
After washing the column and centrifuging at 14 000 × g for 2 min, 80 µL of DNase I mix (10 
µL DNase I and 70 µL RDD, Qiagen) was added to the column, and centrifuged at 14 000 × g 
for 1 min. The flow-through was re-applied to the column, and incubated for 15 min. The 
column was then washed twice to remove any contaminants before elution. RNA was eluted 
successfully from the column 2–3 times with 30–50 µL of elution buffer by centrifuging at 
200 × g for 2 min, and then at 14 000 × g for 1 min. Following purity assessment by 
NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies), the samples were 
separated into several 10 µL aliquots and stored at −80 °C. 
 
 
2.2.2 RNA quantitation 
 
 
All RNA samples were quantified using a Qubit® RNA BR assay and a Qubit® fluorometer 
(Life Technology). The reagent was diluted 1 in 200 with the supplied buffer. Reactions 
contained 1 µL of RNA sample or 10 µL of the standard, and the diluted reagent to a volume 
of 200 µL. After 2 min incubation, a Qubit® fluorometer was calibrated with the standards, 
and then RNA samples were assayed. 
 
 
2.2.3 Deoxyribonuclease (DNase) I treatment 
 
 
To ensure that the RNA samples prepared in Section 2.2.1.1 were free of any contaminating 
DNA, these samples were treated with DNase I (Life Technologies). Reactions contained 1 
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µg of RNA, 1× supplied buffer, 1 U of DNase I, and DEPC-treated ddH2O to a volume of 10 
µL. Digestion was allowed for 15 min, and the DNase I inactivated by adding 1 µL of 25 mM 
EDTA and heating at 65 °C for 10 min.  
 
 
2.2.4 RNA quality assessment 
 
 
2.2.4.1 Formaldehyde gel electrophoresis 
 
 
Gels were prepared by adding 1.2% (w/v) agarose to 1× FA gel buffer, and melted by heating 
in a microwave. Once the gel solution had cooled, formaldehyde and ethidium bromide were 
added to make final concentrations of 1.7% (v/v) and 0.5 µg/mL respectively. After the gel 
had set, it was equilibrated with 1× FA running buffer for at least 30 min. RNA samples (1 µg 
of DNase I treated total RNA) were made up to a volume of 18 µL with RNA loading buffer, 
then heated to 65 °C for 10 min in a PTC-200 Peltier Thermal Cycler (MJ Research Inc). 
RNA samples were briefly cooled on ice and immediately loaded onto the gel. The gel was 
run at constant voltage of 40 V using a Bio-Rad Powerpac 300 (Bio-Rad Laboratories Inc.) 
for 90 min or until the dye front migrated two thirds down the gel. The separated RNA was 







A Bioanalyzer offers several advantages over formaldehyde gel electrophoresis, such as 
higher sensitivity and smaller sample requirement. For samples with low RNA concentration, 
1 µL of RNA sample was applied to the RNA 6000 Nano chip (Agilent Technologies) after 
heating at 70 °C for 2 min to disrupt the RNA secondary structure. The chip was vortexed 
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with a MS3 vortexer (IKA®) at 2 400 rpm for 60 s, loaded onto an Agilent 2100 Bioanalyzer 
(Agilent Technologies), and then assayed using the Eukaryote Total RNA Nano programme.  
 
 
2.2.5 Reverse transcription of RNA 
 
 
RNA quantitation was repeated immediately before this step to ensure that the RNA 
concentration had not been affected by freeze/thaw cycles. The DNase I treated RNA (400 
ng) was mixed with 250 ng of random primers (Life Technologies), 1 µL of 10 mM dNTP 
mix (Life Technologies), and DEPC-treated ddH2O to a volume of 13 µL. The mixture was 
heated at 65 °C for 5 min, and then chilled on ice for at least 1 min.  After brief 
centrifugation, the following reagents were added to the reactions: 4 µL of 5× supplied First-
strand buffer, 1µL of 0.1 M DTT, 1 µL of 40 U/µL RNaseOUT™ (Life Technologies), and 1 
µL of 200 U/µL Superscript®III Reverse Transcriptase (Life Technologies).  Following a 5 
min incubation, reverse transcription was carried out by incubating at 50 °C for 60 min, and 
then terminated by heating at 70 °C for 15 min. 
 
 
2.2.6 Quantitative real time PCR 
 
 
2.2.6.1 Gene expression assay using SYBR Green technology 
 
 
All reagents and cDNAs were allowed to equilibrate to room temperature prior to pipetting. 
The prepared cDNA was diluted 30-fold immediately prior to the assay. Each reaction mix 
contained 3 µL of the diluted cDNA along with 500 nM primers as well as 1× Roche SYBR 
Green I master mix (a mixture of FastStart Taq DNA polymerase, reaction buffer, dNTP, 
SYBR Green I dye, and MgCl2) (Roche Applied Science). All primers were purchased from 
Life Technologies (Table 2.5 and Table 2.6). The final reaction volume was made to 10 µL 
with the PCR-grade H2O. Each cDNA-gene combination was replicated three times on a plate 
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(technical triplicates). The prepared plate was vortexed on a MixMate® (Eppendorf) at 2 600 
rpm for 15 s, and then centrifuged at 1 500 × g for 2 min. In a Roche LightCycler® 480, the 
reactions were heated to 95 °C for 5 min to activate the DNA polymerase, followed by 45 
cycles of amplification process involving denaturation (95 °C for 5 s), annealing (58 °C for 5 
s), and extension (72 °C for 8 s). The fluorescence level was measured during every extension 
period. For a melting curve analysis, the reactions were heated to 95 °C for 30 s, and then 
cooled down to 65 °C for 5 s. A decrease in fluorescence level was continuously monitored 
while the temperature was slowly raised to 95 °C. 
 
 
2.2.6.2 Reference gene selection 
 
 
In addition to the commonly used reference genes, other potential candidate genes were 
searched using the RefGenes in the Genevestigator online search engine (Hruz et al., 2008; 
Hruz et al., 2011). Primers were designed using Primer-BLAST with the following criteria: 
amplicon size was between 100 and 200 bp, primer length was 18–22 nucleotides with a GC 
content of 40–60%, and primers had to bind either two separate exons with an intron larger 
than 250 bp or the primers would span the boundaries of the two exons. Formation of primer 
dimers and hairpins were assessed using Beacon Designer software (Premier Biosoft 
International). 
To find the most suitable reference genes for this work, candidate genes were screened 
for their expressions across all tissue types involved in this study. The number of technical 
replicates was reduced to two in order to analyse all candidate genes on a single plate. 
Screening was repeated using cDNAs derived from animals of different genders to eliminate a 






Table 2.5: Primers for qRT-PCR (Rat) 
Primer name Sequence (5´ to 3´)  Primer name Sequence (5´ to 3´) 
Cyc-1F accgcaggcagtgtccttgt  Rpl13aF gatgaacaccaacccgtctc 
Cyc-1R tggcactcaccgccgaatga  Rpl13aR accaccatccgctttttcttg 
HmbsF cttgccagagaaaagtgccg  TbpF tccagtgccaagtgtgagcct 
HmbsR cagctcatccagcttccgta  TbpR tgtggggacaaaacgagcagcc 
HprtF gcagacgttctagtcctgtggc  YwhazF tgaactccccagagaaagcc 
HprtR agggacgcagcaacagacattt YwhazR tccgatgtccacaatgtcaag 
Hsp90ab1F actactcggctttctcgtcaa  Peg10CDSF ggagttccctgaagagatcg 
Hsp90ab1R tccagggcatcagaagcatta  Peg10CDSR aggaaactgtagctctgtgc 
Pgk1F atcataggaggcggagacac  Peg10 3´UTRF gggcatctgtacggtgcagtct 
Pgk1R acaggaaccaaaggcaggaa  Peg10 3´UTRR tggtcaggtctctccgacagga 
 
 
Table 2.6: Primers for qRT-PCR (Mouse) 
Primer name Sequence (5´ to 3´)  Primer name Sequence (5´ to 3´) 
B2mF agtcgtcagcatggctcgct  PpihF agaatgttcccacaggcccca 
B2mR tgaggcgggtggaactgtgt  PpihR agcagaggacctggttccgt 
Bet1lF agagagaacaagcggatggc  Rplp0F agatccgcatgtcgctccga 
Bet1lR ctgagtccatgccgtctaagt  Rplp0R tgaacacgaagcccacgttccc 
Ccdc71F aagcggaagcacggtgtact  Tfip11F ggcattcagaaagactgcaacc 
Ccdc71R gcctgggtatccacaaacca  Tfip11R acaagtgggacagagacatgg 
Elac2F tgcccatctgtgagaacgac  UbcF tcgagcccagtgttaccaccaa 
Elac2R ccgaacctctccatccactg  UbcR acctcccccatcacacccaaga 
Hsp90ab1F tcggctttcccgtcaagatgc  Wdr33F tagccagcagccaatcaagt 
Hsp90ab1R atgagggacatgagctgggca  Wdr33R acagagatggtcccgagagg 
HprtF ttctgagccattgctgaggcgg  Peg10CDSF agcagccaaccgagaaggtcca 
HprtR tcgctaatcacgacgctggga  Peg10CDSR aacccgcctgttccacacga 
Ipo8F ctggcagcagggcagtttcaca Peg103´UTRF tgcagagggcctagcaatgggt 
Ipo8R actaagcagcagcggtgacg  Peg103´UTRR ttcaccgtcccctgtgagctgt 
Poldip3F aaccaccaggctaaacagaact  
Poldip3R acttttgtgagagggagggc    
 
 
2.2.6.3 Calculation of PCR efficiency 
 
 
PCR efficiency has been traditionally calculated using the standard curve method. This 
method requires a large number of wells for every run because each gene needs a separate 
standard curve and each dilution needs to be at least duplicated. To analyse a larger number of 
samples in each run, the PCR efficiency was separately calculated for each sample using the 
LinReg software (Ramakers et al., 2003) based on the fluorescence level. The calculated PCR 
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efficiencies were then averaged across all cDNA, including technical triplicates, for a 
particular gene within a single run. 
 
 
2.2.6.4 Calculation of fold change in gene expression 
 
 
Gene expression changes were calculated using formulae described in Hellemans et al. (2007) 
(Appendix II). Briefly, reference values for each gene within a single run were calculated by 
taking the average of ‘quantification cycles’ (Cq) for all cDNA analysed. The Cq of three 
technical replicates was averaged and subtracted from the reference value to obtain ΔCq. The 
relative quantity (RQ) of mRNA was calculated by using the averaged PCR efficiency to the 
power of the ΔCq. As a normalisation step, all RQ values were divided by a normalisation 
factor that was the geometric mean of the RQ of the three selected reference genes. Inter-run 
calibration was performed to convert the normalised RQ (NRQ) values into calibrated NRQ 
(CNRQ), which allowed comparisons of data between separate runs. The inter-run calibration 
process was analogous to normalisation but the calibration factor was a geometric mean of the 
NRQ values of the inter-run calibrators (IRCs). All biological replicates were separately 
calculated up to this step, and finally averaged by taking a geometric mean of the CNRQ 
values. Levels of significance were tested using two-tailed paired Student’s t-tests. 
 Two different parameters were calculated as quality control measures, a coefficient of 
variation (CV) and a stability parameter (M). Both of these parameters indicate how stable the 
expressions of the reference genes are among the analysed samples and the IRCs are among 
the separate runs. For the CV of each reference gene, the average NRQ value for all cDNAs 
analysed was first calculated along with the standard deviation (SD). The CV for each 
reference gene was then determined by dividing the SD by the averaged NRQ, and the CV for 
all reference genes was taken as the average of three CV values. The stability parameter (M) 
was determined in a pair-wise manner and calculated for both reference genes and IRCs. For 
reference genes, the log2-transformed ratio of RQs of two reference genes was determined for 
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all samples, then averaged and its SD calculated. The SDs of all pair-wise analyses for a given 
reference gene were averaged to determine the M value for the gene. Finally, M values for 
each gene were averaged to give the M value for all reference genes. For IRCs, calculations 
were similar to those of reference genes; however, the log2-transformed ratio of NRQs of two 
IRCs was calculated for each gene at the first step instead. 
 
 
2.3 Mammalian cell culture 
 
 
Sterilised plasticware and solutions were used for all cell culture work to prevent 
contamination of cultured cells. Solutions were sterilised by autoclaving, and used exclusively 
for cell culture work. All cell culture involved a HEK 293T/17 cell line (a human embryonic 
kidney cell line), purchased from the American Type Culture Collection (ATCC), and 
manipulations took place in a Labculture® Class II Type A2 Biological Safety Cabinet 
(ESCO) under PC2 conditions. Cells were typically grown in 10 mL of Dulbecco’s Modified 
Eagle Medium (DMEM) containing 25 mM glucose, 4 mM L-glutamine, phenol red, and 1 
mM sodium pyruvate (Life Technologies) supplemented with 10% (v/v) fetal bovine serum 
(FBS) (Life Technologies) in 250 mL flasks with filtered caps (Greiner Bio-One). Flasks were 
kept in a Model 371 Forma™ Steri-Cycle™ CO2 incubator (Thermo Fisher Scientific) at 37 °C 
with 5% (v/v) CO2 and 95% (v/v) humidity. An Olympus CK40 microscope was frequently 
used to check cell growth as well as for any signs of bacterial or fungal contamination. 
 
 
2.3.1 Seeding of frozen cells 
 
 
Frozen cells were removed from liquid nitrogen storage, thawed in a water bath at 37 °C, and 
mixed with 5 mL DMEM in a 15 mL conical tube. After centrifuging at 165 × g for 5 min and 
removal of the supernatant, cells were resuspended in 10 mL DMEM, transferred to a 250 mL 
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flask, and grown in the incubator described above. Cells were passaged at least twice at 80% 
confluency before being used for any experiments. 
 
 
2.3.2 Passaging of cells 
 
 
The cells were assessed by microscopic examination until they had reached approximately 
80% confluency. The growth medium was then removed by aspiration, and the cells were 
washed with 5 mL PBS-EDTA. The cells were then detached from the flask by incubating 
with 2 mL of 0.05% (w/v) trypsin (Life Technologies) at 37 °C for approximately 10 min 
with occasional agitation. After adding 5 mL DMEM to inhibit proteolysis, and transfer into a 
15 mL conical tube, cells were centrifuged at 165 × g for 5 min and the supernatant removed. 
The cells were resuspended in 10 mL DMEM, and typically 1 mL was transferred to a flask 
containing 9 mL DMEM. The volume of the resuspended cells was adjusted based on the cell 
growth required for experiments. Cells were passaged a maximum of 12 times before a new 
culture was initiated from frozen cells. 
 
 
2.3.3 Storage of cells 
 
 
Cells were grown to 80% confluency and passaged as described in Section 2.3.2. The cell 
pellet was resuspended in 5 mL freezing medium (90% FBS + 10% DMSO). Aliquots (1 mL) 
were transferred into 1.8 mL Nunc™ CryoTube™ vials (Thermo Fisher Scientific Inc). The 
vials were then placed in a NALGENE™ Cryo 1 °C Freezing Container and stored at −80 °C 







2.3.4 Seeding of cells into 24-well plates 
 
 
Cells (80% confluency) were passaged (Section 2.3.2), and the cell pellet resuspended in 5 
mL DMEM. The cell suspension (20 µL) was diluted 1 in 2 with DMEM, the number of cells 
counted using a hemocytometer (Weber Scientific International Ltd), and the concentration 
then adjusted to 4 × 105 cells per mL using DMEM. The diluted cell suspension was mixed by 
inversion before and during seeding 24-well plates with 4 × 104 cells per well to ensure even 
dispersion of cells. DMEM (900 µL) was added to each well, and the plates were gently 
agitated to achieve even distribution of cells within each well. The seeded plates were then 
placed in an incubator until cells were grown to approximately 60% confluency. 
 
 
2.3.5 Transfection of DNA 
 
 
Cells were transfected with plasmid DNA (250 ng of dual luciferase constructs along with 1 
µg of pcDNA™3.1(+) constructs) using FuGENE® 6 Transfection Reagent (Roche Applied 
Science) once the desired confluency (approximately 60%) was reached. The plasmid DNA 
was diluted in a 1.5 mL microcentrifuge tube to a final volume of 20 µL per well with ddH2O. 
The FuGENE® 6 Transfection Reagent was used in a ratio of 3:1 (3 µL of the reagent to 1 µg 
of plasmid DNA), and diluted with serum-free DMEM to 100 µL per well. After incubating 
for 5 min, the diluted FuGENE® 6 Transfection Reagent was added to the DNA drop-wise, 
mixed by tapping the tube, and then incubated for 15 min. The FuGENE®-DNA mixture (115 
µL per well) was added to each well drop-wise, and the plates were incubated at 37 °C for 2 d 









2.3.6 Harvesting of cells 
 
 
Cells transfected with plasmid DNA were harvested using passive lysis buffer (Promega 
Corporation) in preparation for the luciferase assay. After first removing the growth medium 
by aspiration, cells were carefully washed twice with 200 µL PBS. Passive lysis buffer (100 
µL per well) was then added, incubated for 15 min with vigorous rocking, and the resulting 
cell lysates were transferred to 0.6 mL microcentrifuge tubes. After centrifuging at 17 000 × g 
for 1 min, supernatants were transferred to fresh tubes. Small aliquots of each lysate (3–5 µL) 






2.4.1 Recombinant protein expression 
 
 
2.4.1.1 Small-scale induction 
 
 
The E. coli Rosetta 2 (DE3) cells were grown in 1 mL LB medium with 100 µg/mL ampicillin 
and 30 µg/mL chloramphenicol overnight with orbital shaking. The next day the overnight 
culture was added to 9 mL LB medium containing 100 µg/mL ampicillin and 30 µg/mL 
chloramphenicol, and incubated at 37 °C with shaking until the culture reached the OD600 of 
0.4–0.6. The OD600 of the culture was measured using an Ultrospec II (LKB Biochrom Ltd.). 
A final concentration of 1 mM IPTG was then added to induce the expression of protein after 
taking a pre-induction sample (1 mL) and measuring the OD600. The culture was incubated as 
before, and protein expression was continued for 3 h at 37 °C. Post-induction samples were 
collected every hour along with the OD600 measurement. All samples collected were kept on 
ice until processed. After centrifuging at 17 000 × g for 1 min, the cell pellet was resuspended 
in OD600 × 100 µL of protein loading buffer and stored at −20 °C until required. 
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2.4.1.2 Large-scale induction 
 
 
Large-scale inductions were performed as described in Section 2.4.1.1 with a few 
modifications. The volumes of overnight culture and growth medium were increased 100-fold 
to obtain larger amounts of the recombinant protein. Following 3 h of expression, the culture 
was cooled on ice for at least 30 min, and then centrifuged at 6 000 × g at 4 °C for 10 min. 
 
 
2.4.2 Protein purification using a glutathione column 
 
 
The E. coli cell pellet was resuspended in 40 mL of PBS with 2 mM DTT, and 0.5% (v/v) 
Triton™ X-100. The E. coli cells were sonicated for 30 s × 20 cycles (35% output) with 1 min 
cooling intervals after every 2 cycles using a Sonics Vibra-Cell VCX 500 (Sonics and 
Materials Inc.). The suspension was kept on ice at all times to prevent damage from heating. 
The lysate was centrifuged at 12 000 × g at 4 °C for 15 min to remove insoluble material 
before purification utilising the GST of the fusion protein and using glutathione Sepharose 4B 
resin (GE Healthcare) in an Econo-Column® Chromatography column (2.5 × 10 cm, Bio-Rad 
Laboratories Inc.). The resin was prepared by transferring 5 mL 50% slurry containing 20% 
(v/v) ethanol into a column, drained by gravity, and washed with five column volumes of PBS 
before sample application. After mixing the soluble protein fraction with the resin, both ends 
of the column were sealed, and placed on a rotating wheel at 4 °C overnight to facilitate 
binding of recombinant GST-protein to the glutathione resin. The next day, the column was 
held upright, and the resin was left to settle for 5 min at room temperature. After collecting 
the flow-through, the column was washed with three column volumes of PBS. Elution was 
performed three times with 10 mL, 10 mL, and 5 mL of PBS containing 50 mM reduced 
glutathione (pH 7.4). The column was incubated for 10 min before collecting each elution. 
The eluted fusion protein was stored at −80 °C until required. Samples were collected at each 
step during the procedure, and stored at −20 °C until analysed by SDS-PAGE.  
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To regenerate the column, 5 mL of 6 M guanidine hydrochloride was applied to the 
column, incubated for 15 min, and then the column was drained by gravity. This process was 
repeated twice, and then the column was washed with one column volume of PBS, 70% 
ethanol, and PBS. The column then received three bed volumes of alkaline  (0.1 M Tris-HCl 
+ 0.5 M NaCl, pH 8.5) and acidic (0.1 M NaOAc + 0.5 M NaCl, pH 4.5) washes for three 




2.4.3 Protein concentration 
 
 
2.4.3.1 Ammonium sulphate precipitation 
 
 
Ammonium sulphate crystals were slowly added to the protein solution at 4 °C over a 30 min 
period with magnetic stirring aiding dissolution. The solution was left for another 30 min to 
allow precipitation of the protein before centrifuging to pellet the protein at 10 000 × g at 4 °C 
for 10 min. The protein pellet was immediately resuspended and dissolved in a desired buffer, 






Protein solution was transferred to a dialysis tube and then placed in a buffer ≥ 500 times 
larger than the volume of the protein sample, with magnetic stirring to aid the diffusion. 
Samples were dialysed at 4 °C first for 2 h, with a buffer change for a further 2 h, and then 
overnight after a further buffer change. Once the dialysis was completed, the sample was 





2.4.3.3 Acetone precipitation 
 
 
To increase the protein concentration for SDS-PAGE analysis, four volumes of acetone 
(chilled at −20 °C) were added to the protein sample and mixed by vortexing. The mixture 
was left at −20 °C for 1 h with occasional vortexing. The protein was pelleted by centrifuging 
at 17 000 × g at 4 °C for 30 min, and the supernatant was discarded. The protein pellet was 
air-dried and resuspended in 18 µL of protein loading buffer (see Appendix I). 
 
 
2.4.4 Protein extraction from animal tissues 
 
 
Tissue samples were removed from −80 °C storage, weighed, and extraction buffer added (1 
mL of buffer per 100 mg of tissue). Proteins were extracted from animal tissues with a Sonics 
Vibra-Cell VCX 500 (Sonics and Materials Inc.). To ensure complete disruption, samples 
were sonicated for 6 x 1 min (35% output) with 1 min intervals between each cycle or until 
the lysate became clear of any particulate matter. To ensure that the samples remained cold 
during the procedure, intervals of 1 min cooling occurred between each sonication cycle. 
Insoluble material was removed by centrifugation at 17 000 × g at 4 °C for 30 min. The 
supernatant was aliquoted into microcentrifuge tubes before storage at −80 °C. 
 
 
2.4.5 Protein quantitation 
 
 
Protein concentration was determined using the Qubit® Protein assay with a Qubit® 
fluorometer (Life Technology). Reactions contained 1 µL of undiluted protein sample or 10 
µL of the standard, and 1 in 200 dilution of the reagent (diluted with supplied buffer) to make 
a final volume of 200 µL. The protein samples prepared above (Section 2.4.4) were diluted 1 
in 5 with PBS to minimise interference from Triton™ X-100, and protein standards were 
prepared with the same PBS concentration for better accuracy. The reactions were incubated 
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for 15 min. The Qubit® fluorometer was calibrated using the prepared standards, then the 






Protein samples were analysed by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) using Kolbe buffer with the Mini-PROTEAN 3 system (Bio-
Rad Laboratories Inc.). In this study, gels were prepared with buffers lacking SDS to increase 
the sharpness of protein bands. SDS was still included in the inner running buffer and the 
protein loading buffer. Polyacrylamide concentrations were 12.5% (w/v) and 4% (w/v) for 
separating gels and stacking gels, respectively. Protein samples were heated at 94 °C for 5 
min before loading. For each gel, 7.5 µL of diluted broad range molecular weight markers 
(Bio-Rad Laboratories Inc.) (1 in 20 with protein loading buffer) were also loaded to estimate 
the sizes of the proteins of interest. Gels were run at 100 V for 25 min, and then at 200 V for 
1.3 h using a Model 200/2.0 Power Supply (Bio-Rad Laboratories Inc.). After electrophoresis, 




2.4.7 Coomassie staining of polyacrylamide gels 
 
 
On completion of SDS-PAGE, polyacrylamide gels were soaked in fixing solution for at least 
15 min to remove SDS, and then stained with Coomassie R-250 for 1 h with gentle agitation. 
The gels were destained for 1 h with several changes of fixing solution, and left overnight in 







2.4.8 Zinc staining of polyacrylamide gels 
 
 
Gels were stained with zinc only if the protein was to be electroeluted from the gels (Section 
2.6.3.1). Zinc staining reveals the location of protein bands without fixing proteins in gels. 
This was an important modification to improve the elution efficiency of proteins from gels. 
Gels were soaked in 0.2 M imidazole with 0.1% (w/v) SDS for 10 min with gentle agitation, 
and then stained in 0.3 M ZnCl2 solution for approximately 30 s. Development of an opaque 
background was monitored by eye against a dark background, and gels were rinsed 
thoroughly with dH2O to stop the reaction. 
 
 
2.4.9 Western transfer 
 
 
Proteins were immediately transferred to a nitrocellulose membrane (GE Healthcare) with the 
Mini Trans-Blot system (Bio-Rad Laboratories Inc.) after SDS-PAGE. Gels were separately 
equilibrated with transfer buffer for 5 min, and a Whatman™ Protran 0.45 µm pore size 
nitrocellulose membrane (GE Healthcare) and four pieces of Grade 3MM CHR blotting paper 
(GE Healthcare) were pre-soaked in transfer buffer for at least 10 min. These were assembled 
in a cassette according to the manufacturer’s instructions. Transfer was carried out at 100 V 
for 2 h using a Model 200/2.0 Power Supply (Bio-Rad Laboratories Inc.). An ice pack and a 
small magnetic stirrer bar were included in the transfer tank which was packed in ice, and 
then placed on a magnetic stirrer. After transfer, proteins were stained in Ponceau S for 5 min 
with gentle agitation, and destained with dH2O until the red protein marker bands were 
visible. The positions of the marker bands were marked with a pencil, and the membrane was 
washed in dH2O to remove the staining completely. The membrane was either immediately 








Membranes were blocked in 5% (w/v) skim milk powder in 1× TBST for ≥ 1 h with gentle 
rocking, and then the membranes were incubated with primary antibody solution (Table 2.7) 
typically in a volume of 10 mL with 0.05% (w/v) sodium azide overnight. The next day, the 
membranes were extensively washed with dH2O, and then with 5% (w/v) skim milk powder 
in 1× TBST. The membranes were incubated with secondary antibody solution (Table 2.7) for 
90 min with gentle rocking. The membranes were washed thoroughly and kept in dH2O until 
detection. 
 For simultaneous detection of eRF1 and actin protein, the membrane was incubated 
with anti-eRF1 antibody at 4 °C overnight with gentle rocking after blocking as normal. After 
the membrane received three 5 min washes with 2% (w/v) skim milk powder in 1× TBST the 
following day, anti-actin antibody was applied to the membrane at 4 °C for 1 h with gentle 
rocking, and then washed three times with 5% (w/v) skim milk powder in 1× TBST for 5 min. 
The secondary antibody was applied as described above. 
 The chemiluminescent reagent used in this study was prepared according to Haan and 
Behrmann (2007), and it contained a final concentration of 100 mM Tris-HCl (pH 8.8), 1.25 
mM luminol, 2 mM 4-iodiphenylboronic acid (4-IPBA), and 5.3 mM H2O2. This reagent (2 
mL per membrane) was applied to membranes, and then developed in a FujiFilm LAS-3000 
with the standard sensitivity setting, unless specified.  
 
 
2.4.11 Mass spectrometry 
 
 
Mass spectrometry was performed by the Centre for Protein Research at the University of 
Otago using a LTQ-Orbitrap hybrid mass spectrometer. Protein samples were fractionated on 
a polyacrylamide gel and stained with Coomassie. The protein band of interest was excised, 
 68 
digested with trypsin, and then eluted from the gel. Both the Mascot (Matrix Science Inc.) and 
the SEQUEST (Thermo Fisher Scientific Inc.) were used for peptide identification. 
 
 
Table 2.7: Antibodies used in this study 
Antibody Dilution Solution Source 
Primary antibodies       
Rabbit anti-mPeg10ORF1 1:1 000 5% (w/v) smp Shimaki (2008) 
Goat anti-GST 1:1 000 5% (w/v) smp GE Healthcare 
Rabbit anti-MBP 1:1 000 5% (w/v) smp Santa Cruz Biotechnology Inc. 
Rabbit anti-eRF1 1:10 000 5% (w/v) BSA Janzen and Geballe (2004) 
Rabbit anti-actin (22–33) 1:5 000 2% (w/v) smp Sigma-Aldrich Corp. 
Rabbit anti-mPeg10ORF1 
(99–115) 1:1 000 5% (w/v) smp This study 
Rabbit anti-hmPEG10ORF1 
(160-174) 1:1 000 5% (w/v) smp This study 
Rabbit anti-mPeg10ORF2 
(545–557) 1:1 000 5% (w/v) smp This study 
Rabbit anti-hmPEG10ORF2 
(347–360) 1:1 000 5% (w/v) smp This study 
    
Secondary antibodies    
anti-rabbit HRP 1:10 000 5% (w/v) smp Thermo Fisher Scientific 
anti-goat HRP 1:5 000 5% (w/v) smp Thermo Fisher Scientific 




2.4.12 Luciferase assay 
 
 
Cell lysates prepared in Section 2.3.6 were assayed for luciferase activity using a POLARstar 
OPTIMA (BMG LABTECH). The programme was set up as follows: There was 0.2 s 
positioning delay, and gain was set to 3000. The chemiluminescence from the luciferase 
activity in each well was measured five times with 5 s intervals and 50 µL of buffer (RLuc or 
Luc+) was added with a pump 5.5 s after the measurement started.  
Diluted cell lysates were thawed and kept on ice until required, and two assay buffers 
(RLuc and Luc+) were kept at room temperature but protected from light. Each cell lysate (10 
µL) was duplicated in the 96-well LUMITRAC™ 200 plate (Greiner Bio-one), one each for 
two different buffers used.  
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 The frameshift efficiency was calculated using the formula below based on the 
luciferase activity measured at 10 s. The ratio of the downstream reporter (Luc+) to the 
upstream reporter (RLuc) was first calculated for all constructs, and then the frameshift 
efficiencies for test constructs (WT, Null, and Stop) were determined by dividing the ratios by 
that of the readthrough construct (RT).  
Ratio of Luc+ to RLuc of test construct 
Relative frameshifting (%) = 




2.5 Antibody production 
 
 
2.5.1 Custom peptide ordering 
 
 
Four custom peptides were purchased from Life Technologies (Table 2.8) to raise peptide 
antibodies in rabbits. Half of the synthesised peptides (approximately 5 mg) were conjugated 
with keyhole limpet hemocyanin (KLH) protein to increase the immunogenicity. The 
remaining unconjugated peptides were used for antibody characterisation. 
 
 
Table 2.8: Synthetic peptide antigens 
Peptide name Amino acid sequence No. of residues 
mPeg10ORF1 (99–115) EPDQDELPEYSDDDDLEC 18 
hmPEG10ORF1 (160–174) EKSTRDFSVDRVRVC 15 
mPeg10ORF2 (545–557) HPYLLHHVHPHVHC 14 
hmPEG10ORF2 (347–360) RAMIDSGASGNFIDC 15 
C: extra cysteine residue added for KLH conjugation, numbers in parentheses are based on mPeg10 isoform 1 
(NCBI ID: NP_570947.2) 
 
 
2.5.2 Immunisation of rabbits 
 
 
Immunisation of rabbits was carried out by the Hercus-Taieri Resource Unit (HTRU) with 
approval from the Animal Ethics Committee (AEC No. 6/05). Four rabbits (one rabbit per 
peptide antigen) were immunised three times each with 0.5 mg of peptide mixed 1:1 with 
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Freund’s Complete Adjuvant (primary immunisation) or Incomplete Adjuvant (boosters) 
(Thermo Fisher Scientific) at three week intervals.  
 
 
2.5.3 Collection of bleeds 
 
 
Bleeds (1–2 mL) were obtained before the primary immunisation (pre-immune bleed), and 
three weeks after each booster (1st and 2nd bleeds) to test the specificity and sensitivity of 
antibodies being produced. The rabbits were sacrificed six weeks after the second booster and 
final bleeds (50–100 mL) were collected. 
 
 
2.6 Antibody purification 
 
 
2.6.1 Preadsorption of antibody 
 
 
E. coli Rosetta 2 (DE3) cells were transformed with pQE-80L vector (Section 2.1.10), and 
they were grown in 1 L of medium (Section 2.4.1.2). The cell pellet was resuspended in 40 
mL PBS, sonicated for 6 × 1 min (35% output) with 1 min intervals using a Sonics Vibra-Cell 
VCX 500 (Sonics and Materials Inc.) on ice, and then mixed with four volumes of chilled 
acetone (−20 °C). After incubating at −20 °C for 1 h, the solution was filtered through 
Whatman® No.1 filter paper (GE Healthcare), and dried overnight. The next day, the dried E. 
coli proteins were crushed into small pieces using a ceramic pestle, transferred to 
microcentrifuge tubes, and stored at −20 °C. 
 The dried E. coli proteins (50 mg) were rehydrated in 1 mL of 1× TBST at 4 °C for ≥ 
2 h on a rotating wheel. After making a complete suspension using a plastic pestle, small 
aliquot of antibody (10 µL) was added, and the mixture was incubated at 4 °C for 30 min on a 
rotating wheel before being centrifuged at 17 000 × g at 4 °C for 15 min. The supernatant was 
transferred to a fresh tube and centrifuged as before. The supernatant was diluted with 9 mL 
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of 1× TBST containing 5% (w/v) skim milk powder and used as a primary antibody solution 
for immunoblotting. Nitrocellulose membranes were blocked in 5% (w/v) skim milk powder 




2.6.2 Removal of non-specific antibody 
 
 
2.6.2.1 Antigen preparation 
 
 
E. coli Rosetta 2 (DE3) cells were transformed with pQE-80L or pGEX-6P-3 vector (Section 
2.1.10), and grown in 100 mL culture as described in (Section 2.4.1.2). The cell pellet was 
resuspended in 9 mL coupling buffer (100 mM HEPES, pH 7.5), and sonicated for 6 × 1 min 
(35% output) on ice with 1 min intervals using a Sonics Vibra-Cell VCX 500 (Sonics and 
Materials Inc.). The bacterial lysate was centrifuged at 12 000 × g at 4°C for 15 min to 
remove insoluble material. 
 
 
2.6.2.2 Preparation of a column 
 
 
An affinity column was prepared by immobilising the cleared bacterial cell lysate onto Affi-
Gel® 15 agarose beads (Bio-Rad Laboratories Inc.) with amine coupling. The gel was 
prepared by transferring 6 mL of Affi-Gel® 15 50% slurry into a 15 mL conical tube, 
centrifuging at 1 000 × g at 4 °C for 1 min, and discarding the supernatant. The gel was then 
washed with 9 mL of chilled ddH2O, and then with coupling buffer with centrifugation as 
above after each wash. The soluble bacterial proteins (9 mL) were added to the gels, and the 
tube was placed on a rotating wheel at 4 °C for 4 h. To halt the coupling reaction, 0.3 mL of 1 
M ethanolamine (pH 8.0) was added and mixing continued for another 1 h. The unbound 
proteins were removed by centrifuging at 1 000 × g at 4 °C for 1 min. The gel was transferred 
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into an Econo-Column® Chromatography column (2.5 × 10 cm, Bio-Rad Laboratories Inc.). 
The gel was then washed sequentially with 10 mL of PBS, coupling buffer, PBS, elution 
buffer (100 mM glycine-HCl, 150 mM NaCl, pH 2.4), and finally PBS. The prepared affinity 
column was stored in 10 mL of PBS containing 0.2% (w/v) sodium azide at 4 °C. Samples 
were collected throughout the procedure and stored at −20 °C until analysed by SDS-PAGE. 
 
 
2.6.2.3 Removal of non-specific antibody from rabbit sera 
 
 
The entire procedure was performed at 4 °C. The column was washed with one column 
volume of PBS and coupling buffer before sample application. Rabbit sera (typically 0.5–1 
mL) was applied to the prepared affinity column, and incubated overnight at 4 °C for binding. 
The next day, the flow-through (containing mPeg10ORF1 specific antibody) was collected 
and the column washed with one column volume of PBS. The bound antibody (non-specific 
antibody) was eluted with 10 mL elution buffer, and the elution was collected into a 15 mL 
conical tube containing 2 mL of 1 M Tris-HCl (pH 8.0) to immediately neutralise the pH. 
After washing the column with 10 mL of PBS, coupling buffer, and PBS, the column was 
either stored in 10 mL PBS with 0.2% (w/v) sodium azide at 4 °C or immediately re-used for 
another purification process. The specificity of the antibody in the flow-through and the 




2.6.3 Purification of mPeg10 ORF1 specific antibody 
 
 
2.6.3.1 Antigen preparation by electroelution 
 
 
Protein electroelution after SDS-PAGE was performed to further improve the purity of the 
mPeg10 ORF1 protein sample eluted from a glutathione column. The protein sample 
 
 73 
(approximately 400 µg) was concentrated (Section 2.4.3.3), resuspended in 400 µL of protein 
loading buffer, and then fractionated by SDS-PAGE (Section 2.4.6). A stacking gel was 
prepared using a modified comb to make a single large well that held approximately 400 µL. 
After zinc staining of a polyacrylamide gel (Section 2.4.8), the portion of the gel containing 
the protein of interest was excised using a clean, sharp razor blade, destained in 2% (w/v) 
citric acid with a few changes of solution, and then washed in ddH2O.  
Protein electroelution was performed according to Sá-Pereira et al. (2000) with a 
modified buffer. The gel piece was placed in a dialysis tube along with 9 mL of electroelution 
buffer (50 mM ammonium bicarbonate containing 0.1% (w/v) SDS), both ends of the tube 
were clamped and then positioned perpendicularly to the direction of the electrical current in a 
horizontal gel electrophoresis tank (Bio-Rad Laboratories Inc.) previously filled with the 
same buffer. Protein was eluted from the gel at 400 mA using a Bio-Rad Powerpac 300 (Bio-
Rad Laboratories Inc.) for 30 min, and then the current was reversed for 1 min to detach any 
proteins from the dialysis tube. After transferring the eluted protein into a 15 mL conical tube, 
the dialysis tube was briefly washed with 1 mL of electroelution buffer and added to the 
eluted protein fraction. The elution process was repeated twice to enhance recovery of protein 
from the gel piece. 
The eluted protein (30 mL in total) was chilled on ice for 1 h with occasional mixing 
by inversion to precipitate SDS (which precipitates at ≤ 4 °C), then centrifuged at ≥ 12 000 × 
g at 4 °C for 15 min. The resulting supernatant, containing only residual SDS, was divided 
into 15 × 2 mL aliquots and dried in a SC110 SpeedVac® Concentrator (Savant Instruments 
Inc.). The protein concentration was increased 4-fold by resuspending in only 7.5 mL of 50 
mM ammonium bicarbonate buffer. The protein samples received a total of three cycles of the 
protein concentration/SDS removal procedure to achieve a final concentration of 
approximately 0.5 mg per mL. The dried protein sample was kept at −20 °C until required. 
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2.6.3.2 Preparation of an affinity purification column 
 
 
An affinity column was prepared as in Section 2.6.2.2 with several modifications. The 
electroeluted mPeg10 ORF1 protein (6 × 400 µg) was first dissolved in 6 mL of coupling 
buffer and chilled at 4 °C for 1 h with gentle agitation. The protein solution was centrifuged at 
12 000 × g at 4 °C for 10 min to remove any insoluble protein before being mixed with Affi-
Gel® 15 (Bio-Rad Laboratories Inc.) for coupling. The gel was centrifuged at 1 000 × g at 4 
°C for 1 min after 2 h and the supernatant removed. The protein pellet was resuspended in 6 
mL of coupling buffer, added to the gel, and the coupling reaction allowed to proceed for 
another 2 h. 
 
 
2.6.3.3 Affinity purification of rabbit sera 
 
 
All steps of the procedure were performed at 4 °C. The affinity column was washed with one 
column volume of PBS and coupling buffer before rabbit serum (typically 1 mL) was applied 
to the column for binding overnight at 4 °C. The next day, the flow-through was collected and 
the column was washed with one column volume each of PBS, coupling buffer and PBS. 
Acidic elution buffer (8 mL) was then added to the column and collected in a 15 mL conical 
tube containing 2 mL of 1 M Tris-HCl (pH 8.0) to neutralise the pH. The eluted antibody was 
stored at −80 °C. The column was washed with 1–2 column volumes of PBS and stored in 10 
mL of PBS with 0.2% (w/v) sodium azide at 4 °C. 
 
 
2.7 Animal tissue collection 
 
 
This study used various tissue types from mice and rats of both genders. All tissue samples 
were placed in 1.8 mL Nunc™ CryoTube™ vials (Thermo Fisher Scientific Inc), immediately 
frozen in liquid nitrogen, and stored at −80 °C until processed. 
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2.7.1 Mouse tissues 
 
 
Tissues were collected from young adult male, female (~6 weeks old) and pregnant female 
(gestation between 9 to 15 d.p.c) C57 Black 6 (BL/6) mice for this study by Associate 
Professor Mike Legge (Department of Biochemistry, University of Otago, animal ethics 
number 39/08). All mice were housed at the Taieri Resource Unit and transferred to the 
(University of Otago) Microbiology Animal Facility upon request. To obtain pregnant 
females, mice were mated at the Taieri Resource Unit before delivery. All mice were fed with 
the standard laboratory diet. 
 
 
2.7.2 Rat brain and placenta 
 
 
The brains were removed from young adult male, female (~6 weeks old) and lactating female 
Sprague-Dawley rats. They were first divided into two hemispheres and further dissected into 
five sub-regions. Professor Cliff Abraham (Department of Psychology, University of Otago) 
provided both male and female rats and dissected the brains. Associate Professor Greg 
Anderson (Department of Anatomy, University of Otago) and a PhD student Bradley Hurren 
(Department of Anatomy, University of Otago) kindly provided brains of lactating female rats 









Translational frameshifting in PEG10 
 
 
Rare mechanisms used in gene expression by viruses, or by proteins unique to those viruses 
are regarded as ideal therapeutic targets because chemical substances directed against these 
viral targets are less likely to cause side effects in patients. Backwards (−1) translational 
frameshifting is such a potential target for a therapy applicable to HIV-1 infection. However, 
during the analysis of the human genome in the last 15 years, the mammalian genes, PEG10 
and CCR5, have been discovered to use −1 frameshifting. This posed a question as to whether 
frameshifting was indeed suitable for an antiviral target (Hammell et al., 1999; Ono et al., 
2006; Belew et al., 2014). When the current work was initiated PEG10 was the only human 
gene properly documented to use −1 frameshifting (Clark et al., 2007). Hence, I have focused 
on the mechanism of PEG10 frameshifting in the current study to further evaluate the 
feasibility of −1 frameshifting as the antiviral therapy against HIV-1. In 2014 CCR5 was 
discovered to be a genuine second example (Belew et al., 2014). 
PEG10 is an unusual mammalian protein in that expression of two potential ORFs can 
be regulated by translational frameshifting to give two possible products, a ~50 kDa protein, 
ORF1, in the 0 frame, and an 150 kDa ORF1–2 fusion protein, where the ORF2 is in the −1 
frame. The second larger product is dependent upon noncanonical −1 frameshifting occurring 
during translation so that the stop codon at the end of the encoded ORF1 is avoided. The 
frameshift mechanism utilised by PEG10 seemed a unique example in the expression of the 
human genome. Recent new discoveries have provided evidence that there might be several 
more examples among the interleukin receptors (Belew et al., 2014). 
To study the frameshift mechanism in PEG10 translation, the PEG10 frameshift 
element (a slippery sequence, intercodon and secondary structure) was amplified by PCR and 
cloned into the pGL3s-hRLuc vector. Three mutant constructs (null, RT and stop, see Figure 
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3.2) were also generated by PCR using mutagenic primers and cloned into the same vector 
(Section 3.1). These constructs were separately transfected into HEK293T/17 cells to 
investigate the importance of parts of the element in the −1 frameshift mechanism. To test 
whether the intercodon was being decoded before −1 frameshifting occurred as has been 
demonstrated for HIV-1 (Mathew et al., 2014), the stop construct in particular was co-
transfected with a vector encoding eukaryotic release factor 1 (eRF1) or suppressor tRNA. 
Cells were incubated for 48 h after transfection to allow expression of the reporter proteins 
(Renilla and firefly luciferases, see Figure 3.1). Subsequently, cells were harvested and 
assayed for activities of the two different luciferases (Section 2.3.6 and 2.4.12). Frameshift 
efficiency was calculated using a formula shown in Section 2.4.12, an example of which is 
illustrated in this chapter. 
 
 
3.1 Preparation of PEG10 constructs 
 
 
3.1.1 Cloning of frameshift elements 
 
 
The dual luciferase reporter assay was developed independently in the Tate and Atkins 
laboratories (Grentzmann et al., 1998; McKinney, 2001) to study rare recoding events such as 
frameshifting, and this assay has been used to measure frameshift efficiencies of different 
recoding elements, including HIV-1 (Biswas et al., 2004; Girnary et al., 2007). Constructs 
were prepared by cloning the frameshift element (i.e. a slippery sequence and secondary 
structure) to be studied between open reading frames coding for two different luciferases (for 
example, RLuc, Renilla luciferase; and Luc+, firefly luciferase). The expression of each of 
these luciferases can be accurately measured using a photometric assay. To study −1 
frameshifting, the inserted DNA is designed to place the downstream reporter gene (Luc+) in 
the −1 reading frame relative to the upstream gene (RLuc), so that Luc+ is translated only 
when frameshifting occurs (Figure 3.1). To determine the frameshift ratio, the enzyme 
 
 79 
activities of the two luciferases are measured in an assay with specific substrates. The relative 
light unit (RLU) output activities of Luc+ and RLuc can be normalised against an in-frame (0 
frame) control where the two reporters are in the same frame and produced in equimolar 




Figure 3.1: Two translational products of a dual luciferase reporter system. 
In most translational passages, only the RLuc protein is produced (no frameshifting). The larger fusion protein 
(RLuc and Luc+) is produced only when frameshifting occurs (−1 frameshift product). RLuc, Renilla luciferase; 
Luc+, firefly luciferase and FS, frameshifting site. 
 
 
3.1.2 Cloning strategies 
 
 
In addition to the −1 frameshift test construct where the two reporters are in a different frame, 
two other constructs were required to determine accurately the frameshift efficiency of 
PEG10 (RT and null, Figure 3.2). Both of these mutants contained three substitutions within 
the frameshift promoting slippery sequence to abolish frameshifting. This read-through 
construct included three additional substitutions to disrupt naturally-occurring stop codons 
nearby, and an extra nucleotide was added as an insertion to put the downstream reporter in 
the same reading frame (0 reading frame) as the upstream reporter so that the RLuc-Luc+ 
fusion protein was produced in every ribosome passage. The null construct contained this 
disrupted frameshift element but the downstream Luc+ reporter was kept in the −1 frame. 
Changes are shown in red in Figure 3.2. An additional construct (Stop, Figure 3.2) was 
RLuc Luc+FSmRNA
0 frame −1 frame
No frameshift RLuc
−1 frameshift RLuc Luc+FS
Translation
Stop codon (0 frame)
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prepared to study the effect of the intercodon (TCC) directly downstream of the slippery 
sequence on the mechanism and efficiency of −1 frameshifting in PEG10. The TCC was 
changed to the TGA stop codon. 
 
 
3.1.3 Preparation of constructs 
 
 
Short inserts (81 or 82 nt) corresponding to the frameshift element were amplified by PCR 
using pcDNA™3.1(+)-PEG10 as a template. Primers were designed using PEG10 sequence 
(NCBI reference sequence: NM_015068.3) to amplify nucleotide position of 1416–1496 or 
1497. Primer design included a stuffer sequence followed by a restriction enzyme site (Eco RI 
for forward primer and Sac II for reverse primer) at the 5´ ends of each of the primers. Several 
mutagenic primers (three forward and one reverse primer) were also designed to generate the 
mutant inserts (Table 2.1). The wild-type insert was amplified using the WildTypeF and 
−1frameR primers, and the null insert was generated using the FullF and −1frameR primers, 
which substituted the three nucleotides in the slippery sequence (Figure 3.3 A). To generate 
the insert for the read-through construct, three nucleotides were first substituted to change 
stop codons to sense codons using the NestedF and 0frameR primers (Figure 3.3 A). This 
amplicon was then used in a second step as a template (Figure 3.3 B) and extended to a full 
length using the FullF and 0frameR primers, incorporating the three mutations in the slippery 
sequence (Figure 3.3 B). For the stop insert (Figure 3.2), two nucleotides in the intercodon 




Figure 3.2: Cloned sequences of four constructs for a frameshift analysis. 
The diagram shows the cloned DNA sequences of four different constructs. Substituted nucleotides and the 
additional nucleotide in RT are indicated in red bold letters. Positions of the frameshift elements are shown 









Figure 3.3: Cloning of PEG10 frameshifting elements into a dual luciferase vector. 
(A) Amplification of four different inserts by PCR, (B) second step PCR performed on RT amplicon from A and 
(C) colony screen. The numbers above each lane in A and B indicate replicates 1–4, and the numbers in C 
indicate colonies 1–5. Markers used were a 100 bp ladder (A and B) or a λHE DNA marker (C). M, marker; −, 




Figure 3.4: Sequencing results of the cloned inserts. 
Asterisks (*) indicate the mutations introduced during amplification using mutagenic primers. WT, wild-type 










−1 2 3 4 −1 2 3 4 −1 2 3 41 −
RT





1 2 3 4M 5 1 2 3 4 5





























** * * * * *
 82 
Replicate PCR reactions for each insert were pooled together during the purification 
process to obtain a higher concentration of DNA for each insert. Following restriction enzyme 
digestion of the inserts using Eco RI and Sac II (Section 2.1.4), they were ligated into the 
pGL3s-hRLuc vector (Table 2.1) that had been previously digested with the same enzymes 
(Section 2.1.8). E. coli DH5α cells were transformed with the ligated products and with the 
ligation controls and then plated onto agar plates (Section 2.1.10). A typical transformation 
result is presented in Table 3.1. The set of controls confirmed both a high efficiency of 
transformation and efficient enzyme digestion with the two restriction endonucleases. 
Importantly, the number of potential positive colonies was 5–10 fold higher than those of the 
controls 2 and 3. Several transformant colonies were screened for the presence of inserts by 
PCR using sequencing primers as described in Section 2.1.3.3 (Table 2.4 and Figure 3.3). As 
shown in Figure 3.3 C, all colonies, except for read-through colony 1, showed the expected 
amplicon size of approximately 1.9 kb. Initially, two clones (colonies 2 and 5) for each 
construct were sequenced to determine if these sequences were free of mutations, except for 
those deliberately designed (Section 2.1.11). At least one clone for each construct was 
confirmed to have the designed mutations and was free of any other random mutations 
introduced by the technology (Figure 3.4). 
 
 
Table 3.1: Typical transformations of E. coli DH5α cells. 
 Control 1 Control 2 Control 3 Experimental 
No. of colonies Lawn <5 <20 >100 
Transformation was performed with the products of the different ligation reactions. Control 1, undigested vector 
alone (20 ng); Control 2, vector digested with Eco RI and Sac II; Control 3, vector digested with Eco RI and Sac 
II and then subjected to re-ligation, and Experimental, vector digested with Eco RI and Sac II and re-ligated with 








3.2 The effect of the intercodon 
 
 
The prepared PEG10 constructs were separately transfected into HEK293T/17 cells for 
expression of the luciferase reporters (Figure 3.5). Following 48 h in culture, total cellular 
proteins were extracted from the cells for the two luciferase assays with specific substrates. A 
typical dataset from such a luciferase assay is shown in Table 3.2. A frameshift (FS) ratio for 
each replicate of each construct was first calculated by dividing RLU of Luc+ by that of RLuc 
as shown below.  
 Luc+ RLU  
 Frameshift ratio = RLuc RLU  
 
The RT construct that produces an equal molar ratio of RLuc and Luc+ because they 
are in the same reading frame, can be used to normalise RLU outputs from the two different 
reporters. When Luc+ translation depends on the low efficiency translational mechanism of −1 
frameshifting, by contrast there are much smaller values of Luc+ RLU compared to that of the 
RT construct. To determine frameshift efficiency, a FS ratio (WT, null or stop) was divided 
by FS ratio derived from the RT construct (average of multiple replicates) multiplied by 100. 
 FS ratio of a target construct  
 Frameshift efficiency (%) = Average FS ratio of the RT construct ×100  
 
Assay results for cell extracts harvested 48 h after transfection of PEG10 constructs for 
activities of both luciferases gave frameshift efficiencies for each construct (Figure 3.6). The 
frameshift efficiency was 23% for the WT construct and this was consistent with previous 
preliminary findings from the Tate laboratory (Clark et al., 2007). As expected, the null 
construct that had nullified the slippery sequence gave a low level of frameshifting (<0.3%). 
The stop construct, where the intercodon TCC had been mutated to a TGA stop codon, had 
>70% reduction in frameshift efficiency compared with that of the WT. These results 
therefore suggested that the intercodon might have a significant impact on −1 frameshift 
efficiency, whatever the mechanism. 
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Figure 3.5: Constructs used to generate output data shown in Table 3.2. 
This diagram illustrates the four prepared constructs. The downstream reporter (Luc+) is in the 0 frame for the 
RT construct while it is in the −1 frame relative to the upstream reporter (RLuc) for the other three constructs 
(WT, null and stop). The nucleotides that differ from the WT sequence are highlighted in red bold. SS, slippery 































Table 3.2: A typical output from the analysis of luciferase activities from six replicates. 
RT: Luciferase reporters in the same reading frame (RLuc and Luc+ in 0 frame) 
RLuc RLU Luc+ RLU Ratio Average ratio 
135159 364620 2.70 2.40 
95194 179026 1.88  
67523 152263 2.25  
104142 252450 2.42  
85181 230510 2.71  
99460 242297 2.44  
    
WT: Luciferase reporters in different reading frame (RLuc 0 frame, Luc+ −1 frame) 
RLuc RLU Luc+ RLU FS ratio FS efficiency (%) 
284748 138603 0.49 20.28 
171101 80961 0.47 19.72 
164559 81646 0.50 20.67 
150584 68336 0.45 18.91 
194944 97580 0.50 20.86 
213063 108325 0.51 21.18 
  Average 20.27 
    
Null: Frameshifting site nullified (RLuc 0 frame, Luc+ −1 frame) 
RLuc RLU Luc+ RLU FS ratio FS efficiency (%) 
169266 1056 0.01 0.26 
81746 389 0.00 0.20 
66703 351 0.01 0.22 
85476 379 0.00 0.18 
66353 330 0.00 0.21 
88374 449 0.01 0.21 
  Average 0.21 
    
Stop: Intercodon TCC substituted with TGA (RLuc 0 frame, Luc+ −1 frame) 
RLuc RLU Luc+ RLU FS ratio FS efficiency (%) 
392893 55942 0.14 5.93 
396546 53235 0.13 5.59 
357470 48659 0.14 5.67 
405152 59816 0.15 6.15 
247226 33893 0.14 5.71 
295854 36374 0.12 5.12 
  Average 5.70 
    
RLU, relative light unit; RT, read-through; WT, wild-type; FS, frameshifting; RLuc, Renilla luciferase and Luc+, 





Figure 3.6: The effect of the intercodon on −1 frameshift efficiency. 
The sequences of constructs used for this analysis are shown together with the positions of the frameshift 
element and mutated nucleotides highlighted in red bold letters (A). For RT construct sequence, see Figure 3.2. 
Constructs were transfected into HEK293T/17 cells and cells were grown for 48 h before harvesting. The 
frameshift efficiency was calculated using a formula presented above. The data were obtained from 24 
individually transfected replicates (6 replicates per plate and 4 plates). Error bars represent SEM. **p-value 
<0.01. WT, wild-type; SS, slippery sequence and IC, intercodon. 
 
 
3.3 Overexpression of eRF1 
 
 
3.3.1 Confirmation of eRF1 overexpression 
 
 
The intercodon could be influencing frameshifting because it has been decoded before 
frameshifting occurred, in conflict with most proposed mechanisms of frameshifting. To 
investigate the possibility that the stop construct showed a significantly reduced frameshift 
efficiency because it was decoded in the 0 frame by eRF1, this stop codon decoding molecule 
was overexpressed. It was postulated that overexpression of eRF1 should result in further 
reduction in frameshift efficiency if the intercodon was indeed decoded before frameshifting. 
For overexpression of eRF1, cells were co-transfected with a PEG10 construct and either 
pcDNA™3.1(+)-eRF1 (eRF1 overexpression vector) or pcDNA™3.1(+) (empty control vector). 






























overexpressed in these cells (Figure 3.7). Actin was used as a protein loading control and the 
intensity of the actin band was similar across all lanes. For cells co-transfected with empty 
control vector, a level of eRF1 expression was comparable across samples including the 
untreated control. In contrast, when cells were co-transfected with the eRF1 overexpression 
vector, eRF1 was expressed at a significantly higher level as shown by a much higher 
intensity band of eRF1 (+). This result confirmed that eRF1 was successfully overexpressed 




Figure 3.7: Overexpression of eRF1 confirmed by immunoblotting. 
HEK293T/17 cells were co-transfected with a PEG10 construct and either eRF1 overexpression vector (+) or 
empty control vector (−). After 48 h incubation, cells were harvested, fractionated on a polyacrylamide gel and 
then transferred to a membrane. The membrane was sequentially probed with an anti-actin and an anti-eRF1 
antibody, and then exposed for 2 min. M, marker; WT, wild-type; RT, read-through; U, untreated control; +, co-
transfection with pcDNA™3.1(+)-eRF1 and −, co-transfection with pcDNA™3.1(+). Red arrows indicate the 
positions of eRF1 and actin. 
 
 




After confirmation of eRF1 overexpression, the same cell lysates were assayed for both 
luciferases to determine the frameshift efficiency (Figure 3.8). As expected, overexpression of 
eRF1 did not itself have any impact on frameshift efficiency in the WT or null construct 
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similar frameshift efficiency whether co-transfected with the eRF1 overexpression vector or 
with an empty control vector. This finding can be interpreted in two different ways. It is 
possible that the endogenous level of eRF1 was sufficient and saturating to reduce frameshift 
efficiency and any further increase in the concentration of eRF1 did not increase the 
competitiveness of translational termination over frameshifting. Alternatively, the observed 
reduction in frameshift efficiency with the stop codon might have been independent of 
decoding at the ribosomal A-site. Of note, this result was in contrast to that found with the 
HIV-1 frameshift element intercodon where eRF1 overexpression was shown to reduce 




Figure 3.8: The effect of eRF1 overexpression on −1 frameshift efficiency. 
HEK293T/17 cells were co-transfected with a PEG10 construct and either eRF1 overexpression or empty control 
vector (red and blue bars, respectively). Frameshift efficiencies were calculated using a formula presented in 
Section 2.4.12. The data were obtained from 21 individually transfected replicates (3 replicates per plate and 7 
plates). Error bars represent SEM. WT, wild-type. 
 
 
3.4 Expression of suppressor tRNAs 
 
 
3.4.1 Functionality and specificity of suppressor tRNAs 
 
 
As frameshift efficiency was not modulated in the stop construct by overexpression of eRF1, 

























in cultured cells, an alternative strategy was employed to test whether the intercodon is 
decoded before −1 frameshifting. For better understanding of the effect of the intercodon on 
−1 frameshifting, suppressor tRNAs (amber or opal) were used as alternative stop codon 
decoding molecules. However, prior to using suppressor tRNAs in a combination with the 
PEG10 constructs, the functionality and specificity of these suppressor tRNAs were first 
tested against constructs that carry either an in-frame UGA or UAG stop codon between two 
luciferase genes (Figure 3.9). Both suppressor tRNAs showed high specificity for decoding 
their target stop codon, and did not decode the other non-cognate codon. Their functionality 
was confirmed by very efficient read-through (approximately 30%). The parental tRNA (a 
serine tRNA) recognising a sense codon was included as a negative control and it did not 




Figure 3.9: The function and specificity test of two suppressor tRNAs. 
Two suppressor tRNAs and serine tRNA were tested to decode UGA (left panel) or UAG codon (right panel) for 
assessing their function. Amber (green) recognises UAG while opal (red) decodes UGA codon. Serine tRNA 
(blue) was the parental tRNA that those two suppressor tRNAs were derived from. Frameshift efficiencies were 
calculated using a formula presented in Section 2.4.12. The data were obtained from 6 individually transfected 
















































Suppressor tRNAs were subsequently co-transfected with the PEG10 constructs to test their 
effect on −1 frameshift efficiency (Figure 3.10). As expected, both the WT and null constructs 
showed no difference in frameshift efficiency regardless of the tRNAs added. For the UGA 
stop construct, the cognate opal suppressor tRNA significantly (p <0.01) increased frameshift 
efficiency compared with that of serine tRNA. This supported the hypothesis that the 
intercodon could be decoded before frameshifting occurred because cognate opal suppressor 
tRNA modulates the competition of endogenous eRF1 with −1 frameshifting. Unexpectedly, 
amber tRNA also modulated frameshift efficiency, but not to the same significance (p <0.05). 
It is unclear why amber tRNA could increase frameshift efficiency because it does not 
normally recognise a UGA codon as shown in Figure 3.9. One possibility is that the 
ribosomal site may be significantly distorted immediately prior to frameshifting and the non-
cognate tRNA may be ejected without recognition more slowly than normal, allowing a 




Figure 3.10: The effect of suppressor tRNAs on −1 frameshift efficiency. 
HEK293T/17 cells were co-transfected with a PEG10 construct and either amber, opal or serine tRNA (red, 
green and blue, respectively). Frameshift efficiencies were calculated using a formula presented in Section 
2.4.12. The data were obtained from 20 individually transfected replicates (2 replicates per plate and 10 plates). 



































3.5 Summary of frameshift studies 
 
 
The frameshift mechanism of PEG10 was studied using the WT element sequence and three 
mutant constructs. The result suggested that the intercodon might be decoded for some 
ribosomal passages before −1 frameshifting occurred. This was investigated using 
overexpressed decoding molecules, eRF1 and suppressor tRNAs, for stop codons to provide 
more definitive evidence for the importance of the intercodon on −1 frameshift efficiency. 
Co-transfection of an eRF1 expression vector caused no difference in frameshift efficiency, 
despite clear evidence of eRF1 overexpression. This result raised the possibility that 
frameshifting has occurred before reaching the intercodon and the observed decrease in 
frameshift efficiency of the stop construct was caused by some consequence of the nucleotide 
substitutions. To test this possibility further, suppressor tRNAs were used as alternative 
decoding molecules. However, this result was equivocal despite showing that cognate opal 
suppressor tRNA changed frameshift efficiency (p <0.01). This suggested that the intercodon 
was decoded before −1 frameshifting, but the non-cognate amber suppressor tRNA also 















To assess expression of a gene of interest within a large number of tissues of an animal 
requires careful development of methods that will be appropriate for all tissues. 
 
 
4.1 Preparation of RNA samples 
 
 
4.1.1 Quality assessment 
 
 
Total RNA was extracted from various animal tissues prior to being analysed by quantitative 
real time PCR (qPCR). High quality RNA samples were required since both degradation and 
contamination of samples can have a confounding impact on the subsequent analysis. 
Degraded RNA is unsuitable for reverse transcription or amplification simply because of the 
lower number of available templates or damaged primer binding sites, resulting in an 
underestimation of the specific RNA being analysed. Chemical and protein contaminants can 
cause lower efficiency of amplification and even inhibit such reactions. Therefore, RNA 
samples were subjected first to two important quality assessments for purity and integrity.  
First, the purity of RNA samples was determined using a Nanodrop ND-1000 
Spectrophotometer immediately after extraction (Figure 4.1 and Appendix III). The presence 
of contaminants such as proteins or carried-over chemicals from the purification process was 
suspected if either of the ratios of A260/A280 or A260/A230 fell below 1.8. Most RNA samples 
had values > 1.8 for both ratios although RNA extracted from fibrous tissues (heart and 
muscle) or lipid-rich tissues (brain and adipose) often had lower values. It is well established 
that extraction of high quality RNA from these tissues is more challenging than from other 
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tissue types (Tavangar et al., 1990; Fleige and Pfaffl, 2006). The extraction methods used in 
this study were kept as simple as possible in order to process a large number of samples from 
different tissues efficiently, but more rigorous purification processes were typically used for 
fibrous and lipid-rich tissues to ensure higher quality of samples were produced. With these 





Figure 4.1: The typical purity of RNA as analysed by a Nanodrop ND-1000 
Spectrophotometer. 




Secondly, after a treatment with DNase I (section 2.2.3), the RNA samples were 
analysed for integrity by fractionating either through formaldehyde gel electrophoresis, or 
analysed with a Bioanalyzer (Figure 4.2). Similar to formaldehyde gel electrophoresis, a 
Bioanalyzer separates RNA molecules electrophoretically based on their size, but only 
requires a small amount of RNA and its automated analysis provides high reproducibility 
(Schroeder et al., 2006). The Bioanalyzer calculates an RNA integrity number (RIN) that 
ranges from 1 (most degraded) to 10 (most intact). The RIN value allows a more objective 
estimation of RNA integrity compared with the more subjective analysis by eye of the 




Figure 4.2: Representative samples of RNA assessed for integrity by formaldehyde gel 
electrophoresis and on a Bioanalyzer. 
For formaldehyde gel electrophoresis (A), 1 µg of total RNA for kidney, brain and testis isolated from 6 different 
male animals was loaded onto each lane. For the Bioanalyzer (B), 1 µL of total RNA for heart and adipose tissue 
extracted from 6 different pregnant female animals (concentration range of 25–200 ng/µL) was used for the 
analysis. Positions of 28S and 18S rRNAs as well as small RNA species are indicated. The numbers above each 
lane indicate biological replicates 1–6 from 6 different animals. M, marker; RIN, RNA integrity number; N/A, 
not applicable. The analysis of samples from other tissues can be found in Appendix IV and V. 
 
 
Total RNA analysed by formaldehyde gel electrophoresis showed two distinctive 
bands of 28S and 18S rRNAs together with a slight smear representing multiple mRNAs, 
indicating that these samples were largely intact. A weakly staining band representing small 
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(Figure 4.2 A and Appendix IV). One sample of pregnant female adipose tissue (lane 6, 
Figure 4.2 B) was unsuitable as it had a low amount of intact 28S rRNA and no RIN number. 
Stomach, intestine and pancreas RNA samples showed a different profile to the other 
samples. Stomach and intestine samples were contaminated with bacterial rRNAs, as 
indicated by two additional bands likely to be 23S rRNA and 16S rRNA. Stomach and 
pancreas samples had very faint or no rRNA bands (Appendix IV). The prokaryotic rRNAs 
are most likely derived from stomach or intestinal contents, and therefore they co-purified 
with mouse RNAs. Where significant degradation was observed this was likely due to 
insufficient inactivation of RNases during RNA extraction, especially for pancreas, which is 
known to be rich in nucleases.  
Extracted samples which had a lower concentration of RNA were analysed by a 
Bioanalyzer, and the gel-like image showed a very similar result to that of formaldehyde 
electrophoresis (Figure 4.2 B and Appendix V). Most samples had high RIN values indicating 
predominantly intact RNA. Occasionally, the RIN values could not be calculated because of 
the absence of, or presence of only a faint, 28S rRNA band (as indicated above). The exact 
cause was not always clear because high RIN values were observed for RNA isolated from 
other biological samples of the same tissue that were treated identically. Importantly, no 
samples analysed contained obvious high molecular weight bands representing genomic 
DNA. 
Assessed against the two quality criteria, the majority of samples were shown to be 
free of contaminants and essentially intact. Of the others, some were of lower quality and 
appeared to have trace amounts of contaminants, and some had equivocal integrity. The 
samples showing contaminants were noted but included in the study with the belief the 
contaminants would be highly diluted for cDNA synthesis and subsequent qPCR and so not 
affect the analysis. Samples with unclear integrity were noted but also analysed because they 
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did not show obvious signs of degradation, suggesting that these samples might have 
contained intact RNA molecules. 
 
 
4.1.2 Comparison of two DNase I treatments 
 
 
Although there was no obvious genomic DNA contamination evident by gel analysis of the 
RNA samples, the preparations were treated with DNase I to remove traces of genomic DNA 
prior to RNA quantitation by qPCR. DNase I from two suppliers was used in this study 
because they complemented the different RNA extraction methods. DNase I from Life 
Technologies is better suited for in-solution digestion of DNA and the enzyme can be 
subsequently heat-inactivated. DNase I supplied by Qiagen, by contrast, is suitable for on-
column digestion before the RNA is eluted from the silica spin columns because the enzyme 
can be removed from samples after the reaction. To investigate the effect of DNase I 
treatment on RNA, RNA samples before and after the treatment were analysed on a 




Figure 4.3: Comparison of RNA before and after treatment with DNase I. 
Total RNA extracted from rat cerebellum (3 µg) was treated with DNase I from two suppliers (Life 
Technologies or Qiagen), and then 1 µg was loaded on a formaldehyde gel together with untreated control. 




















There was an apparent downward shift of both rRNA bands and the small RNA bands 
after the treatment, although the cause of this is unclear. Most importantly, the integrity of 
RNA appeared unaffected by DNase I treatment and there was no observable difference 
between a sample treated with DNase I from Life Technologies and DNase I from Qiagen. 
However, it was not possible to determine the efficacy of trace DNA removal because the 
untreated sample itself did not show visible DNA contamination. 
From these studies, it was concluded that isolation of RNA of appropriate quality was 
possible for the subsequent analysis. 
 
 
4.2 Reference genes for qPCR analysis 
 
 
There are two methods, absolute and relative quantitation, for analysing gene expression from 
qPCR data. Relative quantitation has become increasingly popular because it is much simpler 
to perform than absolute quantitation, and gene expression differences can be expressed as 
fold changes, rather than an absolute copy number. This is sufficient for most studies (Klein, 
2002; Schmittgen and Livak, 2008). Relative quantitation determines the expression as fold 
changes compared to reference genes, but reference gene expression must therefore remain 
constant across samples to obtain meaningful results. The use of multiple reference genes 
further increases the reliability of this method of target gene quantitation. However, no one 
gene is known to maintain a constant expression level throughout development and across all 
different tissue types (Thellin et al., 1999; Schmittgen and Zakrajsek, 2000; Radonic et al., 
2004). Therefore, reference gene selection should be empirically determined using the 








4.2.1 Searching for candidate genes 
 
 
To expand the number of candidate reference genes for mouse samples consisting of 18 
different tissue types, the RefGenes tool in the Genevestigator online search engine was used 
to find genes with relatively constant expression levels across multiple tissue types (Hruz et 
al., 2011). Genevestigator consists of publicly available microarray and RNAseq data that are 
manually curated after data quality assessment and normalisation processes (Hruz et al., 
2008). The search identified 75 genes as possible candidate genes. Primers were then 
designed for 10 of the most promising genes (Table 4.1), after assessment for their quality 
based on hairpin and dimer formation and those meeting the quality standards selected for 
screening. After screening in all tissue samples as indicated in Section 4.2.2, three genes were 
selected as potential reference genes, to supplement seven commonly used reference genes. 
For rat samples, eight commonly used reference genes were screened because there were only 
two tissue types studied. 
 
 
Table 4.1: Top 10 candidate genes identified by the RefGenes tool in the Genevestigator 
search engine. 
Name Median SD Status mRNA (NCBI ID) Note 
Tfip11 11.85 0.33 Provisional NM_018783.4  
Poldip3 13.19 0.38 Provisional NM_178627.3  
Wdr33 12.83 0.39 Validated NM_028866.3 4 isoforms 
Bet1l 11.55 0.39 Validated NM_018742.5  
Abt1 11.98 0.39 Provisional NM_013924.3  
Elac2 11.43 0.39 Validated NM_023479.2  
Ccdc71 12.33 0.4 Validated NM_133744.4  
Oraov1 11.84 0.4 Provisional NM_028184.3  
Gpn3 11.94 0.4 Provisional NM_024216.1  
2310033P09Rik 11.53 0.4 Provisional NM_024210.2  
Median, median of gene expression in various tissues; SD, standard deviation of gene expression in various 
tissues. Smaller SD means more stable gene expression. Status is indicated on the NCBI website as provisional, 




4.2.2 Screening of candidate genes 
 
 
All candidate genes (13 for mouse and 8 for rat) were screened for their expression levels in 
all tissue types. To further validate the results, screening was repeated with samples from 
animals of different genders, and the data were analysed using the RefFinder software (Xie et 
al., 2011), and in particular the Normfinder and geNorm algorithms (Figure 4.4). Normfinder 
first calculates variation of gene expression within and between groups, and the stability value 
is then estimated by combining these two values (Andersen et al., 2004). In contrast, geNorm 
treats all samples as one group and calculates the stability value in a pair-wise comparison. It 
then eliminates a single gene with the highest stability value from analysis and repeats this 
process until only a pair of genes remains (Vandesompele et al., 2002). For the mouse 
reference genes, five genes were omitted from the second screening because of large 
variations in their observed gene expression in the first screening. There was a striking 
similarity in the ranking of gene stability between Normfinder and geNorm despite of 
differences in their algorithms, and this consistency reinforced the reliability of the findings. 
As there were a large number of tissue samples to be analysed, it was decided to use the three 
best reference genes for the analyses. The selected reference genes were Hsp90ab1, Wdr33 





Figure 4.4: Gene stability analyses by the Normfinder or geNorm algorithms of 
candidate genes for mouse and rat samples. 








































































4.3 Optimisation of protein techniques 
 
 
4.3.1 Optimisation of protein extraction conditions 
 
 
The same set of tissue samples used to extract RNAs were also used to make protein extracts. 
The presence of Peg10 protein was determined using mPeg10ORF1 specific antibody. Two 
key steps, homogenisation of tissues and solubilisation of cellular proteins, are required for 
successful extraction of proteins from animal tissues. Tissue disruption was primarily 
achieved by grinding in liquid nitrogen using a sterilised mortar and pestle, followed by 
sonication for more thorough homogenisation to improve protein solubility. Detergents and 
reducing agents were used in the extraction buffer. The degree of improved Peg10 yields was 
dependent on the type and concentration of additives used. Several extraction conditions were 
tested to optimise for efficient extraction of Peg10 proteins.  
 
 
4.3.1.1 A comparison of additives 
 
 
To compare the effects of different additives on protein extraction, total proteins were 
extracted from rat placenta using an extraction buffer either without additives or containing 
SDS (2 or 4% w/v) or 7 M urea and 1 M thiourea. After gel fractionation and Western 
transfer, immunoblotting was carried out using a partially purified antibody (‘preadsorbed 
antibody’, Section 2.6.1) against the protein derived from the first open reading frame of 
mPeg10 (mPeg10ORF1). This was used to detect soluble and insoluble proteins (Figure 4.5). 
As expected, a greater amount of Peg10 protein was solubilised when detergent was included 
in the buffer. Both tested concentrations of SDS or urea/thiourea showed similar extraction 
efficiencies. However, a small amount of Peg10 protein was still left in the insoluble fraction 
after extraction in buffers with SDS. This implied that protein extraction was marginally more 
efficient with urea/thiourea than SDS, as there were no visible bands or smears on the 
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immunoblot of the insoluble fraction in this condition. Urea was the preferred option because 
it did not interfere in downstream steps such as protein quantitation and concentration. 
Different concentrations of urea were then tested to determine the minimum concentration 
that gave the best extraction yield (data not shown). Inclusion of 1 M urea increased the 
amount of Peg10 protein in the soluble fraction compared with no additives, but higher 
concentrations of urea gave little improvement in Peg10 yield. From these results, 1 M urea 




Figure 4.5: Immunoblotted protein extracts of rat placenta under different extraction 
conditions. 
Proteins were extracted using SDS (2% or 4%), U/Thio U (7 M urea + 1 M thiourea) or without additives 
(None). Soluble and insoluble proteins were separated by centrifugation. Insoluble proteins were solubilised in 
protein loading buffer (volume was 4 µL × the weight of the insoluble proteins in mg). Equal volumes of soluble 
and insoluble proteins (10 µL) were loaded onto each lane. The membrane was probed with the preadsorbed 




4.3.1.2 The effects of a reducing agent 
 
 
The effect of adding a reducing agent (DTT) was investigated to determine whether it 
increased protein extraction efficiency. DTT breaks existing disulphide bonds and prevents 
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they can facilitate aggregation of proteins and result in protein precipitation. Proteins were 
extracted from rat placenta using 1 M urea buffer with or without DTT and separate protein 
fractions were analysed by immunoblotting (Figure 4.6). The result indicated that DTT 
addition during extraction did not improve Peg10 protein extraction efficiency because there 
was little change in signal intensities of Peg10 proteins between the two conditions. DTT was 




Figure 4.6: Immunoblotted protein fractions extracted from rat placenta with and 
without DTT. 
Proteins were extracted from rat placenta in presence or absence of 2 mM DTT. Proteins were extracted without 




4.3.2 Recovery of Peg10 after protein precipitation 
 
 
Concentrating protein was an important step in this study because it allowed a higher amount 
to be loaded onto gels for analyses of Peg10 protein in tissue samples by immunoblotting. 
This allowed detection of low levels of Peg10 protein that might be present in some tissues. 
Following extraction buffer optimisation, four different protein precipitants; (i) acetone, (ii) 
TCA with an acetone wash, (iii) TCA, and (iv) chloroform-methanol-water were compared to 













Total protein extracts from lactating female rat hypothalamus were immunoblotted to assess 
the precipitation efficiency of Peg10 (Figure 4.7). Importantly, only the sample precipitated 
using acetone for 1 h had a similar intensity of the Peg10 protein compared with the untreated 
control. The other three reagents resulted in significant loss of the Peg10 protein. Overnight 
incubations in order to increase precipitation did not improve Peg10 recovery, and the results 
were similar to those shown in Figure 4.7. Therefore, acetone precipitation for 1 h was chosen 





Figure 4.7: Recovery of Peg10 protein using different precipitation reagents. 
A 75 µg sample of proteins extracted from lactating female rat hypothalamus was precipitated using different 
protein precipitation reagents and 1 h incubations, except for C/M (C/M precipitation does not include an 
incubation step). Precipitated proteins were then resuspended in extraction buffer (10 µL) and centrifuged to 
separate the soluble (S) and insoluble pellet (P). M, marker; Untreated, untreated control; A, acetone 
precipitation; TCA/A, TCA precipitation with an acetone wash; TCA, TCA precipitation; C/M, chloroform-
methanol-water precipitation. The membrane was probed with anti-mPeg10ORF1 and developed for 20 min. 
Contrast was increased to easily visualise the mPeg10 protein bands. 
 
 
4.4 Peptide antibodies 
 
 
Detection of a specific protein can be difficult in a complex sample such as cell lysate 
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exploits the high specificity and sensitivity of antibodies for a particular protein. An antibody 
against mPeg10 ORF1 protein (polyclonal anti-mPeg10ORF1) had previously been developed 
in rabbits (Shimaki, 2008). mPeg10 ORF1 is translated from the 0 frame within the mRNA 
but an antibody raised against this would detect both products of translation (ORF1 and 
ORF1–2 fusion). While the antibody showed high sensitivity against the antigen, it also 
recognised E. coli proteins non-specifically, most likely due to minor contamination of the 
prepared purified antigen that was expressed in bacteria. Such activity of the antibody was 
initially considered unimportant because it was to be used to screen for mPeg10 protein 
expressed in mouse tissues. It was found, however, that the antibody preparation also detected 
some mouse cellular proteins non-specifically. Therefore antibodies were raised against 
specific peptides in mPeg10 that recognised the mPeg10 protein (two each for the 0 frame 
ORF1 and the −1 frame ORF2). Polyclonal antibodies to these peptides were raised to 
validate results obtained using the highly sensitive anti-mPeg10ORF1. The peptide sequences 
were chosen by analysis of protein sequence of mPeg10 using the PeptideSelect™ online tool 
(Life Technologies) with assistance from Dr. Elizabeth Poole. High hydrophilicity and 
antigenicity regions were chosen as the target peptides. The method of antibody production is 
described in Section 2.5. 
 
 
4.4.1 Antibody characterisation 
 
 
Two important aspects of an antibody for detecting the antigen of interest with fidelity are 
sensitivity and specificity. A sensitivity test involves using a wide range of pure antigen and 
different antibody dilutions to find optimal conditions for immunoblotting. The antibody 
dilution that detected <5 ng of antigen was selected for further testing. A specificity test, 
using a sample with a complex array of proteins including the target protein, was performed 







To test the sensitivity of each of the four peptide antibodies that were produced (HM1, HM2 
specific for human and mouse PEG10, and M1 and M2 specific for mouse Peg10), four 
antibody dilutions were tested for their abilities to detect varying amounts of antigen. The 
HM1 and M2 antibodies showed increasing sensitivity as antibody concentration increased, 
detecting 2–5 ng of their antigens at a 1:200 dilution. Further increase to an antibody 
concentration (1:100) improved the sensitivity by only a small degree (Figure 4.8). In 
contrast, the other two antibodies (HM2 and M1) detected only the highest amount of antigen 
(50 ng) regardless of antibody dilutions (data not shown). HM2 and M1 were therefore 




Figure 4.8: A dot blot to test the sensitivity of the peptide antibodies. 
Various amounts of an antigen (0.1–50 ng) were applied to strips of membrane and probed with four different 






To determine the specificity of the two selected peptide antibodies (HM1 and M2) at the pre-
determined dilution (1:200), protein extracted from mouse placenta was used as this tissue 
strongly expresses mPeg10 (Clark et al., 2007). mPeg10 was detected using the two peptide 
antibodies and as well the anti-mPeg10ORF1 previously developed against ORF1 of mPeg10 
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size (150 kDa ORF1-2 fusion and 45kDa ORF1). These were confirmed to be mPeg10 by 
mass spectrometry. The HM1 antibody detected multiple bands between 66 and 96 kDa and 
an expected high molecular weight band (approximately 130 kDa). However, none of the 
smaller bands corresponded to proteins detected by the anti-mPeg10ORF1. The banding 
pattern of the M2 antibody was expected to be different from that of the anti-mPeg10ORF1 
because it was raised against only a small fragment of the ORF2 protein. The M2 antibody 
detected a protein of ~130 kDa (presumed to be the ORF1-2 fusion protein), similar to the 
HM1 antibody, but also a number of other proteins non-specifically when the protein load 
was 50 µg. From these two tests, it was concluded that these peptide antibodies were not 
better than the anti-mPeg10ORF1 because their specificities were inadequate with the higher 




Figure 4.9: Immunoblotting results of the specificity test of peptide antibodies. 
mPeg10 within total protein from mouse placenta was detected using anti-mPeg10ORF1 (1:1 000 or 1:200), 
peptide antibody HM1 or M2 (1:200). The membrane was developed for 3 min. The numbers above each lane 
indicate amount of protein loaded (µg). M, marker and marker protein sizes (from top to bottom) are 200, 116, 
96, 66, 45 and 31 kDa. Asterisks (*) indicate Peg10 ORF1 (50 kDa) and ORF1-2 fusion (150 kDa). 
 
 
4.5 Antibody purification 
 
 
Cross reactivity refers to a phenomenon where an antibody recognises non-target protein(s), 
often arising from similar or identical epitopes shared between more than one protein. 
1050 2 0.5 0.1 1050 2 0.5 0.110 2 0.5 0.1 10 2 0.5 0.1M M
anti-mPeg10ORF1 anti-mPeg10ORF1HM1 M2








Polyclonal antibodies frequently have cross-reactivity because they contain not only 
antibodies that recognise the desired antigen through sequence or conformation, but also 
antibody species recognising other proteins. Therefore, purification of polyclonal antibodies is 
often necessary to improve specificity for unambiguous results. Both positive selection, in 
which antibodies recognising the antigen of interest are purified by affinity binding to the 
specific antigen, and negative selection, in which antibodies recognising the non-target 
proteins are removed by binding, were used here. 
 
 
4.5.1 Removal of a non-specific antibody 
 
 
The antigen (mPeg10ORF1) was originally expressed in E. coli and purified for immunisation 
of rabbits. During this process, some antibodies against very minor contaminating E. coli 
proteins could be raised in addition to the desired antibodies that bind to mPeg10ORF1. To 
remove such non-specific antibodies from rabbit serum containing anti-mPeg10ORF1, an 
affinity column was prepared by coupling E. coli proteins to agarose beads. In the affinity 
purification process, a specific antibody would fail to bind to the prepared resin while the 




4.5.1.1 Buffer optimisation 
 
 
To prepare the affinity column for a non-specific antibody removal, it was necessary to 
determine the conditions that efficiently coupled E. coli proteins to Affi-Gel® 15 agarose 
beads. Protein coupling occurs between primary amines of lysine residues (and the N-
terminus) of proteins and an NHS-ester (N-hydroxysuccinimide) moiety of the Affi-Gel® 15 
at slightly alkaline pH. To find the optimal pH for protein coupling, E. coli proteins were 
coupled to the Affi-Gel® 15 over a wide range of different pHs. For this study, buffers were 
 110 
prepared that not only had different pKa values but also lacked a primary amine group that 
would interfere with the coupling reaction. Following coupling, the resin was washed to 
remove non-coupled proteins, and the coupled proteins were stripped from the resin by 
repeated heating in protein loading buffer. The protein fractions were immunoblotted using 




Figure 4.10: Buffer optimisation for E. coli protein coupling. 
E. coli (transformed with empty pQE-80L vector) proteins were coupled to Affi-Gel® 15 agarose beads (100 µL 
resin bed volume) at various pHs and with different buffer (100 mM). Following the protein coupling, the beads 
were washed and mixed with 100 µL of protein loading buffer. Samples were repeatedly heated and vortexed 
before loading (20 µL). After western transfer, the membrane was probed with anti-mPeg10ORF1 and exposed 
for 2 min. The numbers above each lane indicate pH of the buffer. M, marker. 
 
 
There were three proteins of different molecular weights (approximately 60 kDa, 28 
kDa and a minor 40 kDa component) coupled to the agarose beads. They could be removed 
from the beads by repeated heating and were recognised by anti-mPeg10ORF1 serum. These 
proteins coupled to the resin best at pH 7.5 and pH 8.0. Coupling efficiency dropped as pH 
increased and little immuno-reactive protein coupling occurred above pH 9.0. As a competing 
reaction to protein coupling, the NHS-ester can be hydrolysed in aqueous buffers. To prevent 
this, an organic solvent (DMSO) was also tested as a solvent for protein coupling. However, 
























than in aqueous buffers. An aqueous HEPES buffer of pH 7.5 was therefore chosen for 
subsequent coupling reactions. 
 
 
4.5.1.2 Preparation of an affinity column and antibody purification 
 
 
To prepare the affinity column, E. coli proteins were coupled to the Affi-Gel® 15 using 100 
mM HEPES at pH 7.5 (Section 2.6.2.2), and samples collected for analysis at each step of the 
procedure by SDS-PAGE (Figure 4.11). A significant amount of E. coli protein was coupled 
to the agarose beads because the flow-through fraction (FT) contained significantly less 
protein than was loaded (L) onto the resin (Figure 4.11). Only the first of five different 
washes contained minor amounts of protein (lane 1), and thus likely washed away uncoupled 




Figure 4.11: Preparation of an affinity column using E. coli proteins. 
E. coli (transformed with empty pQE-80L vector) proteins were coupled to Affi-Gel® 15 agarose beads using 
coupling buffer for 4 h. The beads were then washed with PBS (1), coupling buffer (2), PBS (3), acidic elution 
buffer (4) and PBS (5). M, marker; L, soluble fraction of E. coli cell lysate and FT, flow-through. 
 




















Figure 4.12: Immunoblotting results of a non-specific antibody removal. 
Removal of non-specific antibodies was tested under various conditions using the prepared affinity column. 1, 
untreated control; 2, affinity purified antibody (90 min at room temperature) and 3, affinity purified antibody 
(overnight at 4 °C). M, marker; L, soluble fraction of E. coli cell lysate (10 µL) and P, purified GST-
mPeg10ORF1 (5 ng). The membrane was exposed for 5 min. 
 
 
Non-specific antibody reacting species were removed from the immune serum using 
the prepared affinity column. Rabbit serum was added to the column and incubated for 
various periods of time (90 min, 180 min, or overnight) at two different temperatures (room 
temperature or 4 °C). The unbound flow-through antibody fraction (used as 1:1 000 dilution) 
was tested for reactivity against an E. coli cell lysate obtained by sonication (Figure 4.12). 
The untreated serum detected multiple E. coli proteins in the lysate (L) as well as the purified 
GST-mPeg10ORF1 (P), as expected. While there was significant reduction in non-specific 
detection when the serum immune fraction was affinity purified as described and incubated 
with cell lysate for 90 min at room temperature, the signal of the mPeg10ORF1 purified 
antigen was also reduced. Longer incubations (180 min at room temperature) completely 
eliminated both signals against E. coli proteins and the mPeg10ORF1, suggesting that the 
antibodies present in the serum had been largely inactivated. In contrast, an incubation at 4 °C 
preserved antibody activity, despite the long incubation time (overnight). With this condition, 
non-specific immune reactions were significantly but not completely reduced while the 










determined to be the best condition to remove non-specific antibody species using the affinity 
column as a potential first stage purification of the anti-mPeg10ORF1 antibody fraction. 
 
 
4.5.2 Preadsorption of an antibody 
 
 
An alternative method to remove non-specific antibodies is simply to preadsorb rabbit serum 
with non-target proteins. The antibody specific to the desired antigen would remain free in 
solution while the non-specific antibodies interact with their target proteins forming 
aggregates which are subsequently removed from solution by centrifugation (Section 2.6.1). 
To optimise the efficiency of preadsorption of unwanted antibody species, serum was mixed 
with various amounts of E. coli protein extract, the mixture centrifuged, and the remaining 
soluble antibody was then analysed for detection of E. coli proteins and the purified GST-
mPeg10 ORF1 by immunoblotting as before (Figure 4.13). As expected, the untreated control 
detected both the desired antigen, mPeg10ORF1, and multiple E. coli proteins. Preadsorption 
with 10 mg of E. coli proteins significantly reduced non-specific detection of proteins smaller 
than 45 kDa. The signal from a 66 kDa E. coli protein (which has a slightly lower apparent 
molecular weight than mPeg10ORF1) was significantly reduced but still strong. Higher 
amounts of E. coli protein removed more non-specific antibody, although the signal from the 
66 kDa protein could not be reduced further. Importantly, detection of mPeg10ORF1 was 
unaffected by preadsorption because the GST-mPeg10ORF1 had similar intensity across 
treatments. From these results, preadsorption using 50–100 mg of E. coli protein gave similar 





Figure 4.13: Immunoblotting results of preadsorption using E. coli proteins. 
Immunoblotting was performed using a primary antibody (anti-mPeg10ORF1) that had been preadsorbed with 
various amounts of E. coli (transformed with empty pGEX-6P-3 vector) proteins. 1, untreated control; 2, 10 mg; 
3, 50 mg and 4, 100 mg of E. coli protein. M, marker; L, soluble fraction of E. coli cell lysate (10 µL) and P, 
purified GST-mPeg10 ORF1 (5 ng). The membrane was exposed for 10 min. 
 
 
Both preadsorption and affinity purification, effectively reduced non-specific 
detection of E. coli proteins without lowering the sensitivity of anti-mPeg10ORF1. However, 
the preadsorption method is simpler and also has utility to easily adjust the purification serum 
volumes depending on the needs of the particular experiment. Therefore, preadsorption was 
used subsequently as the method of choice to remove non-specific antibodies for experiments. 
 
 
4.5.3 Purification of the mPeg10ORF1 specific antibody 
 
 
While non-specific antibodies were successfully reduced by the two negative selection 
methods, they were not completely removed. Additionally, purification by positive selection 
was performed to improve specificity. A large amount of soluble antigen (mPeg10ORF1) was 
required to prepare an affinity column. To produce soluble mPeg10ORF1, mPeg10ORF1 was 
cloned into a bacterial expression vector (pGEX-6P-3 or pMAL-c2) and expressed as a fusion 
protein (a GST- or MBP-mPeg10ORF1, respectively) in E. coli. Both fusion partners are 
highly soluble proteins and they are commonly used as partners to solubilise a protein of 
interest. The expressed fusion protein was first affinity-purified utilising the fusion partner, 
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and then isolated by electroelution after SDS-PAGE. The rabbit serum containing anti-
mPeg10 was then affinity purified and finally tested for its specificity and sensitivity. 
 
 
4.5.3.1 Cloning of mPeg10ORF1 
 
 
Insert (mPeg10ORF1) was amplified by PCR using pSP64T-Edr as a template. Primers were 
designed to amplify nucleotide position of 491–1501 of mPeg10 (NCBI reference sequence: 
NM_130877.2), and they included a restriction enzyme site (Bam HI for a forward primer and 
Xho I or Hind III for reverse primers). A stuffer sequence was at their 5´ ends (Table 2.1). The 
inserts for pGEX-6P-3 or pMAL-c2 were amplified using mPeg10ORF1F and 
mPeg10ORF1R1 or mPeg10ORF1R2 primers, respectively (Figure 4.14 A). Identical inserts 
(except for a restriction site) were cloned into two different bacterial expression vectors to 
determine which fusion partner was more suitable for the production of soluble 
mPeg10ORF1. After restriction digestion of the PCR products (corresponding to the inserts) 
and vectors using the appropriate restriction enzymes (Section 2.1.4), the inserts were ligated 
into the digested vectors (Section 2.1.8), and then transformed into E. coli DH5α cells 
(Section 2.1.10). As one of the ligation controls (digested vector + ligase) had many 
transformant colonies, one of the two restriction enzymes had not cut the vector efficiently, 
allowing for self-ligation to form a transformation-competent product. To overcome this 
problem, restriction digestion was repeated, but the digested vectors were then treated with 
alkaline phosphatase to prevent self-ligation of the vector in the absence of the inserts 
(Section 2.1.6). This step significantly reduced the number of transformant colonies in the 
ligation controls, while the ligated products still produced several hundred colonies. Selected 
colonies were screened for the presence of the inserts by PCR using the same primers as the 
initial amplification process (Figure 4.14 B and C). All colonies, except for pMAL-ORF1 
colony 3, showed a band at the expected size of approximately 1 kb. Two clones (colony 2 
and 5) from each of pGEX-ORF1 and pMAL-ORF1 were sequenced using their specific 
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sequencing primers (Table 2.4) and one example of each of the two clones (pGEX-ORF1 




Figure 4.14: Cloning of mPeg10ORF1 into pGEX-6P-3 and pMALc2 vector. 
Amplification of mPeg10ORF1 by PCR (A), PCR colony screening for pGEX-6P-3 (B) and pMALc2 (C). The 
numbers (1&2) in A represent the amplified inserts for pGEX-6P-3 (1) and pMALc2 (2). The numbers in B&C 
indicate recombinant colonies 1–6. M, marker; −, negative control and +, positive control. 
 
 
4.5.3.2 Expression of mPeg10ORF1 
 
 
The prepared constructs were transformed into E. coli Rosetta 2 cells and small-scale 
recombinant protein expression was performed as described in Section 2.4.1.1, except that 
protein expression for the pMAL-ORF1 construct was carried out at 18 °C and continued for 
20 h. The samples collected during the procedure were analysed by SDS-PAGE and 
immunoblotting. For the pGEX-ORF1 (Figure 4.15 A), there was a prominent band slightly 
larger than 66 kDa representing GST-mPeg10ORF1 (expected molecular weight of 65 kDa) 
clearly appearing at 1 h post-induction and of greater intensity at 3 h. Following the 3 h 
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insoluble proteins. Immunoblotting of these samples along with the 3 h post-induction sample 




Figure 4.15: Expression of recombinant proteins in E. coli Rosetta 2. 
Two constructs prepared were transformed into E. coli Rosetta 2 cells and protein expression was continued for 
3 h at 37 °C or 20 h at 18 °C. The samples collected at specific time points, soluble and insoluble fractions were 
analysed by SDS-PAGE and immunoblotting.  The membrane was probed with anti-GST (A) or anti-MBP (B) 
and exposed for 1 min or 8 min, respectively. The numbers above lanes indicate hours post-induction, and 0 
represents pre-induction. The red arrows indicate positions of induced protein bands. M, marker; S, soluble and 
I, insoluble proteins. 
 
 
In contrast, the pMAL-ORF1 did not produce as clear a difference in banding pattern 
over time after the induction of protein expression (Figure 4.15 B). However, immunoblotting 
analysis using anti-MBP revealed a band of approximately 96 kDa (expected molecular 
weight of 82 kDa) in both the 20 h post-induction sample and soluble fraction, indicating that 
the MBP-mPeg10ORF1 expression was properly induced and the expressed MBP-
mPeg10ORF1 was soluble. 
 Both fusion partners were effective in solubilisation of mPeg10ORF1. Compared to 
the MBP-mPeg10ORF1 expression, the GST-mPeg10ORF1 was expressed at a higher level 
and was also soluble so it was therefore more suitable for producing the large amount of 
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4.5.3.3 Purification of mPeg10ORF1 using a glutathione column 
 
 
To produce the required amount of the GST-mPeg10ORF1, a recombinant protein expression 
was performed on a large scale (Section 2.4.1.2), and the expressed GST-mPeg10ORF1 was 
purified using glutathione Sepharose 4B resin (Section 2.4.2). Samples were collected at each 
step of the procedure and analysed by SDS-PAGE (Figure 4.16). The 3 h post-induction 
sample showed that the expressed GST-mPeg10ORF1 band (approximately 66 kDa), and the 
flow-through fraction from the affinity column still contained a large amount of GST-
mPeg10ORF1 after overnight binding (Figure 4.16 A). The first wash removed some proteins 
that were likely trapped in the resin and the other two washes contained no apparent protein. 
However, the eluted GST-mPeg10ORF1 still contained low amounts of several other proteins 
(molecular weights of between 31 and 45 kDa). After purification and regeneration of the 
resin (Section 2.4.2), the flow-through (FT lane, Figure 4.16 A) was re-applied to the resin in 
an attempt to recover more GST-mPeg10ORF1 (Figure 4.16 B). This process successfully 
recovered some GST-mPeg10ORF1, although the yield was lower than for the first round of 
purification.  
A protein sample used for affinity column preparation needs to be as highly purified as 
possible to make sure that the purified antibody will recognise only the desired antigen. Due 
to the presence of contaminating proteins in the elution fractions, further purification was 







Figure 4.16: Purification of GST-mPeg10ORF1 using glutathione Sepharose 4B resin. 
The GST-mPeg10ORF1 was purified using glutathione Sepharose 4B resin (A). After collecting the flow-
through, the resin was washed three times with 50 mL PBS (wash 1–3). The bound protein was eluted in three 
fractions with 10 mL, 10 mL and 5 mL of 50 mM reduced glutathione in PBS (pH 7.4). Another cycle of 
purification was performed using the flow-through of the 1st purification (B). The bound protein was eluted in 
two fractions with 10 mL (1st elution) and 5 mL (2nd elution). M, marker; 3, 3 h post-induction sample; I, 
insoluble material and FT, flow-through. 
 
 




Electroelution is a method to recover proteins from a polyacrylamide gel, and it is similar to 
Western transfer although the eluted proteins remain in solution rather than being transferred 
onto a membrane. Protein samples can be fractionated first on a polyacrylamide gel and 
protein bands visualised using zinc staining (Section 2.4.8). A protein band of interest is 
excised using a razor blade, the gel piece destained and the protein of interest is then 
transferred from the gel piece to solution within a dialysis bag by electroelution (Section 
2.6.3.1). The eluted protein should be pure and contain only the protein of interest. 
 To find a suitable condition for electroelution of the GST-mPeg10ORF1, it was 
performed using two different buffers (Figure 4.17). One of the buffers tested was the transfer 
buffer consisting of Tris and glycine, which is used for Western transfer. The other buffer was 
prepared using ammonium bicarbonate that readily decomposes to volatile compounds 
(ammonia and carbon dioxide). Both buffers contained 0.1% (w/v) SDS to maintain protein 
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ammonium bicarbonate buffer (condition i, Figure 4.17) but not with this large amount of 
protein using the transfer buffer (condition ii, Figure 4.17). Of the 2 mL elution volume, lane 
2 and 3 contains 100 µL (a maximum of 5 µg if elution were 100% efficient). This result 
suggested that the ammonium bicarbonate buffer is more suitable for elution of large amounts 
of the GST-mPeg10ORF1 from a polyacrylamide gel piece. Most importantly, the eluted 
GST-mPeg10ORF1 was free of apparent contamination, indicating that electroelution 
successfully purified the GST-mPeg10ORF1 away from the contaminants. Yields from 
electroelution were further enhanced by changing from one 4 h elution to three 30 min 




Figure 4.17: Electroelution of the purified GST-mPeg10ORF1. 
After electroelution using two different buffers, the eluted protein was run on a polyacrylamide gel to compare 
the elution efficiency (A). Conditions of electroelution are summarised in B. Elution efficiency (recovery rate) 
was calculated by dividing ‘densitometry’ (amount of protein estimated by densitometry) with ‘expectation’ 
(theoretical maximum amount of protein) multiplied by 100 (C). M, marker; 1, 1 µg of GST-mPeg10ORF1; 
2&3, 100 µL of the eluted protein (duplicate) and 4&5, 100 µL or 200 µL of the eluted protein, respectively. 
 
 
 When coupling the GST-mPeg10ORF1 to Affi-Gel® 15, free SDS in solution has the 
potential to interfere with the reaction due to electrostatic interaction between the beads 
(positively charged) and the dodecyl sulphate ion (negatively charged). To minimise such 
possible interference, SDS was removed from the electroelution fractions after trialling 
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precipitate SDS, exploiting the low solubility of SDS in water at low temperature. Acetone 
and chloroform-methanol-water precipitation methods remove SDS by precipitating protein 
while keeping SDS soluble in the organic solvent. In contrast, addition of KCl or guanidine-
HCl precipitates SDS by forming insoluble ‘KDS’ or ‘GDS’, respectively, while protein 
remains in solution. Following SDS removal, the protein fractions (either in the solution or 
pellet depending on the methods) were analysed by SDS-PAGE (Figure 4.18). The 
electroeluted GST-mPeg10ORF1 appeared to migrate slower than that of control sample 
purified through a glutathione column, possibly due to residual ammonium bicarbonate (lane 
P compared with U). The low temperature method showed comparable band intensity to the 
untreated control, suggesting that it successfully removed SDS without protein loss (lane 1). 
In contrast, acetone precipitated only a small amount of the GST-mPeg10ORF1 shown as a 
fainter band (lane 2). With the other three methods the protein was lost during SDS removal 
(lane 3–5). Low temperature treatment was therefore chosen as the method to remove SDS 




Figure 4.18: A comparison of five different methods to remove SDS. 
Following electroelution of the GST-mPeg10ORF1 (100 µg in 4 mL), various methods were tested for their 
efficiency to remove SDS using 100 µL of the eluted protein. Prior to SDS-PAGE analysis, samples were 
concentrated by drying in a SC110 SpeedVac® Concentrator (samples U and 1), TCA (sample 4) or ethanol 
precipitation (sample 5). M, marker; P, glutathione-column purified GST-mPeg10ORF1 (5 µg); U, untreated 
control (100 µL of electroeluted GST-mPeg10ORF1); 1, low temperature treatment; 2, acetone precipitation; 3, 
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4.5.3.5 Preparation of an affinity column 
 
 
Prior to linking the highly purified GST-mPeg10ORF1 to the Affi-Gel® 15, coupling 
conditions were optimised to ensure efficient covalent interaction. Protein coupling was tested 
using 100 mM MOPS or HEPES buffer (pH 7.0 or 7.5) and both buffers and pHs appeared 
equally effective at 4 °C. Therefore, the same condition (100 mM HEPES, pH 7.5) that had 




Figure 4.19: Coupling of the purified GST-mPeg10ORF1 to the Affi-Gel® 15. 
Electroeluted (SDS removed) GST-mPeg10ORF1 was coupled to the Affi-Gel® 15 at 4 °C using coupling 
buffer. Samples collected during the procedure were analysed by SDS-PAGE. M, marker; 1, GST-mPeg10ORF1 
resuspended in coupling buffer (6 µL of 6 mL); 2, supernatant after removal of precipitate that formed on 
cooling (6 µL); 3, resuspended precipitate that formed on cooling (6 µL of 6 mL); 4, supernatant sample (10 µL) 
of protein shown in lane 2 after 2 h coupling and 5, supernatant sample (10 µL) of sample from lane 3 after a 
further 2 h coupling.  
 
 
The coupling was first carried out in a pilot study (data not shown) using the purified 
GST-mPeg10ORF1 as described above and in Section 2.6.3.2, and samples before and after 2 
h coupling were taken and analysed by SDS-PAGE. No visible amount of the GST-
mPeg10ORF1 was left in solution after 2 h of coupling, suggesting that coupling reaction was 
complete. Figure 4.19 shows the analysis of the subsequent larger scale coupling experiment 
and preparation of the affinity column. The GST-mPeg10ORF1 was efficiently coupled to the 
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small precipitate occurred during initial cooling of the sample in the larger scale study prior to 
coupling, it was removed, resuspended in buffer, and as no further precipitation occurred with 
cooling, coupling was repeated with this fraction. However, analysis on SDS-PAGE (lanes 3) 
indicated that the precipitate that formed on initial cooling did not contain the GST-
mPeg10ORF1 or any other protein and not surprisingly none was seen in lane 5. It was likely 
to be residual SDS.  
 
 
4.5.3.6 Purification of mPeg10ORF1 specific antibody 
 
 
Rabbit serum (typically 1 mL) was applied to the prepared affinity column and mPeg10ORF1 
specific antibody was purified as described in Section 2.6.3.3. Briefly, the flow-through was 
collected after overnight binding at 4 °C and the column was washed first with PBS, then 
coupling buffer, and finally PBS. The bound antibody was eluted with acidic elution buffer 
(pH 2.4) and immediately neutralised with 1 M Tris-HCl (pH 8.0). Untreated, flow-through 
and elution fractions were used as a primary antibody to determine their specificity against E. 




Figure 4.20: A specificity test of the affinity purified anti-mPeg10ORF1. 
After affinity purification using the prepared column, the purified antibody was tested for its specificity. M, 
marker; L, 10 µL of soluble E. coli cell lysate; P, purified GST-mPeg10ORF1 (5 ng); 1, untreated control; 2, 
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The untreated rabbit serum detected both the purified GST-mPeg10ORF1 and multiple 
E. coli proteins (Figure 4.20 1, L and P). Antibodies in the flow-through fraction (2, L and P) 
from the affinity purification recognised similar E. coli lysate protein bands at a comparable 
intensity to that of the untreated control but not the purified GST-mPeg10ORF1, which was 
now only very weakly detected. The eluted antibody fraction detected the purified GST-
mPeg10ORF1 while only very weakly recognising any E. coli proteins. An mPeg10ORF1 
specific antibody was successfully purified from rabbit serum using affinity purification and 
its specificity was significantly improved compared to preadsorption (Figure 4.13). 
Following the specificity test of the purified anti-mPeg10ORF1, a sensitivity test was 
performed using the purified antibody at various dilutions to detect mPeg10ORF1 and 
mPeg10ORF1–2 in two different amounts of mouse placental protein extract. This tissue had 




Figure 4.21: A sensitivity test of the affinity purified anti-mPeg10ORF1. 
The purified anti-mPeg10ORF1 was tested for its sensitivity using different dilutions ranging from 1:50 to 1:1 
000 to detect mPeg10 expressed in mouse placental protein extract (10 or 50 µg). The numbers above each lane 
indicate the amount of mouse placental protein extract loaded onto each lane (µg). The membrane was exposed 
for 30 s. Asterisks (*) indicate Peg10 ORF1 (50 kDa) and ORF1–2 fusion (150 kDa). M, marker. 
 
 
Two bands representing mPeg10 (ORF1 at 45 kDa and ORF1-2 fusion at 150 kDa) 
were detected, and the signal of these bands intensified with increasing antibody 


















1:100) showed comparable results, it was decided therefore to use the purified antibody at a 
1:100 dilution for later experiments. 
 
 
4.5.4 Summary of antibody purification 
 
 
An antibody against mPeg10ORF1 raised in rabbits showed high sensitivity against its 
antigen but it also recognised E. coli proteins non-specifically, because the ORF1 protein had 
been expressed in bacteria. To improve specificity, the rabbit serum was purified by 
preadsorbing with E. coli proteins. The preadsorbed antibody improved specificity and had 
the same sensitivity against mPeg10ORF1 compared to the untreated rabbit serum. The 
affinity purified antibody showed significantly improved specificity with a slightly reduced 
sensitivity against mPeg10ORF1. The best antibody preparation for specificity and sensitivity 
was obtained by a single round of purification. Two rounds of negative and positive selections 
resulted in significant losses of specific antibody. Therefore, the anticipated method of 
coupling positive selection to negative selection protocols was not used. Either of these 
methods successfully improved specificity of anti-mPeg10ORF1 for use in screening for 








Expression of Peg10 
 
 
Understanding in which tissues the expression of PEG10 into proteins with frameshifting 
occurs is important to the strategy of targeting −1 frameshifting in HIV-1 as a drug target. 
 
 
5.1 mPeg10 mRNA in mouse tissues 
 
 
5.1.1 qPCR data acquisition and processing 
 
 
Total RNA samples extracted from various mouse tissues that had been assessed to be of 
adequate purity, integrity and concentration (Section 4.1.1), were used as a template to 
prepare cDNA for analysis of mPeg10 mRNA expression by quantitative real time PCR 
(qPCR). Samples with concentrations of <45 ng/µL (Appendix III) were excluded at this step 
due to the limited reaction volume. For cDNA synthesis, 400 ng of total RNA was reverse-
transcribed using random primers and Superscript®III Reverse Transcriptase (Section 2.2.5). 
Six ovary samples were pooled together before RNA extraction due to their small size, and so 
ovary cDNA samples were prepared in triplicate in three independent reactions. The prepared 
cDNAs were diluted 30-fold and used as templates to amplify a target cDNA using gene-
specific primers and Roche SYBR Green I master mix (Table 2.6 and Section 2.2.6.1). 
Primers were designed with the help of Primer-BLAST, which identifies potential non-
specific targets, so that specific amplification of target genes could be ensured (Section 
2.2.6.2). Following completion of the programmed thermal cycles, measured fluorescence 
data for all samples were retrieved from the Roche LightCycler® 480 software for calculation 
of PCR amplification efficiency using the LinReg software (Ramakers et al., 2003). Roche 
LightCycler® 480 software was used to calculate a quantification cycle (Cq) value for each 
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sample based on the measured fluorescence, using the second derivative maximum method, 
which automatically calculates Cq values and eliminates baseline error. Samples with a Cq 
value ≥40 were excluded from the analysis because such Cq values were unreliable 
(Appendix VI). To confirm the amplification was specific for the target gene, melting curve 
analyses were performed after the completion of thermal cycles (Section 2.2.6.1 and Figure 
5.1). These analyses showed a single peak, representing a specific amplification of the target 
cDNA for all primer pairs in most reactions. A minority of amplifications showed two peaks 
indicating more than one product, and these were excluded from the analysis (Appendix VI 
and VII). In some negative control reactions where H2O replaced cDNA, there was an 
additional peak at a lower temperature than expected for the target products, suggesting the 
formation and amplification of primer dimers (red arrows in Figure 5.1). Importantly, these 
peaks were absent in the cDNA samples with the same primers. To further validate the 
specific amplification of target genes after qPCR data had been collected, the reaction (10 µL) 
was analysed by agarose gel electrophoresis (Figure 5.1). These results showed single 
appropriately-sized products for each reaction, providing strong evidence that the target gene 






Figure 5.1: Representatives of melting curve analyses and agarose gel electrophoresis. 
DNAs amplified by qPCR were analysed by melting curve (A–E) and by agarose gel electrophoresis (F). The red 
arrows indicate the melting curves of primer dimer products from control samples containing no cDNA. The 
representative samples shown in this figure were derived from mouse placenta RNA. (F) M, marker; 1, 
Hsp90ab1; 2, Bet1l; 3, Wdr33; 4, Peg10CDS and 5, Peg103´UTR. 
 
 
5.1.2 mPeg10 mRNA detection in mouse tissues 
 
 
The fold change in gene expression was calculated using formulae described in Hellemans et 
al. (2007) (Section 2.2.6.4 and Appendix II), and rescaled against a tissue that showed the 
least expression of mPeg10 mRNA (Figure 5.2). As expected, the transcript of mPeg10 was 
expressed at the highest level in placenta (4600-fold higher than kidney, a tissue with very 
low expression used for normalisation). Placenta is a tissue where mPeg10 protein has been 











mRNA at a high level (3600- and 330-fold above that in kidney, respectively). Additionally, 
several tissues, such as brain, testis and ovary, showed a significant level of mPeg10 mRNA 
expression (30–50-, 120- and 90-fold above kidney, respectively). Interestingly, adipose and 
muscle tissues in female and pregnant female mice had an increased level of mPeg10 mRNA. 
In other tissues such as kidney, mPeg10 mRNA was detectable but its expression was very 
low (Figure 5.2). 
 Expression of PEG10 in human tissues has been analysed previously by Northern 
blotting and the full-length PEG10 transcript (approximately 6.5 kb) was consistently 
detected including in embryonic tissues (Ono et al., 2001; Okabe et al., 2003; Smallwood et 
al., 2003; Brandt et al., 2005; Lux et al., 2005). Additionally, a smaller transcript of 2.1 kb 
was detected in human placentae (Smallwood et al., 2003). This finding suggested that the 
smaller transcript was derived from PEG10 3´ UTR since the probe used for Northern blotting 
targeted the end of the 3´ UTR, although this observation could be non-specific since other 
groups failed to detect it. To determine if other mouse tissues also expressed this smaller 
mRNA, mPeg10 mRNA was measured in various mouse tissues by qPCR using primers to 
the mPeg10 3´UTR (Figure 5.3). The primers were designed to amplify nucleotide positions 
4904–5054 of mPeg10 within the 3´ UTR (NCBI reference sequence: NM_130877.2). These 
primers would also prime on the full-length transcript as well as the smaller transcript. 
Therefore, detection of higher levels of mPeg10 expression using such Peg103´UTR primers 
compared with that of Peg10CDS primers would imply transcription of the smaller mRNA 
from mPeg10 3´ UTR. As shown in Figure 5.3, the results indicated the same trend 
confirming the tissue-specific expression of full-length mPeg10. The measured levels of 
mPeg10 expression were actually lower rather than higher with these primers compared to 
those used in Figure 5.2. This may have been due to some mRNAs having shorter 3´ ends 
thereby lacking a site(s) where the primers bind. The results were not informative for possible 
expression of the smaller mPeg10 mRNA in any of the mouse tissues tested. 
 
 131 
 To account for the quality of mPeg10 mRNA expression analyses by qPCR, two 
parameters, the coefficient of variation (CV) and the stability parameter (Mgene and Mirc), 
were calculated for the selected reference genes and inter-run calibrators (IRCs) in each run 
(Appendix VIII). Both parameters represent the stability of gene expression or IRCs within 
and among independent runs. The acceptable reference values for these parameters are <50% 
CV and <1.0 Mgene for reference genes while IRCs should have a stability parameter Mirc 
value of ≅0.1 (Hellemans et al., 2007). The selected reference genes (Hsp90ab1, Bet1l and 
Wdr33) had both overall CV and Mgene values well within the acceptable reference values for 
all groups, indicating that the selected reference genes were expressed at similar levels across 
various tissue types. Three different IRCs were included in each run for mouse samples and 
they were prepared by mixing cDNAs from all tissues of male, female or pregnant female 
mice. The IRC stability value was slightly higher than the reference value of 0.1 mainly due 
to the larger variations of target gene expression (mPeg10) among the three calibrators.  
Significant expression of mPeg10 mRNA was detected in many tissue types, including 
embryonic tissues (where mPeg10 protein has been confirmed as being expressed) while 
some tissues expressed mPeg10 mRNA at a very low level, illustrating a pattern of tissue-
specific expression of mPeg10 mRNA. The two quality control measures, CV and stability 
parameter (Mgene and Mirc), showed that both the selected reference genes and the IRCs were 
stably expressed among 18 different tissues types from three groups of mice (male, female 





Figure 5.2: mPeg10 mRNA detected in mouse tissues using Peg10CDS primers. 
Expression of mPeg10 mRNA was measured by qPCR in various tissues from male (A), female (B) and 
pregnant female mice (C). The expression level of mPeg10 mRNA was normalised against the three reference 
genes (Hsp90ab1, Bet1l and Wdr33). Fold change in mPeg10 mRNA expression was rescaled against kidney (set 
at 1.0) for male and female mice, or liver for pregnant female mice. Generally, usable data from 4 or 5 of 6 
biological replicates were obtained in most cases. For more detail, see Appendix VI. Values for ovary, amnion, 
embryo and placenta are shown on the right with a separate scale (in red). *p-value <0.05 and **p-value <0.01, 










































































































































































































Figure 5.3: mPeg10 mRNA detected in mouse tissues using Peg103´UTR primers. 
Expression of mPeg10 mRNA was measured by qPCR in various tissues from male (A), female (B) and 
pregnant female mice (C). The expression level of mPeg10 mRNA was normalised against the three reference 
genes (Hsp90ab1, Bet1l and Wdr33). Fold change in mPeg10 mRNA expression was rescaled against kidney for 
male and female mice, or intestine for pregnant female mice. Generally, usable data from 4 or 5 of 6 biological 
replicates were obtained in most cases. For more detail, see Appendix VI. Values for amnion, embryo and 
placenta are shown on the right with a separate scale (in red). *p-value <0.05 and **p-value <0.01, compared 








































































































































































































5.2 mPeg10 protein in mouse tissues 
 
 
Expression analysis of mPeg10 mRNA by qPCR identified tissues expressing mPeg10 mRNA 
at higher levels. To determine whether mPeg10 protein expression correlated with levels of 
expressed mRNA in mouse tissues, total protein was extracted from the mouse tissues 
(Section 2.4.4), the concentration determined, and protein extracts were concentrated by 
acetone precipitation to approximately 10 mg/mL (Section 2.4.3.3). The concentrated protein 
samples (200 µg) were fractionated by SDS-PAGE and then transferred to a membrane for 
immunoblotting. Initially, six biological replicates of the same tissue type were screened by 
immunoblotting using anti-mPeg10ORF1 to test the degree of biological variation among 
samples from different animals (Appendix IX). The results indicated that there was little 
variation among the replicates in the Peg10 products of interest.  
A representative mouse was subsequently selected from each group (one each for 
male, female and pregnant females), and protein extracts of all tissues from the same animal 
were subjected to immunoblotting using both anti-mPeg10ORF1 and the more specific 
preadsorbed antibody for a more detailed analysis (Figure 5.4, Figure 5.5 and Figure 5.6). 
Anti-mPeg10ORF1 detected proteins of varying molecular weights in all tissues except for 
spleen and kidney. However, immuno-reactive bands were considered non-specific because 
they were not detected when the preadsorbed antibody of higher specificity against mPeg10 
ORF1 was used. Some bands such as one seen in heart samples were reduced but still 
detectable using the preadsorbed antibody but this was deduced to result from their high 
immuno reactivity. For the male mouse samples, brain, muscle, adipose and testis had shown 
significant levels of mPeg10 mRNA. However, immunoblotting did not detect bands at the 
expected positions of the two expected mPeg10 proteins in these tissues. Five different tissue 
samples (brain, muscle, adipose, uterus and ovary) of the female mouse were found to express 
mPeg10 mRNA significantly. Immunoblotting using the preadsorbed antibody detected a 
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band at the approximate size of mPeg10 ORF1–2 but not of mPeg10 ORF1 in muscle, 
adipose tissues and in uterus. This finding was intriguing considering that the translation of 
mPeg10 ORF1–2 fusion protein depends on the −1 frameshifting that is usually a low 
frequency event compared with the canonical translation event at the site. Similarly, muscle 
and adipose from the pregnant female mouse with an increased mPeg10 mRNA expression 
had a protein band at the expected molecular weight of mPeg10 ORF1–2 without any 
evidence of a mPeg10ORF1. By contrast, expression of both mPeg10 ORF1 and ORF1–2 
were clearly detected in placenta (Figure 5.4) and both were also detected in amniotic 
membranes and faintly detected in embryo (Figure 5.6). This difference in expression levels 
among embryonic tissues was consistent with the results of mRNA expression in these tissues 





Figure 5.4: mPeg10 expression analysed by immunoblotting (male mouse). 
Total protein extracts (200 µg) were concentrated by acetone precipitation, fractionated on a polyacrylamide gel, 
and transferred to a membrane. The membrane was then probed with either anti-mPeg10ORF1 (left) or the 
preadsorbed antibody (right). The membrane was exposed for 1 min. M, marker and placental sample as a 













































































































Figure 5.5: mPeg10 expression analysed by immunoblotting (female mouse). 
Total protein extracts (200 µg except for ovary which was 50 µg) were concentrated by acetone precipitation, 
fractionated on a polyacrylamide gel, and transferred to a membrane. The membrane was then probed with either 
anti-mPeg10ORF1 (left) or the preadsorbed antibody (right). The membrane was exposed for 1 min. M, marker 
















































































































Figure 5.6: mPeg10 expression analysed by immunoblotting (pregnant female mouse). 
Total protein extracts (200 µg) were concentrated by acetone precipitation, fractionated on a polyacrylamide gel, 
and transferred to a membrane. The membrane was then probed with either anti-mPeg10ORF1 (left) or the 
preadsorbed antibody (right). The membrane was exposed for 1 min. M, marker and placental sample as a 














































































































































The preadsorbed antibody had higher specificity than crude serum but still recognised 
other proteins non-specifically. For a more thorough analysis of mPeg10 expression in tissues 
with an increased level of mPeg10 mRNA, several tissues were selected and analysed by 




Figure 5.7: Immunoblotting analysis of the selected mouse tissues using the purified 
anti-mPeg10ORF1 antibody. 
The selected mouse samples were analysed for mPeg10 protein expression using the purified mPeg10ORF1 
antibody. The membrane was exposed for 15 min. Brain, muscle and adipose were from a pregnant female 
mouse while testis and uterus were from a male and a female mouse, respectively. M, marker and placental 
sample as a positive control (10 µg of mouse placental protein) 
 
 
From this analysis, no mPeg10 band was detected in brain. Muscle and adipose 
showed a very weak band at a similar molecular weight to the mPeg10 ORF1–2, and a similar 
band was observed in uterus with higher intensity although these samples lacked a band at 45 
kDa representing the mPeg10 ORF1. Testis, by contrast, had two distinctive bands slightly 
above and below the 45 kDa mPeg10 ORF1. To determine whether the immunopositive bands 
at high molecular weight are indeed mPeg10, placenta, muscle and adipose samples from the 
pregnant female mouse were analysed by mass spectrometry (Section 2.4.11). The uterus 
sample from the female mouse was not analysed by mass spectrometry because limiting 
sample availability. Five distinct peptides were identified as mPeg10 in the placenta sample 

























However, no peptides matching any of the five reference peptides were detected in muscle or 
adipose samples. An example is shown in Figure 5.8 with peptide HVFEDPQRR (15.73 min). 
Therefore, mass spectrometry results could not confirm mPeg10 expression in adipose tissue 




Figure 5.8: Extracted ion chromatographs for placenta, adipose tissue and muscle. 
Placenta (A), adipose tissue (B) and muscle (C) from the pregnant female mouse were analysed for mPeg10 
expression using a LTQ-Orbitrap hybrid mass spectrometer. The figure shows the extracted ion chromatographs 
of three tissue samples for one of the five peptides (HVFEDPQRR, retention time of 15.73 min). For other 
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5.3 Peg10 mRNA expression in rat brains 
 
 
In mouse brain samples, a higher expression level of mPeg10 mRNA was detected in all 
sample groups by qPCR compared with most tissues but immunoblotting did not confirm the 
expression of mPeg10 protein in these samples. Since mPeg10 was originally identified 
through screening of a cDNA library prepared using a mouse fetal brain (Steplewski et al., 
1998), it was decided to investigate further the expression of Peg10 in brain. Rat brains were 
used because of their larger size compared with those from mice. Significantly, use of rat 
brains allowed dissection of different parts of a brain in sufficient amounts for the more 
detailed analysis of Peg10 expression in each region. The brains were first divided into two 
hemispheres and then five different parts (cerebellum, cortex, hippocampus, hypothalamus 
and thalamus) were isolated (Section 2.7.2). Total RNA was extracted using TRIzol® Reagent 
from the samples from left hemispheres (Section 2.2.1.1), and treated with DNase I to remove 
residual genomic DNA contaminants (Section 2.2.3). In subsequent procedures (cDNA 
synthesis, qPCR reaction and data processing), rat samples were essentially treated identically 
to the mouse samples described in Section 4.1 with two modifications. Rat gene specific 
primers were used for the qPCR reactions (Table 2.5) and the relative gene expression was 
rescaled against cerebellum (CB).  
Melting curve analyses (Section 2.2.6.1) showed a single peak indicating specific 
amplification of the target gene for all primer pairs (Figure 5.9). Without template added Hprt 
primers had a peak representing amplification of primer dimer (a red arrow in Figure 5.9) 
while other primers lacked any signal without added template. When the whole reaction (10 
µL) was analysed by agarose gel electrophoresis, it confirmed specific amplification of the 




Figure 5.9: Representatives of melting curve analyses and agarose gel electrophoresis. 
DNAs amplified by qPCR were analysed by melting curve (A–E) and by agarose gel electrophoresis (F). The red 
arrow indicates the melting curve of the primer dimer product from control samples containing no cDNA. The 
representative samples shown in this figure were derived from rat placenta RNA. (F) M, marker; 1, Hprt; 2, 
Hsp90ab1; 3, Cyc-1; 4, Peg10CDS and 5, Peg103´UTR. 
 
 
Rat brain samples from these groups of animals (male, female and lactating female 
rats) showed very similar expression patterns. Significantly, Peg10 mRNA expression was 
considerably higher in hypothalamus compared with the four other brain regions tested 
(Figure 5.10). The hypothalamus from the lactating female group had an even higher level of 
Peg10 expression (1.8-fold) compared with male and female rats (similar). As expected, rat 
placenta used as a control showed the highest Peg10 mRNA expression (120-fold greater). 












(Figure 5.11), both the expression pattern and the fold change of Peg10 mRNA were 
surprisingly similar to that of Peg10CDS primers (Figure 5.10) unlike that in the mouse 
samples. However, the smaller transcript of 2.1 kb may also not be expressed in rat brains, 
since the expression level of Peg10 was comparable between the two sets of primers.  
 Two parameters, the CV and the stability parameter (Mgene), were calculated for the 
reference genes to check the quality of the rat Peg10 mRNA expression measured by qPCR 
(Appendix VIII). The reference values for these parameters were <25% CV and <0.5 Mgene, 
which was a half of those values for the mouse samples due to a higher degree of 
homogeneity within the rat samples. The CV and Mgene for the selected reference genes (Hprt, 
Hsp90ab1 and Cyc-1) were <19 % and <0.49, respectively. These values indicated that the 
reference gene expression was stable across all sample types. The quality control parameter 
for the IRC (Mirc) could not be calculated as only one IRC was used for the rat samples. 
In conclusion, a marked level of Peg10 mRNA expression was detected in brain but 
only in the hypothalamus, consistent across the different rat brain samples of the three animal 
groups. The hypothalamus from the lactating female rats had the highest level of Peg10 
expression. These results provided evidence that Peg10 is expressed in specific regions or cell 
types within a tissue and also implied that the Peg10 expression may change according to 







Figure 5.10: Peg10 mRNA detected in rat brain samples using Peg10CDS primers. 
Expression of Peg10 mRNA was measured by qPCR in various tissues from male (A), female (B) and lactating 
female rats (C). The expression level of Peg10 mRNA was normalised against the three reference genes (Hprt, 
Hsp90ab1 and Cyc-1). Fold change in Peg10 mRNA expression was rescaled against cerebellum. The data were 
obtained from 3 animals in each group. Values for placenta refer to the scale on the right. *p-value <0.05 and 
**p-value <0.01, compared with cerebellum. Error bars represent SD. CB, cerebellum; CTX, cortex; HPC, 






























































































Figure 5.11: Peg10 mRNA detected in rat brain samples using Peg103´UTR primers. 
Expression of Peg10 mRNA was measured by qPCR in various tissues from male (A), female (B) and lactating 
female rats (C). The expression level of Peg10 mRNA was normalised against the three reference genes (Hprt, 
Hsp90ab1 and Cyc-1). Fold change in Peg10 mRNA expression was rescaled against cerebellum. The data were 
obtained from 3 animals in each group. Values for placenta refer to the scale on the right. *p-value <0.05 and 
**p-value <0.01, compared with cerebellum. Error bars represent SD. CB, cerebellum; CTX, cortex; HPC, 






























































































5.4 Peg10 protein expression in rat brains 
 
 
Of the Peg10 expression determined by qPCR in rat brain samples, the hypothalamus was 
consistently found to have higher levels of Peg10 mRNA across three sample groups. To 
investigate expression of Peg10 protein in rat brain, total protein was extracted from the five 
regions of the rat brain (right hemisphere) from the same rats analysed for mRNA levels as 
described in Section 2.4.4. Total protein extracts (200 µg) were concentrated by acetone 
precipitation (Section 2.4.3.3), fractionated by SDS-PAGE and then transferred to a 
nitrocellulose membrane. Although anti-mPeg10ORF1 had been raised against mPeg10 
ORF1, the antibody was inferred to likely recognise the rat homologue since alignment of the 
two Peg10 protein sequences (NCBI reference: NP_570947.2 and XP_008760959.1 for 
mouse and rat, respectively) showed a 68% identity with 76% similar residues. Indeed, anti-
mPeg10ORF1 recognised rat Peg10 in rat placental extract, and so both the preadsorbed 
antibody and the purified anti-mPeg10ORF1 antibody were used to detect Peg10 protein 
expression in rat brain samples (Figure 5.12).  
Rat placental extract showed two major bands, one at the expected position of 
approximately 150 kDa and one at a greater than expected 60 kDa. The greater molecular 
weight protein represents Peg10 ORF1–2 protein while the smaller one at 60 kDa is larger 
than the predicted molecular weight of ORF1 (~45 kDa). It seemed likely to be ORF1 since 
there was no band in the rat placental extract at the expected position of ORF1. In brain 
samples, there were several bands detected by the preadsorbed antibody in all samples 
including intense bands at approximately 130, 66 and 40 kDa (Figure 5.12 A–C). All of these 
bands were considered as non-specific as the corresponding bands were absent in the rat 
placental extracts. An approximately 60 kDa protein band observed as weakly immunostained 




Figure 5.12: Immunoblotting analyses of rat brain and placenta samples. 
Total protein extracts (200 µg) were concentrated by acetone precipitation, fractionated on a polyacrylamide gel, 
and transferred to a membrane. The membrane was probed with the preadsorbed antibody (A–C) or the purified 
mPeg10ORF1 antibody (D), and then exposed for 30 min or 5 min, respectively. Samples were from a male (A), 
a female (B) and a lactating female rat (C and D). Asterisks (*) indicate two species of rat Peg10 proteins 
detected using both the preadsorbed and the purified mPeg10ORF1 antibody. M, marker; CB, cerebellum; CTX, 
cortex; HPC, hippocampus; HYP, hypothalamus; TH, thalamus; PL, placenta (50 µg of rat placenta was used as 
a positive control). 
 
 
As the signal from the lactating female hypothalamus was stronger than that of the 
hypothalamus in the male and non-lactating female rat, immunoblotting was repeated to 
determine if there was a different banding pattern or intensity in the lactating female 
hypothalamus using the purified anti-mPeg10ORF1 antibody (Figure 5.12 D). This result 
showed a strong immunopositive band in both the lactating female hypothalamus and placenta 
at the same molecular weight of 60 kDa, suggesting that Peg10 protein may be expressed in 



































Was the 60 kDa immunostaining band detected in both placental and hypothalamus 
sample ORF1 as presumed? To investigate the immunoblotting results further, the 
immunopositive band in the lactating female hypothalamus was analysed by mass 
spectrometry (Section 2.4.11 and Figure 5.13). Three peptides were identified as rat Peg10 
from the rat placenta sample in the initial analysis and these peptides were searched for in 
both the rat placenta and hypothalamus samples. A Peg10 peptide (VCFVTSMLTGR) from 
ORF1 was detected in both samples (Figure 5.13 A). The signal intensity of this peptide in a 
rat placental extract was twice as strong as that of a rat hypothalamus extract although a 30-
fold greater amount of the hypothalamus protein extract was used. A peptide (SIVFNSDYcR) 
identified as Peg10 ORF2 was detected only in a rat placental extract (Figure 5.13 D). 
However, this peptide had 8-fold lower intensity compared with the other peptide (Figure 
5.13 A and D). This may explain why this peptide was not detected in the rat hypothalamus 
extract. Another ORF2 peptide (EILSFDVTQSPFFPIVLGIR) was not found in either sample 
although it was detected in the rat placenta in the previous analysis. Despite identification of 
only a single Peg10 peptide in the rat hypothalamus sample, for the first time mass 
spectrometry results confirmed Peg10 expression in a tissue other than embryonic tissues 
under physiological conditions. As the molecular weight of the immunopositive band was 60 
kDa, it may be a degradation product derived from the ORF1–2 protein. This would imply 





Figure 5.13: Mass spectrometry detected a Peg10 peptide in rat hypothalamus. 
Total protein extracts (7× 200 µg of rat hypothalamus and 50 µg rat placenta) were analysed for Peg10 
expression using a LTQ-Orbitrap hybrid mass spectrometer. The extracted ion chromatograph of a peptide 
identified in both samples (VCFVTSMLTGR, 161–171 of rat Peg10 ORF1) is presented in A together with 
fragmentation pattern (B and C). The extracted ion chromatograph of another peptide only identified in rat 
placental extract (SIVFNSDYcR, 502–511 of rat Peg10 ORF2) is shown in D. The amino acid number is based 



























































































































































5.5 Summary of Peg10 expression studies 
 
 
mPeg10 protein was confirmed only in placenta as previously shown and no other tissues, 
despite RNA being detected in all tissues. By contrast, rat Peg10 protein expression was 
confirmed in hypothalamus from rat brain. An apparent proteolytic ORF1–2 fragment of the 
same size was found in hypothalamus and placenta. The placenta sample had peptides from 
ORF1 and ORF2 as identified by mass spectrometry whereas only an ORF1 peptide was 










6.1 Comparison of −1 frameshifting 
between HIV-1 and PEG10 
 
 
6.1.1 The effect of the intercodon 
 
 
Results from the studies of PEG10 frameshifting obtained in this study are summarised in 
Table 6.1 together with those of HIV-1 for comparison (Mathew et al., 2015). Consistent with 
the previous study with HIV-1, a stop codon introduced at the intercodon position 
(immediately downstream of the X XXY YYZ slippery sequence) in the PEG10 frameshift 




Table 6.1: Effect of the intercodon on −1 frameshifting in HIV-1 and PEG10. 
 Wild-type intercodon UGA intercodon 
HIV-1 10% (GGG) 4% 
PEG10 23% (UCC) 6% 
This table summarises a comparison of HIV-1 and PEG10 frameshift efficiency with WT (GGG for HIV-1 and 
UCC for PEG10) or UGA intercodon. HIV-1 data were taken from Mathew (2008). 
 
 
Specific activities of both luciferases were considered carefully to ensure that the 
observed reduction in frameshift efficiency indeed was due to a reduced amount of the 
downstream (firefly luciferase, Luc+) reporter and not an increase in the upstream RLuc 
reporter (Table 6.2). It is important to note that the Michaelis constants (Km) of the specific 
substrates for the two luciferases in the fusion form (RLuc-Luc+) that is produced after 
frameshifting, were equivalent to those with the individual RLuc and Luc+ native proteins, 
suggesting that an active conformation of each of the substrate binding centres was retained 
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within the fusion product, even though they had N- or C-terminal extensions (Cridge, 2004). 
This supported the idea that the difference in luciferase expression levels was a true reflection 
of the relative amounts of reporter proteins synthesised. However, a caveat is that the non-
frameshifted RLuc products have slightly different lengths of extension at the C-terminus (the 
stop construct produced an RLuc with a 10 amino acid C-terminal extension compared with 
15 amino acids with the WT construct). This could result in these having different specific 
activities. The relative light unit (RLU) data suggest however, that any such variation in 
specific activity is small. RLuc activity from the datasets within a biological replicate was 
comparable between the WT (RLuc = 15 amino acid extention) and RT construct (RLuc-Luc+ 
= 582 amino acid extention). The stop construct with the 10 amino acid extension gave a 1.4-
fold higher RLU for RLuc on average over 5 biological replicates and a total of 21 technical 
replicates. Each biological replicate (new transfection and new cells) differed in absolute 
activity from each other but the technical replicates within each set were consistent, even 
given they represented cells in different wells. 
Therefore, a change in specific activity of the different sized RLuc (1.4-fold) cannot 
account for the 4-fold change in frameshift efficiency, rather the RLU for the Luc+ activity 
decreased significantly to give the lower frameshift efficiency. At most, the absolute value of 
the frameshift efficiency for the stop construct might be slightly underestimated because of 
the apparent slightly higher specific activity of the shortest RLuc. This would simply be an 
experimental artifact however, as the 15 amino acid and 582 amino acid extended RLuc 
products showed similar specific activities. It should be noted that this would only affect the 
comparison of the WT and stop construct. 
Taken in isolation, the Luc+ activity was highest in the RT construct as expected while 
the WT and stop construct showed significantly lower activities as measured by RLU (25% 
and 10% of the RT construct). This large change in frameshift efficiency by substitution of 
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UCC with UGA at the intercodon indicated, as in the HIV-1 frameshift element, the 
intercodon has a strong influence. 
 
 
Table 6.2: Measured luciferase activities (RLU) for each construct. 
 
Measured activity (RLU) of Renilla luciferase (RLuc) comes from extended products of different lengths. In 
contrast, the same extended frameshifted product contributes to the activity of firefly luciferase (Luc+) in all 
cases. Red and green rectangles represent RLuc and Luc+, respectively, and these are connected by the translated 
PEG10 frameshift element (black line). A non-frameshifted product of the stop construct is 5 residues shorter 
(10 a.a extension in the diagram) compared to the WT construct (15 a.a extension) because of UGA codon at the 
intercodon position. The extended product RLuc-Luc+ is 582 a.a longer. Numbers represent the reporter activity 
in RLU. WT, wild-type; RT, read-through. 1–5 are biological replicates representing different transfections and 
batches of cells. Within each biological replicates there are six (1–2) or three (3–5) technical replicates. 
 
 
Considering how a stop codon at the intercodon reduced −1 frameshifting, eRF1 
mediated decoding was a possible mechanism because it decodes the UGA substituted codon. 
While down-regulation of eRF1 using RNA interference would have been a preferred strategy 















































































































































saturating, it was not attempted in this study because our HIV-1 study found the small hairpin 
RNAs generally increased −1 frameshifting regardless of their sequences even with the 
natural GGG intercodon. Frustratingly for my study, a reduced level of eRF1 (a half of the 
untreated control) using RNA interference was specific and sufficient to reduce +1 frameshift 
efficiency at the human antizyme frameshift element (Mathew, 2008). Therefore, the non-
specific small hairpin effects were specific for the −1 frameshift elements. In hindsight, it 
may have been prudent to check whether it was similar at the PEG10 frameshift site. 
The effect of eRF1 on the intercodon was tested instead by overexpression. In HIV-1 a 
further reduction of −1 frameshifting was observed with eRF1 overexpression but it had little 
effect in PEG10 (Table 6.3). Translational termination efficiency is influenced strongly by the 
nucleotide following the stop codon and by up to six downstream nucleotides (Cridge, 2004). 
For the UGA stop codon, the fidelity of translational termination is higher if a purine (A or G) 
is in the following position whereas a pyrimidine (U or C), especially C, gives a significantly 
higher rate of translational read-through of the termination codon. In the HIV-1 study, it was 
found that a weak stop signal could be improved by increasing amounts of eRF1. As shown in 
Figure 6.1, the HIV-1 stop construct had an adenine immediately following the stop codon (a 





Figure 6.1: A sequence comparison of the stop construct of HIV-1 and PEG10. 
Nucleotide sequences shown start with the slippery sequence and the six nucleotides immediately downstream of 
the intercodon are included. A UGA stop codon (red) was introduced at the intercodon position. Up to six 
nucleotides following the stop codon influences translational termination efficiency (Cridge, 2004). 
 
 
Although the PEG10 context is the strongest among the weak UGA CNN variants, it 
still rates as a weak stop signal. This alone would predict that eRF1 overexpression should 





might have reduced −1 frameshift efficiency further with the PEG10 construct. The observed 
results were in fact the opposite to those anticipated. However, eRF1 is acting at a distorted 
decoding site in each case during −1 frameshifting. Each frameshift element has distinct 
features, for example, the different RNA secondary structures (stem-loop in HIV-1 and 
pseudoknot in PEG10). Prediction on the basis of strength of stop signal is clearly too 
simplistic. Indeed, as indicated in Table 6.1, the UGA intercodon reduced frameshifting 
efficiency 2–3-fold at the HIV-1 element, but 4-fold with the PEG10 element suggesting, if 
decoding is the mechanism for the decrease in frameshift efficiency with a UGA intercodon in 
both cases, more efficient termination is occurring at the PEG10 site and may not be further 
modulated by increasing eRF1, consistent with my observations.  
 
 
Table 6.3: A summary table of −1 frameshifting in PEG10 and HIV-1. 
 PEG10 HIV-1 
Wild-type intercodon 0 0 
UGA intercodon   
UGA intercodon + eRF1 n.c  
UGA intercodon + Opal suppressor tRNA   
UGA intercodon + Amber suppressor tRNA  n.c 




The effect of the intercodon substituted with a stop codon was further investigated 
using a different decoding molecule for stop codons, a suppressor tRNA. Functional analysis 
of these suppressor tRNAs confirmed that they recognised only their designated stop codons 
(opal suppressor tRNA for UGA and amber suppressor tRNA for UAG) at termination signal 
elements. The opal suppressor tRNA significantly increased −1 frameshift efficiency (Table 
6.3). An increase in −1 frameshifting by the opal suppressor tRNA was consistent with that 
found in the HIV-1 study. However, surprisingly there was an apparent small increase with 
the amber suppressor tRNA at UGA as well that would represent miscoding. It remains 
unclear how the amber suppressor tRNA could have such an effect compared with the lack of 
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effect of the parental serine tRNA used as a negative control. However, at the distorted A-site, 
tRNAs are predicted to have different decoding capabilities depending on their primary 
structure and concentrations (Mathew et al., 2015). Together with the context of the stop 
signal (a weak UGAC) in PEG10, it apparently responds strongly to endogenous eRF1 and 
the distorted A-site may not reject the non-cognate amber suppressor tRNA with such fidelity 
and so miscoding could occur. The UGA stop signal is a near cognate match against the 
3´AUC5´ anticodon for the amber suppressor tRNA if G:U base pairing is now allowed at the 
second position. The HIV-1 construct contained a strong stop signal (UGAA) and if the site is 
less distorted, the amber suppressor tRNA may be discriminated better for decoding the UGA 
codon compared with endogenous eRF1 in this context, producing little effect on −1 
frameshift efficiency. Under canonical translation and read-through of the stop codons that 
was used to test the functionality of the suppressor tRNAs, this phenomenon would not have 
been observed as the ribosomal decoding A-site is not distorted and is in its natural highly 
discriminating conformation. It is known in bacteria that this occurs with a conformational 
change in rRNA bases that form a neat fit within the minor groove of the correct 
codon:anticodon helix if it is the cognate codon (Ogle et al., 2001). 
 
 
6.1.2 The frameshifting mechanism 
 
 
Both HIV-1 and PEG10 use the rare translational mechanism, −1 frameshifting, to express 
their gag-pol or ORF1–2 polyproteins. The outcome of this event in both instances 
(translation of a downstream gene) appears to be identical, but they have different underlying 
mechanisms. Two independent studies from our group support this contention. First, a high-
throughput screening of a library containing over 100 000 compounds identified three 
frameshift enhancers as potential therapeutic agents against HIV-1 (Cardno et al., 2015). 
When these frameshift enhancers were tested against the PEG10 frameshift element, one had 
no effect, while the other two reduced frameshift efficiency. As these compounds by contrast 
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were all shown to be potent enhancers for −1 frameshifting in HIV-1, this result suggested 
that the frameshift mechanism of HIV-1 was likely to be different from that of PEG10.  
Second, and concurrent with my studies, our group has designed and expressed the 
constructs carrying either the HIV-1 or PEG10 frameshift signal between two protein tags 
(maltose-binding protein on the N-terminus and a 6×His-tag on the C-terminus in the −1 
frame) for expression in bacteria (Figure 6.2 A). The frameshifted product was purified using 
the 6×His-tag and analysed by mass spectrometry to determine where −1 frameshifting had 
occurred (Figure 6.2 B). For the HIV-1 construct, three different peptides were identified 
representing three distinct frameshift positions. One peptide confirmed that the intercodon 
was being decoded prior to −1 frameshifting in a significant fraction of translational events, as 
it contained glycine encoded by the intercodon GGG in the 0 frame. Such identification of 
multiple frameshift sites for HIV-1 was consistent with the recent study concerning the dnaX 
gene from E. coli (Yan et al., 2015). Despite these frameshift elements being of quite 
different origins (retrovirus and bacteria), these share some similarities such as the stem-loop 





Figure 6.2: Frameshift site analysis of HIV-1 and PEG10. 
A, the frameshift signals of HIV-1 and PEG10 were independently cloned into a bacterial expression vector 
carrying MBP (N-terminus) and a 6×His-tag (C-terminus, −1 frame). The non-frameshifted product has MBP 
but not a 6×His-tag while the frameshifted product contains both. B, mass spectrometric analysis of the 
frameshifted product from the HIV-1 construct (upper) and that from the PEG10 construct (lower) showed three 
and two frameshift sites for HIV-1 and PEG10, respectively (indicated by the red arrows). Detection of the 
peptide for the third frameshift site in the PEG10 element was suggestive but inconclusive (indicated by the red 
dotted arrow). The amino acid sequences of the 0 frame and the −1 frame are shown above and below the 
nucleotide sequence. Bolded nucleotides represent the slippery sequence and the intercodon is indicated in green. 
MBP, maltose-binding protein; FS, frameshift signal (either HIV-1 or PEG10) and His, 6×His-tag. Figure 6.2 B 




By contrast, two frameshifted peptides were identified for the PEG10 construct, 
implying that −1 frameshifting had occurred at two sites. At the third possible site, the amino 
acid sequence of the PEG10 frameshifted product and its abundance suggested that, at least 































on the bacterial ribosomes, the intercodon would have reached the A-site prior to 
frameshifting in a small number of passages. Therefore, it was decoded in these cases (red 
dotted arrow in Figure 6.2 B lower). Although this analysis showed a clear difference in the 
frameshift sites between HIV-1 and PEG10, it cannot explain my results of the dual luciferase 
reporter expression in human cells where the UGA intercodon significantly not just slightly 
reduced −1 frameshifting on the human ribosomes. The identity of the intercodon would not 
be expected to have any influence on −1 frameshift efficiency if frameshifting had occurred 
before the intercodon reached the A-site. Decoding suppressor tRNA should also have no 
effect on the efficiency as the UGA stop codon would now be in the wrong reading frame. 
This apparent paradox may be attributed to the difference in how the PEG10 element behaves 
between prokaryotic and eukaryotic ribosomes. It will be important to repeat this analysis of 
the frameshifted products prepared after expression in human cells to determine the frameshift 
sites on human ribosomes. Nevertheless, the different RNA secondary structures (stem-loop 
in HIV-1 and pseudoknot in PEG10) seem to cause differences in the mechanisms at the 
frameshift sites. This could be tested using hybrid constructs that carry an HIV-1 slippery 
sequence, and a PEG10 pseudoknot and vice versa. Mass spectrometric analysis of the 
frameshifted product from these constructs would determine if the RNA secondary structure 
type influences where −1 frameshifting occurs. 
 
 
6.2 Expression of Peg10 in mammals 
 
 
6.2.1 Finding suitable reference genes 
 
 
Quantitative real time PCR (qPCR) has become the method of choice for measurement of 
mRNA expression and its abundance. Data analysis, especially the normalisation process, is 
the key factor to produce reliable and reproducible results. Although the importance of 
reference gene selection is widely acknowledged, a large number of studies continue to use 
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‘commonly used’ or ‘traditional’ reference genes without proper validation within their 
experimental conditions. Commonly used reference genes show considerable variation 
depending on cell/tissue types and experimental conditions (Radonic et al., 2004; Hruz et al., 
2011; Jacob et al., 2013). To identify appropriate reference genes for analysis of 18 different 
mouse tissue types, the RefGene tool in the Genevestigator online program was used to search 
candidate genes, and some of those were subsequently analysed for their expression in a 
subset of samples (Hruz et al., 2008; Hruz et al., 2011). This method allowed us to expand a 
range of candidate genes beyond ‘commonly used’ genes, and use an independent validation 
process to ensure their suitability as reference genes for samples analysed in my study.  
Reference genes were selected based on the gene ranking by the two widely used 
algorithms, geNorm and NormFinder, in the RefFinder (Xie et al., 2011). Three top-ranked 
genes were selected as reference genes in this study for more accurate analysis of Peg10 
mRNA expression, as three reference genes are sufficient to control for small variations 
(Vandesompele et al., 2002). For rat samples, a screening of ‘commonly used’ genes was 
acceptable as there were only two tissue types (brain and placenta). The expression stability 
of reference genes was calculated as the coefficient of variation (CV) and gene stability 
parameter (Mgene), and these values indicated the selected reference genes were stably 
expressed within the set of samples analysed (Appendix VIII). The mouse reference genes 
showed larger variations in their expression compared with those for rat samples. This 
difference can be attributed largely to the number of tissue types analysed in the study (18 
tissues for mouse). Careful design and an independent validation process successfully 
identified suitable reference genes despite the large variations in a panel of tissue types. 
 
 
6.2.2 The expression of Peg10 in mammalian tissues 
 
 
A screening of various mouse tissues for mPeg10 expression by qPCR showed that it was 
expressed at a significantly high level in the amnion, embryo and placenta as expected. 
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Consistent with this finding, Peg10 mRNA has been detected repeatedly in placenta using 
mRNA sequencing (Wang et al., 2011; Wang et al., 2013). An increased level of mPeg10 was 
also detected in the brain, testis, ovary, adipose and muscle. mPeg10 expression was very 
weak but detectable in other tissues, suggesting that mPeg10 was ubiquitously transcribed in a 
wide range of tissue types in adult animals, although at a low level. These results differed 
from previous studies where PEG10 expression was analysed by Northern blotting or reverse 
transcription PCR because these studies suggested that PEG10 was expressed in a subset of 
specific tissue types (Ono et al., 2001; Okabe et al., 2003; Smallwood et al., 2003; Brandt et 
al., 2005; Lux et al., 2005). Each experimental technique offers varying degrees of sensitivity, 
and this might have resulted in a discordant pattern of PEG10 expression in different tissues. 
By contrast, mRNA sequencing analysis of human tissues in the Human Protein Atlas showed 
a consistent trend where a low level of PEG10 transcript was detected in most tissues tested. 
In specific tissues such as adrenal gland, cortex, ovary and testis, a level of PEG10 mRNA 
was highly elevated, but the highest PEG10 expression was expectedly found in placenta 
(Uhlen et al., 2015). 
 The detailed analysis of Peg10 mRNA expression in brain regions in my study 
produced an interesting outcome in that a highly increased level of Peg10 mRNA was 
detected in hypothalamus across all sample groups, male, female and lactating female. 
However, the hypothalamus of lactating females expressed Peg10 mRNA at a higher level 
than that from males and females. Although mPeg10 mRNA was originally identified from a 
brain cDNA library (Steplewski et al., 1998), most studies concerning PEG10 have focused 
on its expression and function in placenta or cancer cells (Okabe et al., 2003) and, therefore, 
the expression pattern of PEG10 in brain was poorly understood until recently (Henke et al., 
2013). With the in situ hybridisation data deposited in the Allen Mouse Brain Atlas, a recent 
study re-evaluated expression patterns of many imprinted genes including mPeg10 in over 
100 brain regions (Lein et al., 2007; Gregg et al., 2010). A heat map representation of the 
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result clearly identified several specific brain regions as hot spots of imprinted gene 
expression. These regions contain aminergic neurons (neurons that use serotonin or 
noradrenalin as neurotransmitters), and these include the hypothalamus and other regions that 
govern motivation and reward learning. PEG10 expression in the hypothalamus could not be 
confirmed in the Human Protein Atlas because it was not included in a panel of tissue types, 
but a recent study investigating mate choice in mice detected mPeg10 mRNA in the 
hypothalamus using mRNA sequencing (Lorenc et al., 2014; Uhlen et al., 2015). 
 Gene expression is a complex process involving a number of steps with various 
factors having either a positive or negative regulation to fine-tune the level of the expression 
of each gene. Due to this added complexity, mRNA abundance generally shows a low 
correlation to the amount of protein present in cells or tissues. In yeast, some genes with 
similar mRNA levels had a 20-fold difference in protein abundance (Gygi et al., 1999). With 
recent advances in technologies such as next-generation sequencing and mass spectrometry, a 
more global analysis of mRNA and protein abundance has become possible (Vogel and 
Marcotte, 2012). Many studies found correlations of 0.4–0.7 between mRNA and protein 
abundance in bacteria and yeast but correlation was lower in humans mainly due to the 
limited number of genes analysed (de Sousa Abreu et al., 2009; Maier et al., 2009). 
Nevertheless, correlation of mRNA and protein abundance in humans was estimated to be 0.4 
in a detailed study analysing a large number of genes (Schwanhausser et al., 2011). Together 
with an earlier study, two major determinants were identified. The level of mRNA, its 
sequence, and a combination of these explain ~60% of variation in protein abundance (Vogel 
et al., 2010; Schwanhausser et al., 2011). As shown by these recent studies, protein 
expression cannot be assumed by mRNA presence or abundance and it is, therefore, important 










Large-scale human proteomic studies have been reported very recently and databases created 
using the collected data covering a significant proportion of the annotated human genes (Kim 
et al., 2014; Wilhelm et al., 2014; Uhlen et al., 2015). Three such databases constructed at the 
later part of my study period contain PEG10 protein expression data and the tissues in which 
PEG10 protein has been detected. The data are summarised in Table 6.4.  
 
 
Table 6.4: Comparison of PEG10-positive tissue types in different databases. 
Human Proteome Map Adrenal gland, frontal cortex, retina, ovary, testis, pancreas, 
(Kim et al., 2014) placenta, B-cells and NK cells 
Proteomics DB Lung, liver, adrenal gland, placenta, brain, testis, ovary, heart, retina, 
(Wilhelm et al., 2014) prefrontal cortex, pancreas, B-lymphocytes and pancreatic islet 
Human Proteome Atlas Placenta, adrenal gland, testis and bronchus 
(Uhlen et al., 2015)       
Tissues in which PEG10 protein peptides have been identified are listed for each human proteomic database. 
Colours of tissue types represent those identified by three studies (red), by two studies (green) or unique to an 
individual study (black). NK cells, natural killer cells. 
 
 
Although the expression pattern of PEG10 protein appears to vary significantly among 
the databases, PEG10 protein has been consistently detected in three tissues (placenta, adrenal 
gland and testis). Several other tissues including brain and ovary may also express PEG10 
protein as peptides of PEG10 protein have been detected in those tissues in two of the 
databases. Compared with these databases, from our group’s research and my study 
immunoblot screening of mouse tissues detected a high level of mPeg10 protein in amnion 
and placenta and to a lesser degree in embryo. Although most tissues did not show bands at 
corresponding molecular weights of either the mPeg10 ORF1 or the ORF1–2 fusion protein in 
my study regardless of the level of mPeg10 mRNA, muscle and adipose tissue of the pregnant 
female mouse showed an interesting band at a similar molecular weight to the ORF1–2 fusion 
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protein. However, mass spectrometric analyses of these protein bands did not identify any 
peptides from the mPeg10 protein.  
For rat brain regions, the lactating female hypothalamus had a band at a similar 
molecular weight to that of the rat placental extract. To determine the identity of the protein in 
the hypothalamus, analysis by mass spectrometry confirmed a peptide corresponding to rat 
Peg10 ORF1 as was found in the rat placental sample. Therefore, for the first time this result 
confirmed expression of Peg10 protein in tissues other than embryo and extraembryonic 
samples, although my finding could not be compared with the human proteomic studies as 
none investigated the human hypothalamus. 
Immunoblotting is suitable for screening of a large number of samples for expression 
of a particular protein. However, this method is limited by the amount of protein able to be 
analysed. Therefore, successful detection of a protein depends on a sufficient level of protein 
expression within a tissue. As evident from the rat brain analysis, Peg10 transcription can 
vary significantly among different regions of rat brain. This is possibly due to the difference 
in cell types and/or cellular composition of each region that expresses Peg10 protein. In 
tissues with high PEG10 protein expression such as adrenal gland and placenta, major cell 
types may express PEG10 protein. By contrast, PEG10 may be selectively expressed in minor 
cell types of other tissues, which could be undetectable or perceived as low expression at the 
tissue level. This dilution effect might prevent the detection of PEG10 protein. To improve 
detection of Peg10 protein, total tissue extracts could be immunoprecipitated before mass 
spectrometry. The use of a specific antibody would allow concentration of Peg10 protein from 
a large amount of tissue extracts and remove most contaminating proteins. Peg10 protein 
could be detected in samples with low Peg10 expression at a tissue level using this approach. 
In the future, high priority should be given to tissues with an increased level of Peg10 mRNA 
and those that have been reported to express human PEG10 protein in proteomic databases 
because these are more likely to express Peg10 protein. 
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Table 6.5: A summary of PEG10 expression in various tissue types. 
 mRNA Protein Frameshifted product 
 Mouse/Rata Humand Mouse/Rata Human Mouse/Rata Humane 
Brain       
Whole ++ n.d − +c N n.d 
Cerebellum ++ n.d − −d N n.d 
Cortex ++ ++ − +b,c N n.d 
Hippocampus ++ n.d − −d N n.d 
Hypothalamus ++ n.d ++ n.d N n.d 
Thalamus ++ n.d − n.d N n.d 
Reproductive       
Testis ++ ++ − ++b,c,d N n.d 
Ovary ++ ++ − +b,c N n.d 
Uterus + n.d − −d N n.d 
Amnion +++ + +++ n.d Y n.d 
Embryo ++ + +++ n.d Y n.d 
Placenta +++ +++ +++ +++b,c,d Y Y 
Endocrine       
Thyroid + + − −d N n.d 
Stomach + + − −d N n.d 
Liver + + − +c N n.d 
Pancreas + + − +b,c N n.d 
Kidney + + − −d N n.d 
Skeletal muscle + + − −d N n.d 
Adipose tissue + + − −d N n.d 
Other       
Heart + + − +c N n.d 
Lung + + − +c N n.d 
Spleen + + − −d N n.d 
Intestine + + − −d N n.d 
Not examined in current study      
Lateral ventricle n.d + n.d −d n.d n.d 
Retina n.d n.d n.d +b,c n.d n.d 
Salivary gland n.d + n.d −d n.d n.d 
Bronchus n.d n.d n.d +d n.d n.d 
Esophagus n.d + n.d −d n.d n.d 
Parathyroid gland n.d n.d n.d −d n.d n.d 
Adrenal gland n.d +++ n.d ++b,c,d n.d n.d 
Appendix n.d + n.d −d n.d n.d 
Colon n.d + n.d −d n.d n.d 
Rectum n.d + n.d −d n.d n.d 
Urinary bladder n.d + n.d −d n.d n.d 
Skin n.d + n.d −d n.d n.d 
B-lymphocytes n.d n.d n.d +b,c n.d n.d 
A level of expression is shown as ‘+’ (low), ‘++’ (medium) or ‘+++’ (high), and absence of expression is 
indicated by ‘−’. This table is constructed based on the data from a, current study; b, Kim et al. (2014); c, 
Wilhelm et al. (2014); d, Uhlen et al. (2015) and e, Clark et al. (2007). Y, Yes; N, No and n.d, not determined. 
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Most tissues reported to express PEG10 mRNA have not had confirmation of protein 
expression by mass spectrometry (Table 6.5). This could be due simply to a low level of 
PEG10 mRNA expression in these tissues so that PEG10 protein is synthesised in a small 
amount, is not produced at all, or rapidly processed. Gene expression can be regulated at a 
post-transcriptional level by microRNAs and our group has previously shown that both miR-
34a and miR-182 repressed PEG10 translation in cultured cells (Saurat, 2009). To extend this 
knowledge, it would be interesting to perform microRNA profiling for the tissues that express 
Peg10, like placenta, compared with those that do not. This would identify candidate 
microRNAs with a differential expression pattern in these tissues and placenta that have the 
potential to control PEG10 translation in vivo. These candidates would be tested for PEG10 
translational repression in cultured cells to validate their ability. This microRNA profiling 




6.2.4 PEG10 in hypothalamus and placenta 
 
 
Numerous molecular domestication events have occurred during the evolutionary course of 
placental mammals (Kokosar and Kordis, 2013), and these genes are considered to be 
responsible for emergence of novel structures such as placenta and neocortex (Oldham et al., 
2006; Kaneko-Ishino and Ishino, 2012). Together with a significant proportion of imprinted 
genes that is expressed in both brain and placenta (Section 1.4.6), the discovery of higher 
level Peg10 expression in the rat hypothalamus was perhaps not too surprising because Peg10 
is a retrotransposon-derived imprinted gene. Consistent with the studies of Peg1 and Peg3 
(Lefebvre et al., 1998; Li et al., 1999), detection of Peg10 protein in the rat hypothalamus and 
placenta provided further support for the hypothesis that coordinated functions of brain and 
placenta significantly contribute to successful reproduction (Curley et al., 2004). Although 
Peg10 protein expression was confirmed in the rat hypothalamus by mass spectrometry, there 
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is yet no direct evidence that −1 frameshifting occurs in the rat hypothalamus because the 
detected peptide was derived from the rat Peg10 ORF1. However, the immunopositive band 
in the lactating female rat hypothalamus was larger than the expected molecular weight of the 
rat Peg10 ORF1, implying that it could be a degradation or processed product of the rat Peg10 
ORF1–2. Frameshift efficiency of Peg10 was estimated to be 60–70% in placenta so that the 




6.2.5 PEG10 and the endocrine system 
 
 
The function of PEG10 in placenta remains largely unknown but the first study of Peg10 
found the loss of spongiotrophoblasts in Peg10 knockout mouse placentae, suggesting that 
Peg10 normally plays a function in this cell type (Ono et al., 2006). In the developing mouse 
placenta, spongiotrophoblasts differentiate from the ectoplacental cone, and both cell types 
can give rise to trophoblast giant cells (Simmons and Cross, 2005). Considering the 
differentiation pathway of spongiotrophoblasts, Peg10 may promote the differentiation of the 
ectoplacental cone to spongiotrophoblasts or it may maintain the spongiotrophoblast state by 
inhibiting differentiation to trophoblast giant cells. Although it is difficult to distinguish 
between the two possible roles of Peg10 without further examination, studies of Mash2 may 
aid elucidation of Peg10 function. Peg10 and Mash2 have an opposite imprinting status 
(paternally and maternally expressed, respectively), but deletion of these genes resulted in a 
surprisingly similar phenotype of embryonic lethality due to the loss of spongiotrophoblasts 
and reduced labyrinth layer (Guillemot et al., 1994; Guillemot et al., 1995; Ono et al., 2006). 
Analysis of the Mash2 role in trophoblast differentiation showed that this gene was required 
for spongiotrophoblast development (Tanaka et al., 1997). Therefore, it is possible that Peg10 
has a similar function to Mash2 in this process based on the observed phenotypic similarity. 
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Another potential function of Peg10 has been suggested by a recent study 
investigating the development of the mouse placenta (Henke et al., 2013). A significant 
expression of Peg10 was detected in sinusoidal and parietal trophoblast giant cells by in situ 
hybridisation but Peg10 is unlikely to regulate differentiation in this cell type as the cells are 
already terminally differentiated. These subtypes of trophoblast giant cells are known to 
secrete hormones that regulate important processes to ensure successful placentation 
(Simmons et al., 2007). Considering the expression pattern of the PEG10 gene, it appears to 
be more highly expressed in endocrine organs such as the adrenal gland and placenta although 
a low level of PEG10 mRNA can be detected in most tissues. This trend becomes more 
obvious for PEG10 protein where tissues in which PEG10 protein peptides have been 
detected by mass spectrometry are members of the endocrine system (Table 6.4). Both retina 
and the immune system (B-lymphocytes) are seemingly unrelated to the endocrine system but 
these organs have a profound influence on endocrine functions through hormone or cytokine 
production, respectively (Silverman et al., 2005; Hernandez et al., 2006; Klein, 2006; 
Hernandez and Simo, 2012; ThyagaRajan and Priyanka, 2012; Straub, 2014). This 
preferential expression of PEG10 in endocrine organs suggests that PEG10 has a shared 




6.3 Is it feasible to target −1 frameshifting 




Analysis of Peg10 expression confirmed that embryonic and extraembryonic tissues 
expressed a high level of Peg10 protein, and it also provided new information that Peg10 
protein was expressed in the lactating female hypothalamus. This finding implies that Peg10 
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is likely to have some function in this brain region under physiological conditions. Human 
proteomic studies have also detected PEG10 protein in adrenal gland and testis, suggesting a 
possible complication for a strategy to target −1 frameshifting. These new findings are 
valuable information in themselves but do not speak to whether frameshifting is occurring. It 
is more important to define the PEG10 ORF2 expression pattern in various tissues because its 
translation is dependent on the −1 frameshift mechanism. Although this information clearly 
holds the key to determining the feasibility of such strategy, detection of the PEG10 ORF1–2 
fusion protein has been limited to the conceptus. I did not find evidence of a frameshifted 
protein product in any tissue examined. The hypothalamus contained only ORF1 peptides on 
mass spectrometric analysis. Due to a lack of information, it is difficult to assess the 
feasibility of this strategy exclusively based on the expression pattern of PEG10 without 
further studies. 
 Regarding the −1 frameshift mechanism, the PEG10 frameshift element showed 
unique features and responses to manipulation of the intercodon and decoding molecules 
compared to that of HIV-1. This difference in frameshift mechanism was more clearly 
observed in high-throughput drug screening (Cardno et al., 2015). As two of the three 
frameshift enhancers for HIV-1 in that study behaved as frameshift suppressors for PEG10, 
and the third compound had no effect at all. Indeed, my results further emphasised that while 
−1 frameshifting in HIV-1 and PEG10 is functionally equivalent (production of pol and 
ORF2 for HIV-1 and PEG10, respectively), the mechanisms vary significantly. For example, 
differences occur in frameshift efficiency, response of the intercodon to decoding molecules 
and in the sites within the element where frameshifting occurs. In addition, there are specific 
structural features of the PEG10 element that differ from the HIV-1 element. The HIV-1 
frameshift modulators affect HIV-1 and PEG10 frameshifting quite differently. Most 
importantly, as high-throughput screening has already identified such compounds that 
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interfere only with −1 frameshifting in HIV-1 and not PEG10, selective targeting of −1 
frameshifting in HIV-1 seems possible. 
 
 
6.4 Future directions 
 
 
My study of the PEG10 frameshift mechanism suggested that there are different mechanisms 
involved in −1 frameshifting between PEG10 and HIV-1. To elucidate the unexpected results 
using the suppressor tRNAs, it would be interesting to test the effect of the intercodon 
substituted with three stop codons together with effects of three cognate suppressor tRNAs. 
This should enable us to determine whether the apparent non-cognate decoding event 
observed was unique to the UGA-amber interaction or it is possible in other contexts. Our 
preliminary study to determine the sites of −1 frameshifting identified two and three 
frameshift sites for PEG10 and HIV-1, respectively, on at least bacterial ribosomes. It will be 
interesting to test if this finding is replicated in mammalian cells. Concurrent with this 
approach, it is important to identify the cause of the observed difference in frameshift sites. 
This work is already in progress in our laboratory using hybrid constructs of the PEG10 and 
HIV-1 frameshift elements. 
This study analysed expression of Peg10 in mouse and rat tissue samples using qPCR 
and immunoblotting. Despite an increased level of Peg10 mRNA in a subset of tissues such 
as testis and ovary, Peg10 protein expression was not observed in those tissues. As very 
recent human proteomic studies have reported PEG10 protein expression in those tissues, it 
will be interesting to repeat the analysis using samples that have been immunoprecipitated to 
enrich for Peg10 protein. This modified sample preparation should facilitate collection of 
more conclusive evidence for Peg10 protein expression in tissues. Adrenal gland is a tissue in 
which PEG10 protein has been repeatedly detected, and should be added to an existing panel 
of tissues to see if Peg10 expression is conserved between human and mouse. For more 
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comprehensive Peg10 expression analyses, microRNA expression profiling will facilitate 
comparison of tissues with or without Peg10 protein. This may identify candidate microRNAs 
that have potential to repress or indirectly enhance Peg10 protein synthesis, providing 
valuable information for the regulation of Peg10 expression. 
Is it possible for PEG10 to function without translation? A number of recent studies 
have shown that different classes of RNAs including long non-coding RNAs and pseudogene 
mRNAs can serve as a ‘sponge’ for microRNAs (Ebert and Sharp, 2010; Poliseno et al., 
2010; Pasquinelli, 2012). As PEG10 has an unusually long (~4 kb) 3´ UTR (Section 1.3 and 
Figure 1.4), it contains numerous microRNA binding sites (Crowe-McAuliffe, 2009) and may 
function as a microRNA sponge, allowing expression of other genes. 
A previous study in our group provided supportive evidence that a protease domain 
found in the PEG10 ORF2 was functional in mammalian cells (Clark et al., 2007), and more 
recently its potential substrate was identified using in vitro assays and mass spectrometry 
(Crow-McAuliffe, unpublished). Further characterisation of the PEG10 protease is currently 






The PEG10 frameshift mechanism was studied with a view to a comparison with that of HIV-
1. The PEG10 element has a different slippery sequence, a different type of secondary 
structure and the intercodon sequence that differs from that of HIV-1. Substitution of the 
sense codon at the intercodon position significantly reduced PEG10 −1 frameshift efficiency 
as had occurred when the same substitution was made at the intercodon of the HIV-1 element. 
Unlike with the HIV-1 element, however, PEG10 −1 frameshift efficiency remained 
unchanged with overexpression of stop codon decoding factor, eRF1. It was increased, 
however, by the alternative stop codon decoding molecule, opal (UGA) suppressor tRNA, but 
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also unexpectedly by the non-cognate amber (UAG) suppressor tRNA, although with a 
modest effect. These results implied possible differences in the frameshift mechanisms of 
PEG10 and HIV-1. It was reinforced by mass spectrometry analysis of isolated peptides 
synthesized across the frameshift elements. Frameshifitng occurs at three sites within the 
HIV-1 element, and one site, after the intercodon, results in the generation of a relatively 
abundant peptide. This latter observation is consistent with the effects of the decoding 
molecules at the 0 frame intercodon. By contrast, with PEG10, frameshifting occurred 
predominantly at two sites before the intercodon. Nevertheless there was evidence of a low 
frequency event with detection of a small amount of a peptide arising from a frameshift event 
after the intercodon.  
Peg10 expression was analysed in mouse and rat tissue samples by qPCR and 
immunoblotting. Peg10 mRNA was ubiquitously expressed at a low level in most tissues and 
at a significantly increased level in a small subset of tissues, endocrine organs in particular. 
For the first time Peg10 protein expression was confirmed in a tissue outside of embryo and 
extra-embryonic tissues under physiological conditions — the hypothalamus. An ORF1-
ORF2 fragment was found in placenta protein extracts and this fragment had both ORF1 and 
ORF2 peptides. Although the hypothalamus fragment was of identical size and deduced to be 
an ORF1-ORF2 fragment, only ORF1 peptide was detected by mass spectrometry. Hence 
while no direct evidence of frameshifting in hypothalamus was obtained, it was inferred from 








Adelman, D.M., Gertsenstein, M., Nagy, A., Simon, M.C. and Maltepe, E. (2000) Placental cell fates are 
regulated in vivo by HIF-mediated hypoxia responses. Genes Dev, 14: 3191-203 
 
Advani, V.M., Belew, A.T. and Dinman, J.D. (2013) Yeast telomere maintenance is globally controlled by 
programmed ribosomal frameshifting and the nonsense-mediated mRNA decay pathway. Translation (Austin), 
1: e24418 
 
Albrecht, U., Sutcliffe, J.S., Cattanach, B.M., Beechey, C.V., Armstrong, D., Eichele, G. and Beaudet, A.L. 
(1997) Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje 
neurons. Nat Genet, 17: 75-8 
 
Allen, N.D., Logan, K., Lally, G., Drage, D.J., Norris, M.L. and Keverne, E.B. (1995) Distribution of 
parthenogenetic cells in the mouse brain and their influence on brain development and behavior. Proc Natl Acad 
Sci U S A, 92: 10782-6 
 
Amrane, S., Kerkour, A., Bedrat, A., Vialet, B., Andreola, M.L. and Mergny, J.L. (2014) Topology of a DNA G-
quadruplex structure formed in the HIV-1 promoter: a potential target for anti-HIV drug development. J Am 
Chem Soc, 136: 5249-52 
 
Andersen, C.L., Jensen, J.L. and Orntoft, T.F. (2004) Normalization of real-time quantitative reverse 
transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, 
applied to bladder and colon cancer data sets. Cancer Res, 64: 5245-50 
 
Andrieu, D., Watrin, F., Niinobe, M., Yoshikawa, K., Muscatelli, F. and Fernandez, P.A. (2003) Expression of 
the Prader-Willi gene Necdin during mouse nervous system development correlates with neuronal differentiation 
and p75NTR expression. Gene Expr Patterns, 3: 761-5 
 
Arima, T., Kamikihara, T., Hayashida, T., Kato, K., Inoue, T., Shirayoshi, Y., Oshimura, M., Soejima, H., 
Mukai, T. and Wake, N. (2005) ZAC, LIT1 (KCNQ1OT1) and p57KIP2 (CDKN1C) are in an imprinted gene 
network that may play a role in Beckwith-Wiedemann syndrome. Nucleic Acids Res, 33: 2650-60 
 
Arion, D., Kaushik, N., McCormick, S., Borkow, G. and Parniak, M.A. (1998) Phenotypic mechanism of HIV-1 
resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity 
to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry, 37: 15908-17 
 
Arnaud, P., Monk, D., Hitchins, M., Gordon, E., Dean, W., Beechey, C.V., Peters, J., Craigen, W., Preece, M., 
Stanier, P., Moore, G.E. and Kelsey, G. (2003) Conserved methylation imprints in the human and mouse GRB10 
genes with divergent allelic expression suggests differential reading of the same mark. Hum Mol Genet, 12: 
1005-19 
 
Arts, E.J. and Hazuda, D.J. (2012) HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med, 2: 
a007161 
 
Asmus, F., Hjermind, L.E., Dupont, E., Wagenstaller, J., Haberlandt, E., Munz, M., Strom, T.M. and Gasser, T. 
(2007) Genomic deletion size at the epsilon-sarcoglycan locus determines the clinical phenotype. Brain, 130: 
2736-45 
 
Baba, M., Nishimura, O., Kanzaki, N., Okamoto, M., Sawada, H., Iizawa, Y., Shiraishi, M., Aramaki, Y., 
Okonogi, K., Ogawa, Y., Meguro, K. and Fujino, M. (1999) A small-molecule, nonpeptide CCR5 antagonist 
with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A, 96: 5698-703 
 
Baba, M., Tanaka, H., De Clercq, E., Pauwels, R., Balzarini, J., Schols, D., Nakashima, H., Perno, C.F., Walker, 
R.T. and Miyasaka, T. (1989) Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-
substituted acyclouridine derivative. Biochem Biophys Res Commun, 165: 1375-81 
 
Baril, M., Dulude, D., Steinberg, S.V. and Brakier-Gingras, L. (2003) The frameshift stimulatory signal of 
human immunodeficiency virus type 1 group O is a pseudoknot. J Mol Biol, 331: 571-83 
 
 174 
Barlow, D.P. (1993) Methylation and imprinting: from host defense to gene regulation? Science, 260: 309-10 
 
Barlow, D.P. and Bartolomei, M.S. (2014) Genomic imprinting in mammals. Cold Spring Harb Perspect Biol, 6 
 
Barlow, D.P., Stoger, R., Herrmann, B.G., Saito, K. and Schweifer, N. (1991) The mouse insulin-like growth 
factor type-2 receptor is imprinted and closely linked to the Tme locus. Nature, 349: 84-7 
 
Bartolomei, M.S. and Ferguson-Smith, A.C. (2011) Mammalian genomic imprinting. Cold Spring Harb 
Perspect Biol, 3 
 
Bartolomei, M.S., Zemel, S. and Tilghman, S.M. (1991) Parental imprinting of the mouse H19 gene. Nature, 
351: 153-5 
 
Belcourt, M.F. and Farabaugh, P.J. (1990) Ribosomal frameshifting in the yeast retrotransposon Ty: tRNAs 
induce slippage on a 7 nucleotide minimal site. Cell, 62: 339-52 
 
Belew, A.T., Meskauskas, A., Musalgaonkar, S., Advani, V.M., Sulima, S.O., Kasprzak, W.K., Shapiro, B.A. 
and Dinman, J.D. (2014) Ribosomal frameshifting in the CCR5 mRNA is regulated by miRNAs and the NMD 
pathway. Nature, 512: 265-9 
 
Berkhout, B. (1999) HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness. J 
Biomed Sci, 6: 298-305 
 
Bilodeau, S., Roussel-Gervais, A. and Drouin, J. (2009) Distinct developmental roles of cell cycle inhibitors 
p57Kip2 and p27Kip1 distinguish pituitary progenitor cell cycle exit from cell cycle reentry of differentiated 
cells. Mol Cell Biol, 29: 1895-908 
 
Biswas, P., Jiang, X., Pacchia, A.L., Dougherty, J.P. and Peltz, S.W. (2004) The human immunodeficiency virus 
type 1 ribosomal frameshifting site is an invariant sequence determinant and an important target for antiviral 
therapy. J Virol, 78: 2082-7 
 
Blake, A., Pickford, K., Greenaway, S., Thomas, S., Pickard, A., Williamson, C.M., Adams, N.C., Walling, A., 
Beck, T., Fray, M., Peters, J., Weaver, T., Brown, S.D., Hancock, J.M. and Mallon, A.M. (2010) MouseBook: an 
integrated portal of mouse resources. Nucleic Acids Res, 38: D593-9 
 
Blanco, J.L., Varghese, V., Rhee, S.Y., Gatell, J.M. and Shafer, R.W. (2011) HIV-1 integrase inhibitor resistance 
and its clinical implications. J Infect Dis, 203: 1204-14 
 
Bleul, C.C., Wu, L., Hoxie, J.A., Springer, T.A. and Mackay, C.R. (1997) The HIV coreceptors CXCR4 and 
CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci U S A, 94: 1925-
30 
 
Brandt, J., Schrauth, S., Veith, A.M., Froschauer, A., Haneke, T., Schultheis, C., Gessler, M., Leimeister, C. and 
Volff, J.N. (2005) Transposable elements as a source of genetic innovation: expression and evolution of a family 
of retrotransposon-derived neogenes in mammals. Gene, 345: 101-11 
 
Bressan, F.F., De Bem, T.H., Perecin, F., Lopes, F.L., Ambrosio, C.E., Meirelles, F.V. and Miglino, M.A. 
(2009) Unearthing the roles of imprinted genes in the placenta. Placenta, 30: 823-34 
 
Brierley, I., Gilbert, R. and Pennel, S. (2010). Pseudoknot-Dependent Programmed -1 Ribosomal Frameshifting: 
Structures, Mechanisms and Models. In: Atkins JF and Gesteland RF (eds). Recoding: Expansion of Decoding 
Rules Enriches Gene Expression. Springer: New York. pp 149–174. 
 
Butler, M., Goodwin, T., Simpson, M., Singh, M. and Poulter, R. (2001) Vertebrate LTR retrotransposons of the 
Tf1/sushi group. J Mol Evol, 52: 260-74 
 
Caliskan, N., Katunin, V.I., Belardinelli, R., Peske, F. and Rodnina, M.V. (2014) Programmed -1 frameshifting 
by kinetic partitioning during impeded translocation. Cell, 157: 1619-31 
 
Cardno, T.S., Poole, E.S., Mathew, S.F., Graves, R. and Tate, W.P. (2009) A homogeneous cell-based 
bicistronic fluorescence assay for high-throughput identification of drugs that perturb viral gene recoding and 




Cardno, T.S., Shimaki, Y., Sleebs, B.E., Lackovic, K., Parisot, J.P., Moss, R.M., Crow-McAuliffe, C., Mathew, 
S.F., Edgar, C.D., Kleffmann, T. and Tate, W.P. (2015) HIV-1 and Human PEG10 Frameshift Elements Are 
Functionally Distinct and Distinguished by Novel Small Molecule Modulators. PLoS One, 10: e0139036 
 
Cassidy, S.B. and Driscoll, D.J. (2009) Prader-Willi syndrome. Eur J Hum Genet, 17: 3-13 
 
Cattanach, B.M. and Kirk, M. (1985) Differential activity of maternally and paternally derived chromosome 
regions in mice. Nature, 315: 496-8 
 
Charalambous, M., Cowley, M., Geoghegan, F., Smith, F.M., Radford, E.J., Marlow, B.P., Graham, C.F., Hurst, 
L.D. and Ward, A. (2010) Maternally-inherited Grb10 reduces placental size and efficiency. Dev Biol, 337: 1-8 
 
Charalambous, M., Smith, F.M., Bennett, W.R., Crew, T.E., Mackenzie, F. and Ward, A. (2003) Disruption of 
the imprinted Grb10 gene leads to disproportionate overgrowth by an Igf2-independent mechanism. Proc Natl 
Acad Sci U S A, 100: 8292-7 
 
Charbonneau, J., Gendron, K., Ferbeyre, G. and Brakier-Gingras, L. (2012) The 5' UTR of HIV-1 full-length 
mRNA and the Tat viral protein modulate the programmed -1 ribosomal frameshift that generates HIV-1 
enzymes. RNA, 18: 519-29 
 
Chen, G., Chang, K.Y., Chou, M.Y., Bustamante, C. and Tinoco, I., Jr. (2009) Triplex structures in an RNA 
pseudoknot enhance mechanical stability and increase efficiency of -1 ribosomal frameshifting. Proc Natl Acad 
Sci U S A, 106: 12706-11 
 
Chen, H., Sun, M., Zhao, G., Liu, J., Gao, W., Si, S. and Meng, T. (2012) Elevated expression of PEG10 in 
human placentas from preeclamptic pregnancies. Acta Histochem, 114: 589-93 
 
Chen, J., Petrov, A., Johansson, M., Tsai, A., O'Leary, S.E. and Puglisi, J.D. (2013) Dynamic pathways of -1 
translational frameshifting. Nature, 512: 328-32 
 
Choe, H., Farzan, M., Sun, Y., Sullivan, N., Rollins, B., Ponath, P.D., Wu, L., Mackay, C.R., LaRosa, G., 
Newman, W., Gerard, N., Gerard, C. and Sodroski, J. (1996) The beta-chemokine receptors CCR3 and CCR5 
facilitate infection by primary HIV-1 isolates. Cell, 85: 1135-48 
 
Christy, R.J. and Huang, R.C. (1988) Functional analysis of the long terminal repeats of intracisternal A-particle 
genes: sequences within the U3 region determine both the efficiency and direction of promoter activity. Mol Cell 
Biol, 8: 1093-102 
 
Clark, M.B., Janicke, M., Gottesbuhren, U., Kleffmann, T., Legge, M., Poole, E.S. and Tate, W.P. (2007) 
Mammalian gene PEG10 expresses two reading frames by high efficiency -1 frameshifting in embryonic-
associated tissues. J Biol Chem, 282: 37359-69 
 
Coan, P.M., Burton, G.J. and Ferguson-Smith, A.C. (2005) Imprinted genes in the placenta--a review. Placenta, 
26 Suppl A: S10-20 
 
Constancia, M., Angiolini, E., Sandovici, I., Smith, P., Smith, R., Kelsey, G., Dean, W., Ferguson-Smith, A., 
Sibley, C.P., Reik, W. and Fowden, A. (2005) Adaptation of nutrient supply to fetal demand in the mouse 
involves interaction between the Igf2 gene and placental transporter systems. Proc Natl Acad Sci U S A, 102: 
19219-24 
 
Constancia, M., Hemberger, M., Hughes, J., Dean, W., Ferguson-Smith, A., Fundele, R., Stewart, F., Kelsey, G., 
Fowden, A., Sibley, C. and Reik, W. (2002) Placental-specific IGF-II is a major modulator of placental and fetal 
growth. Nature, 417: 945-8 
 
Cordaux, R. and Batzer, M.A. (2009) The impact of retrotransposons on human genome evolution. Nat Rev 
Genet, 10: 691-703 
 
Cowden Dahl, K.D., Fryer, B.H., Mack, F.A., Compernolle, V., Maltepe, E., Adelman, D.M., Carmeliet, P. and 
Simon, M.C. (2005) Hypoxia-inducible factors 1alpha and 2alpha regulate trophoblast differentiation. Mol Cell 





Cowley, M., Garfield, A.S., Madon-Simon, M., Charalambous, M., Clarkson, R.W., Smalley, M.J., Kendrick, 
H., Isles, A.R., Parry, A.J., Carney, S., Oakey, R.J., Heisler, L.K., Moorwood, K., Wolf, J.B. and Ward, A. 
(2014) Developmental programming mediated by complementary roles of imprinted Grb10 in mother and pup. 
PLoS Biol, 12: e1001799 
 
Craigen, W.J., Cook, R.G., Tate, W.P. and Caskey, C.T. (1985) Bacterial peptide chain release factors: 
conserved primary structure and possible frameshift regulation of release factor 2. Proc Natl Acad Sci U S A, 82: 
3616-20 
 
Cridge, A.G. (2004). Characterization of the eukaryotic translation termination sequence element. Doctor of 
Philosophy, University of Otago, Dunedin. 
 
Cross, J.C., Baczyk, D., Dobric, N., Hemberger, M., Hughes, M., Simmons, D.G., Yamamoto, H. and Kingdom, 
J.C. (2003) Genes, development and evolution of the placenta. Placenta, 24: 123-30 
 
Crowe-McAuliffe, C. (2009). Potential targeting of PEG10 by microRNAs. Summer Student Report, University 
of Otago, Dunedin. 
 
Curley, J.P., Barton, S., Surani, A. and Keverne, E.B. (2004) Coadaptation in mother and infant regulated by a 
paternally expressed imprinted gene. Proc Biol Sci, 271: 1303-9 
 
De Clercq, E. (2002) Strategies in the design of antiviral drugs. Nat Rev Drug Discov, 1: 13-25 
 
De Clercq, E. (2005) New approaches toward anti-HIV chemotherapy. J Med Chem, 48: 1297-313 
 
de Sousa Abreu, R., Penalva, L.O., Marcotte, E.M. and Vogel, C. (2009) Global signatures of protein and 
mRNA expression levels. Mol Biosyst, 5: 1512-26 
 
DeChiara, T.M., Robertson, E.J. and Efstratiadis, A. (1991) Parental imprinting of the mouse insulin-like growth 
factor II gene. Cell, 64: 849-59 
 
Delelis, O., Malet, I., Na, L., Tchertanov, L., Calvez, V., Marcelin, A.G., Subra, F., Deprez, E. and Mouscadet, 
J.F. (2009) The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due 
to the resistance Q148H mutation. Nucleic Acids Res, 37: 1193-201 
 
Deng, Y. and Wu, X. (2000) Peg3/Pw1 promotes p53-mediated apoptosis by inducing Bax translocation from 
cytosol to mitochondria. Proc Natl Acad Sci U S A, 97: 12050-5 
 
Dinman, J.D., Ruiz-Echevarria, M.J., Czaplinski, K. and Peltz, S.W. (1997) Peptidyl-transferase inhibitors have 
antiviral properties by altering programmed -1 ribosomal frameshifting efficiencies: development of model 
systems. Proc Natl Acad Sci U S A, 94: 6606-11 
 
Diplas, A.I., Lambertini, L., Lee, M.J., Sperling, R., Lee, Y.L., Wetmur, J. and Chen, J. (2009) Differential 
expression of imprinted genes in normal and IUGR human placentas. Epigenetics, 4: 235-40 
 
Donzella, G.A., Schols, D., Lin, S.W., Este, J.A., Nagashima, K.A., Maddon, P.J., Allaway, G.P., Sakmar, T.P., 
Henson, G., De Clercq, E. and Moore, J.P. (1998) AMD3100, a small molecule inhibitor of HIV-1 entry via the 
CXCR4 co-receptor. Nat Med, 4: 72-7 
 
Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, 
C., Napier, C., Webster, R., Armour, D., Price, D., Stammen, B., Wood, A. and Perros, M. (2005) Maraviroc 
(UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 
with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother, 49: 
4721-32 
 
Dragic, T., Litwin, V., Allaway, G.P., Martin, S.R., Huang, Y., Nagashima, K.A., Cayanan, C., Maddon, P.J., 
Koup, R.A., Moore, J.P. and Paxton, W.A. (1996) HIV-1 entry into CD4+ cells is mediated by the chemokine 
receptor CC-CKR-5. Nature, 381: 667-73 
 
Dragic, T., Trkola, A., Thompson, D.A., Cormier, E.G., Kajumo, F.A., Maxwell, E., Lin, S.W., Ying, W., Smith, 
S.O., Sakmar, T.P. and Moore, J.P. (2000) A binding pocket for a small molecule inhibitor of HIV-1 entry 




Dulude, D., Baril, M. and Brakier-Gingras, L. (2002) Characterization of the frameshift stimulatory signal 
controlling a programmed -1 ribosomal frameshift in the human immunodeficiency virus type 1. Nucleic Acids 
Res, 30: 5094-102 
 
Dulude, D., Berchiche, Y.A., Gendron, K., Brakier-Gingras, L. and Heveker, N. (2006) Decreasing the 
frameshift efficiency translates into an equivalent reduction of the replication of the human immunodeficiency 
virus type 1. Virology, 345: 127-36 
 
Dulude, D., Theberge-Julien, G., Brakier-Gingras, L. and Heveker, N. (2008) Selection of peptides interfering 
with a ribosomal frameshift in the human immunodeficiency virus type 1. RNA, 14: 981-91 
 
Dykes, C., Fox, K., Lloyd, A., Chiulli, M., Morse, E. and Demeter, L.M. (2001) Impact of clinical reverse 
transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants. Virology, 285: 193-203 
 
Ebert, M.S. and Sharp, P.A. (2010) Emerging roles for natural microRNA sponges. Curr Biol, 20: R858-61 
 
Essien, K., Vigneau, S., Apreleva, S., Singh, L.N., Bartolomei, M.S. and Hannenhalli, S. (2009) CTCF binding 
site classes exhibit distinct evolutionary, genomic, epigenomic and transcriptomic features. Genome Biol, 10: 
R131 
 
Falix, F.A., Tjon-A-Loi, M.R.S., Gaemers, I.C., Aronson, D.C. and Lamers, W.H. (2013) DLK1 protein 
expression during mouse development provides new insights into its function. ISRN Develomental Biology, 
2013: 10 
 
Farabaugh, P.J. (1996) Programmed translational frameshifting. Microbiol Rev, 60: 103-34 
 
Fatkenheuer, G., Pozniak, A.L., Johnson, M.A., Plettenberg, A., Staszewski, S., Hoepelman, A.I., Saag, M.S., 
Goebel, F.D., Rockstroh, J.K., Dezube, B.J., Jenkins, T.M., Medhurst, C., Sullivan, J.F., Ridgway, C., Abel, S., 
James, I.T., Youle, M. and van der Ryst, E. (2005) Efficacy of short-term monotherapy with maraviroc, a new 
CCR5 antagonist, in patients infected with HIV-1. Nat Med, 11: 1170-2 
 
FDA. (2015). Antiretroviral drugs used in the treatment of HIV infection. [Online] Available from 
http://www.fda.gov/ForPatients/Illness/HIVAIDS/Treatment/ucm118915.htm. 
 
Ferguson-Smith, A.C., Cattanach, B.M., Barton, S.C., Beechey, C.V. and Surani, M.A. (1991) Embryological 
and molecular investigations of parental imprinting on mouse chromosome 7. Nature, 351: 667-70 
 
Filikov, A.V., Mohan, V., Vickers, T.A., Griffey, R.H., Cook, P.D., Abagyan, R.A. and James, T.L. (2000) 
Identification of ligands for RNA targets via structure-based virtual screening: HIV-1 TAR. J Comput Aided Mol 
Des, 14: 593-610 
 
Fleige, S. and Pfaffl, M.W. (2006) RNA integrity and the effect on the real-time qRT-PCR performance. Mol 
Aspects Med, 27: 126-39 
 
Fowden, A.L., Coan, P.M., Angiolini, E., Burton, G.J. and Constancia, M. (2011) Imprinted genes and the 
epigenetic regulation of placental phenotype. Prog Biophys Mol Biol, 106: 281-8 
 
Friedman, E.R. and Fan, C.M. (2007) Separate necdin domains bind ARNT2 and HIF1alpha and repress 
transcription. Biochem Biophys Res Commun, 363: 113-8 
 
Frost, J.M. and Moore, G.E. (2010) The importance of imprinting in the human placenta. PLoS Genet, 6: 
e1001015 
 
Garfield, A.S., Cowley, M., Smith, F.M., Moorwood, K., Stewart-Cox, J.E., Gilroy, K., Baker, S., Xia, J., 
Dalley, J.W., Hurst, L.D., Wilkinson, L.S., Isles, A.R. and Ward, A. (2011) Distinct physiological and 
behavioural functions for parental alleles of imprinted Grb10. Nature, 469: 534-8 
 
Gaudin, C., Mazauric, M.H., Traikia, M., Guittet, E., Yoshizawa, S. and Fourmy, D. (2005) Structure of the 






Gendron, K., Charbonneau, J., Dulude, D., Heveker, N., Ferbeyre, G. and Brakier-Gingras, L. (2008) The 
presence of the TAR RNA structure alters the programmed -1 ribosomal frameshift efficiency of the human 
immunodeficiency virus type 1 (HIV-1) by modifying the rate of translation initiation. Nucleic Acids Res, 36: 
30-40 
 
Gerard, M., Hernandez, L., Wevrick, R. and Stewart, C.L. (1999) Disruption of the mouse necdin gene results in 
early post-natal lethality. Nat Genet, 23: 199-202 
 
Gesteland, R.F., Weiss, R.B. and Atkins, J.F. (1992) Recoding: reprogrammed genetic decoding. Science, 257: 
1640-1 
 
Giedroc, D.P. and Cornish, P.V. (2009) Frameshifting RNA pseudoknots: structure and mechanism. Virus Res, 
139: 193-208 
 
Girnary, R., King, L., Robinson, L., Elston, R. and Brierley, I. (2007) Structure-function analysis of the 
ribosomal frameshifting signal of two human immunodeficiency virus type 1 isolates with increased resistance to 
viral protease inhibitors. J Gen Virol, 88: 226-35 
 
Green, L., Kim, C.H., Bustamante, C. and Tinoco, I., Jr. (2008) Characterization of the mechanical unfolding of 
RNA pseudoknots. J Mol Biol, 375: 511-28 
 
Gregg, C., Zhang, J., Weissbourd, B., Luo, S., Schroth, G.P., Haig, D. and Dulac, C. (2010) High-resolution 
analysis of parent-of-origin allelic expression in the mouse brain. Science, 329: 643-8 
 
Grentzmann, G., Ingram, J.A., Kelly, P.J., Gesteland, R.F. and Atkins, J.F. (1998) A dual-luciferase reporter 
system for studying recoding signals. RNA, 4: 479-86 
 
Grobler, J.A., Stillmock, K., Hu, B., Witmer, M., Felock, P., Espeseth, A.S., Wolfe, A., Egbertson, M., 
Bourgeois, M., Melamed, J., Wai, J.S., Young, S., Vacca, J. and Hazuda, D.J. (2002) Diketo acid inhibitor 
mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase 
enzymes. Proc Natl Acad Sci U S A, 99: 6661-6 
 
Gu, W.G. (2015) Genome editing-based HIV therapies. Trends Biotechnol, 33: 172-179 
 
Guillemot, F., Caspary, T., Tilghman, S.M., Copeland, N.G., Gilbert, D.J., Jenkins, N.A., Anderson, D.J., 
Joyner, A.L., Rossant, J. and Nagy, A. (1995) Genomic imprinting of Mash2, a mouse gene required for 
trophoblast development. Nat Genet, 9: 235-42 
 
Guillemot, F., Nagy, A., Auerbach, A., Rossant, J. and Joyner, A.L. (1994) Essential role of Mash-2 in 
extraembryonic development. Nature, 371: 333-6 
 
Gygi, S.P., Rochon, Y., Franza, B.R. and Aebersold, R. (1999) Correlation between protein and mRNA 
abundance in yeast. Mol Cell Biol, 19: 1720-30 
 
Hall, J.G. (1990) Genomic imprinting: review and relevance to human diseases. Am J Hum Genet, 46: 857-73 
 
Hammell, A.B., Taylor, R.C., Peltz, S.W. and Dinman, J.D. (1999) Identification of putative programmed -1 
ribosomal frameshift signals in large DNA databases. Genome Res, 9: 417-27 
 
Hansen, T.M., Reihani, S.N., Oddershede, L.B. and Sorensen, M.A. (2007) Correlation between mechanical 
strength of messenger RNA pseudoknots and ribosomal frameshifting. Proc Natl Acad Sci U S A, 104: 5830-5 
 
Hare, S., Vos, A.M., Clayton, R.F., Thuring, J.W., Cummings, M.D. and Cherepanov, P. (2010) Molecular 
mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci U S A, 
107: 20057-62 
 
Harger, J.W. and Dinman, J.D. (2003) An in vivo dual-luciferase assay system for studying translational 
recoding in the yeast Saccharomyces cerevisiae. RNA, 9: 1019-24 
 
Harger, J.W., Meskauskas, A. and Dinman, J.D. (2002) An "integrated model" of programmed ribosomal 





Hark, A.T., Schoenherr, C.J., Katz, D.J., Ingram, R.S., Levorse, J.M. and Tilghman, S.M. (2000) CTCF mediates 
methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature, 405: 486-9 
 
Hasegawa, K., Kawahara, T., Fujiwara, K., Shimpuku, M., Sasaki, T., Kitamura, T. and Yoshikawa, K. (2012) 
Necdin controls Foxo1 acetylation in hypothalamic arcuate neurons to modulate the thyroid axis. J Neurosci, 32: 
5562-72 
 
Hatada, I. and Mukai, T. (1995) Genomic imprinting of p57KIP2, a cyclin-dependent kinase inhibitor, in mouse. 
Nat Genet, 11: 204-6 
 
Heard, E. and Disteche, C.M. (2006) Dosage compensation in mammals: fine-tuning the expression of the X 
chromosome. Genes Dev, 20: 1848-67 
 
Hellemans, J., Mortier, G., De Paepe, A., Speleman, F. and Vandesompele, J. (2007) qBase relative 
quantification framework and software for management and automated analysis of real-time quantitative PCR 
data. Genome Biol, 8: R19 
 
Hendrix, C.W., Collier, A.C., Lederman, M.M., Schols, D., Pollard, R.B., Brown, S., Jackson, J.B., Coombs, 
R.W., Glesby, M.J., Flexner, C.W., Bridger, G.J., Badel, K., MacFarland, R.T., Henson, G.W. and Calandra, G. 
(2004) Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in 
HIV-1 infection. J Acquir Immune Defic Syndr, 37: 1253-62 
 
Henke, C., Ruebner, M., Faschingbauer, F., Stolt, C.C., Schaefer, N., Lang, N., Beckmann, M.W., Strissel, P.L. 
and Strick, R. (2013) Regulation of murine placentogenesis by the retroviral genes Syncytin-A, Syncytin-B and 
Peg10. Differentiation, 85: 150-60 
 
Hernandez, C., Fonollosa, A., Garcia-Ramirez, M., Higuera, M., Catalan, R., Miralles, A., Garcia-Arumi, J. and 
Simo, R. (2006) Erythropoietin is expressed in the human retina and it is highly elevated in the vitreous fluid of 
patients with diabetic macular edema. Diabetes Care, 29: 2028-33 
 
Hernandez, C. and Simo, R. (2012) Erythropoietin produced by the retina: its role in physiology and diabetic 
retinopathy. Endocrine, 41: 220-6 
 
Hikichi, T., Kohda, T., Kaneko-Ishino, T. and Ishino, F. (2003) Imprinting regulation of the murine Meg1/Grb10 
and human GRB10 genes; roles of brain-specific promoters and mouse-specific CTCF-binding sites. Nucleic 
Acids Res, 31: 1398-406 
 
Hirasawa, R., Chiba, H., Kaneda, M., Tajima, S., Li, E., Jaenisch, R. and Sasaki, H. (2008) Maternal and zygotic 
Dnmt1 are necessary and sufficient for the maintenance of DNA methylation imprints during preimplantation 
development. Genes Dev, 22: 1607-16 
 
Hishida, T., Naito, K., Osada, S., Nishizuka, M. and Imagawa, M. (2007) peg10, an imprinted gene, plays a 
crucial role in adipocyte differentiation. FEBS Lett, 581: 4272-8 
 
Hiura, H., Obata, Y., Komiyama, J., Shirai, M. and Kono, T. (2006) Oocyte growth-dependent progression of 
maternal imprinting in mice. Genes Cells, 11: 353-61 
 
Hore, T.A., Rapkins, R.W. and Graves, J.A. (2007) Construction and evolution of imprinted loci in mammals. 
Trends Genet, 23: 440-8 
 
Horsfield, J.A., Wilson, D.N., Mannering, S.A., Adamski, F.M. and Tate, W.P. (1995) Prokaryotic ribosomes 
recode the HIV-1 gag-pol-1 frameshift sequence by an E/P site post-translocation simultaneous slippage 
mechanism. Nucleic Acids Res, 23: 1487-94 
 
Hruz, T., Laule, O., Szabo, G., Wessendorp, F., Bleuler, S., Oertle, L., Widmayer, P., Gruissem, W. and 
Zimmermann, P. (2008) Genevestigator v3: a reference expression database for the meta-analysis of 
transcriptomes. Adv Bioinformatics, 2008: 420747 
 
Hruz, T., Wyss, M., Docquier, M., Pfaffl, M.W., Masanetz, S., Borghi, L., Verbrugghe, P., Kalaydjieva, L., 
Bleuler, S., Laule, O., Descombes, P., Gruissem, W. and Zimmermann, P. (2011) RefGenes: identification of 




Huang, X., Yang, Y., Wang, G., Cheng, Q. and Du, Z. (2014) Highly conserved RNA pseudoknots at the Gag-
Pol junction of HIV-1 suggest a novel mechanism of -1 ribosomal frameshifting. RNA, 20: 587-93 
 
Hung, M., Patel, P., Davis, S. and Green, S.R. (1998) Importance of ribosomal frameshifting for human 
immunodeficiency virus type 1 particle assembly and replication. J Virol, 72: 4819-24 
 
Iglesias-Platas, I., Martin-Trujillo, A., Petazzi, P., Guillaumet-Adkins, A., Esteller, M. and Monk, D. (2014) 
Altered expression of the imprinted transcription factor PLAGL1 deregulates a network of genes in the human 
IUGR placenta. Hum Mol Genet, 23: 6275-85 
 
Imamura, S., Ichikawa, T., Nishikawa, Y., Kanzaki, N., Takashima, K., Niwa, S., Iizawa, Y., Baba, M. and 
Sugihara, Y. (2006) Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent 
Anti-HIV-1 activity. J Med Chem, 49: 2784-93 
 
Ip, W.K., Lai, P.B., Wong, N.L., Sy, S.M., Beheshti, B., Squire, J.A. and Wong, N. (2007) Identification of 
PEG10 as a progression related biomarker for hepatocellular carcinoma. Cancer Lett, 250: 284-91 
 
Jacks, T., Madhani, H.D., Masiarz, F.R. and Varmus, H.E. (1988) Signals for ribosomal frameshifting in the 
Rous sarcoma virus gag-pol region. Cell, 55: 447-58 
 
Jacks, T., Power, M.D., Masiarz, F.R., Luciw, P.A., Barr, P.J. and Varmus, H.E. (1988) Characterization of 
ribosomal frameshifting in HIV-1 gag-pol expression. Nature, 331: 280-3 
 
Jacks, T. and Varmus, H.E. (1985) Expression of the Rous sarcoma virus pol gene by ribosomal frameshifting. 
Science, 230: 1237-42 
 
Jacob, F., Guertler, R., Naim, S., Nixdorf, S., Fedier, A., Hacker, N.F. and Heinzelmann-Schwarz, V. (2013) 
Careful selection of reference genes is required for reliable performance of RT-qPCR in human normal and 
cancer cell lines. PLoS One, 8: e59180 
 
Jain, S., Maltepe, E., Lu, M.M., Simon, C. and Bradfield, C.A. (1998) Expression of ARNT, ARNT2, HIF1 
alpha, HIF2 alpha and Ah receptor mRNAs in the developing mouse. Mech Dev, 73: 117-23 
 
Janicke, M. (2005). Backwards ribosomal frameshifting in the human Paternally Expressed Gene 10. Master of 
Science, University of Otago, Dunedin. 
 
Janssen, P.A., Lewi, P.J., Arnold, E., Daeyaert, F., de Jonge, M., Heeres, J., Koymans, L., Vinkers, M., 
Guillemont, J., Pasquier, E., Kukla, M., Ludovici, D., Andries, K., de Bethune, M.P., Pauwels, R., Das, K., 
Clark, A.D., Jr., Frenkel, Y.V., Hughes, S.H., Medaer, B., De Knaep, F., Bohets, H., De Clerck, F., Lampo, A., 
Williams, P. and Stoffels, P. (2005) In search of a novel anti-HIV drug: multidisciplinary coordination in the 
discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile 
(R278474, rilpivirine). J Med Chem, 48: 1901-9 
 
Kainz, B., Shehata, M., Bilban, M., Kienle, D., Heintel, D., Kromer-Holzinger, E., Le, T., Krober, A., Heller, G., 
Schwarzinger, I., Demirtas, D., Chott, A., Dohner, H., Zochbauer-Muller, S., Fonatsch, C., Zielinski, C., 
Stilgenbauer, S., Gaiger, A., Wagner, O. and Jager, U. (2007) Overexpression of the paternally expressed gene 
10 (PEG10) from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukemia. 
Int J Cancer, 121: 1984-93 
 
Kamiya, M., Judson, H., Okazaki, Y., Kusakabe, M., Muramatsu, M., Takada, S., Takagi, N., Arima, T., Wake, 
N., Kamimura, K., Satomura, K., Hermann, R., Bonthron, D.T. and Hayashizaki, Y. (2000) The cell cycle 
control gene ZAC/PLAGL1 is imprinted--a strong candidate gene for transient neonatal diabetes. Hum Mol 
Genet, 9: 453-60 
 
Kaneda, M., Okano, M., Hata, K., Sado, T., Tsujimoto, N., Li, E. and Sasaki, H. (2004) Essential role for de 
novo DNA methyltransferase Dnmt3a in paternal and maternal imprinting. Nature, 429: 900-3 
 
Kaneko-Ishino, T. and Ishino, F. (2012) The role of genes domesticated from LTR retrotransposons and 
retroviruses in mammals. Front Microbiol, 3: 262 
 
Kaneko-Ishino, T., Kohda, T. and Ishino, F. (2003) The regulation and biological significance of genomic 




Kaneko-Ishino, T., Kohda, T., Ono, R. and Ishino, F. (2006) Complementation hypothesis: the necessity of a 
monoallelic gene expression mechanism in mammalian development. Cytogenet Genome Res, 113: 24-30 
 
Kato, Y., Kaneda, M., Hata, K., Kumaki, K., Hisano, M., Kohara, Y., Okano, M., Li, E., Nozaki, M. and Sasaki, 
H. (2007) Role of the Dnmt3 family in de novo methylation of imprinted and repetitive sequences during male 
germ cell development in the mouse. Hum Mol Genet, 16: 2272-80 
 
Kernohan, K.D., Vernimmen, D., Gloor, G.B. and Berube, N.G. (2014) Analysis of neonatal brain lacking 
ATRX or MeCP2 reveals changes in nucleosome density, CTCF binding and chromatin looping. Nucleic Acids 
Res, 42: 8356-68 
 
Keverne, E.B. (2013) Importance of the matriline for genomic imprinting, brain development and behaviour. 
Philos Trans R Soc Lond B Biol Sci, 368: 20110327 
 
Keverne, E.B. (2014) Genomic imprinting, action, and interaction of maternal and fetal genomes. Proc Natl 
Acad Sci U S A, 
 
Keverne, E.B., Fundele, R., Narasimha, M., Barton, S.C. and Surani, M.A. (1996) Genomic imprinting and the 
differential roles of parental genomes in brain development. Brain Res Dev Brain Res, 92: 91-100 
 
Kikuno, R., Nagase, T., Ishikawa, K., Hirosawa, M., Miyajima, N., Tanaka, A., Kotani, H., Nomura, N. and 
Ohara, O. (1999) Prediction of the coding sequences of unidentified human genes. XIV. The complete sequences 
of 100 new cDNA clones from brain which code for large proteins in vitro. DNA Res, 6: 197-205 
 
Kilby, J.M., Hopkins, S., Venetta, T.M., DiMassimo, B., Cloud, G.A., Lee, J.Y., Alldredge, L., Hunter, E., 
Lambert, D., Bolognesi, D., Matthews, T., Johnson, M.R., Nowak, M.A., Shaw, G.M. and Saag, M.S. (1998) 
Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. 
Nat Med, 4: 1302-7 
 
Kim, H.K., Liu, F., Fei, J., Bustamante, C., Gonzalez, R.L., Jr. and Tinoco, I., Jr. (2014) A frameshifting 
stimulatory stem loop destabilizes the hybrid state and impedes ribosomal translocation. Proc Natl Acad Sci U S 
A, 111: 5538-43 
 
Kim, K.A., Kim, J.H., Wang, Y. and Sul, H.S. (2007) Pref-1 (preadipocyte factor 1) activates the 
MEK/extracellular signal-regulated kinase pathway to inhibit adipocyte differentiation. Mol Cell Biol, 27: 2294-
308 
 
Kim, M.S., Pinto, S.M., Getnet, D., Nirujogi, R.S., Manda, S.S., Chaerkady, R., Madugundu, A.K., Kelkar, D.S., 
Isserlin, R., Jain, S., Thomas, J.K., Muthusamy, B., Leal-Rojas, P., Kumar, P., Sahasrabuddhe, N.A., 
Balakrishnan, L., Advani, J., George, B., Renuse, S., Selvan, L.D., Patil, A.H., Nanjappa, V., Radhakrishnan, A., 
Prasad, S., Subbannayya, T., Raju, R., Kumar, M., Sreenivasamurthy, S.K., Marimuthu, A., Sathe, G.J., Chavan, 
S., Datta, K.K., Subbannayya, Y., Sahu, A., Yelamanchi, S.D., Jayaram, S., Rajagopalan, P., Sharma, J., Murthy, 
K.R., Syed, N., Goel, R., Khan, A.A., Ahmad, S., Dey, G., Mudgal, K., Chatterjee, A., Huang, T.C., Zhong, J., 
Wu, X., Shaw, P.G., Freed, D., Zahari, M.S., Mukherjee, K.K., Shankar, S., Mahadevan, A., Lam, H., Mitchell, 
C.J., Shankar, S.K., Satishchandra, P., Schroeder, J.T., Sirdeshmukh, R., Maitra, A., Leach, S.D., Drake, C.G., 
Halushka, M.K., Prasad, T.S., Hruban, R.H., Kerr, C.L., Bader, G.D., Iacobuzio-Donahue, C.A., Gowda, H. and 
Pandey, A. (2014) A draft map of the human proteome. Nature, 509: 575-81 
 
Kim, Y.G., Maas, S. and Rich, A. (2001) Comparative mutational analysis of cis-acting RNA signals for 
translational frameshifting in HIV-1 and HTLV-2. Nucleic Acids Res, 29: 1125-31 
 
King, N.M., Prabu-Jeyabalan, M., Bandaranayake, R.M., Nalam, M.N., Nalivaika, E.A., Ozen, A., Haliloglu, T., 
Yilmaz, N.K. and Schiffer, C.A. (2012) Extreme entropy-enthalpy compensation in a drug-resistant variant of 
HIV-1 protease. ACS Chem Biol, 7: 1536-46 
 
Kishino, T., Lalande, M. and Wagstaff, J. (1997) UBE3A/E6-AP mutations cause Angelman syndrome. Nat 
Genet, 15: 70-3 
 
Klein, D. (2002) Quantification using real-time PCR technology: applications and limitations. Trends Mol Med, 
8: 257-60 
 
Klein, F., Mouquet, H., Dosenovic, P., Scheid, J.F., Scharf, L. and Nussenzweig, M.C. (2013) Antibodies in 
HIV-1 vaccine development and therapy. Science, 341: 1199-204 
 182 
Klein, J.R. (2006) The immune system as a regulator of thyroid hormone activity. Exp Biol Med (Maywood), 
231: 229-36 
 
Kobayashi, S., Wagatsuma, H., Ono, R., Ichikawa, H., Yamazaki, M., Tashiro, H., Aisaka, K., Miyoshi, N., 
Kohda, T., Ogura, A., Ohki, M., Kaneko-Ishino, T. and Ishino, F. (2000) Mouse Peg9/Dlk1 and human 
PEG9/DLK1 are paternally expressed imprinted genes closely located to the maternally expressed imprinted 
genes: mouse Meg3/Gtl2 and human MEG3. Genes Cells, 5: 1029-37 
 
Kohlstaedt, L.A., Wang, J., Friedman, J.M., Rice, P.A. and Steitz, T.A. (1992) Crystal structure at 3.5 A 
resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science, 256: 1783-90 
 
Kokosar, J. and Kordis, D. (2013) Genesis and regulatory wiring of retroelement-derived domesticated genes: a 
phylogenomic perspective. Mol Biol Evol, 30: 1015-31 
 
Kondru, R., Zhang, J., Ji, C., Mirzadegan, T., Rotstein, D., Sankuratri, S. and Dioszegi, M. (2008) Molecular 
interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol Pharmacol, 73: 
789-800 
 
Kozak, K.R., Abbott, B. and Hankinson, O. (1997) ARNT-deficient mice and placental differentiation. Dev Biol, 
191: 297-305 
 
Kuwajima, T., Hasegawa, K. and Yoshikawa, K. (2010) Necdin promotes tangential migration of neocortical 
interneurons from basal forebrain. J Neurosci, 30: 3709-14 
 
Kuwajima, T., Nishimura, I. and Yoshikawa, K. (2006) Necdin promotes GABAergic neuron differentiation in 
cooperation with Dlx homeodomain proteins. J Neurosci, 26: 5383-92 
 
Kuwako, K., Hosokawa, A., Nishimura, I., Uetsuki, T., Yamada, M., Nada, S., Okada, M. and Yoshikawa, K. 
(2005) Disruption of the paternal necdin gene diminishes TrkA signaling for sensory neuron survival. J 
Neurosci, 25: 7090-9 
 
Latos, P.A., Pauler, F.M., Koerner, M.V., Senergin, H.B., Hudson, Q.J., Stocsits, R.R., Allhoff, W., Stricker, 
S.H., Klement, R.M., Warczok, K.E., Aumayr, K., Pasierbek, P. and Barlow, D.P. (2012) Airn transcriptional 
overlap, but not its lncRNA products, induces imprinted Igf2r silencing. Science, 338: 1469-72 
 
Le Goff, X., Philippe, M. and Jean-Jean, O. (1997) Overexpression of human release factor 1 alone has an 
antisuppressor effect in human cells. Mol Cell Biol, 17: 3164-72 
 
Lefebvre, L., Viville, S., Barton, S.C., Ishino, F., Keverne, E.B. and Surani, M.A. (1998) Abnormal maternal 
behaviour and growth retardation associated with loss of the imprinted gene Mest. Nat Genet, 20: 163-9 
 
Leger, M., Dulude, D., Steinberg, S.V. and Brakier-Gingras, L. (2007) The three transfer RNAs occupying the 
A, P and E sites on the ribosome are involved in viral programmed -1 ribosomal frameshift. Nucleic Acids Res, 
35: 5581-92 
 
Lein, E.S., Hawrylycz, M.J., Ao, N., Ayres, M., Bensinger, A., Bernard, A., Boe, A.F., Boguski, M.S., 
Brockway, K.S., Byrnes, E.J., Chen, L., Chen, T.M., Chin, M.C., Chong, J., Crook, B.E., Czaplinska, A., Dang, 
C.N., Datta, S., Dee, N.R., Desaki, A.L., Desta, T., Diep, E., Dolbeare, T.A., Donelan, M.J., Dong, H.W., 
Dougherty, J.G., Duncan, B.J., Ebbert, A.J., Eichele, G., Estin, L.K., Faber, C., Facer, B.A., Fields, R., Fischer, 
S.R., Fliss, T.P., Frensley, C., Gates, S.N., Glattfelder, K.J., Halverson, K.R., Hart, M.R., Hohmann, J.G., 
Howell, M.P., Jeung, D.P., Johnson, R.A., Karr, P.T., Kawal, R., Kidney, J.M., Knapik, R.H., Kuan, C.L., Lake, 
J.H., Laramee, A.R., Larsen, K.D., Lau, C., Lemon, T.A., Liang, A.J., Liu, Y., Luong, L.T., Michaels, J., 
Morgan, J.J., Morgan, R.J., Mortrud, M.T., Mosqueda, N.F., Ng, L.L., Ng, R., Orta, G.J., Overly, C.C., Pak, 
T.H., Parry, S.E., Pathak, S.D., Pearson, O.C., Puchalski, R.B., Riley, Z.L., Rockett, H.R., Rowland, S.A., 
Royall, J.J., Ruiz, M.J., Sarno, N.R., Schaffnit, K., Shapovalova, N.V., Sivisay, T., Slaughterbeck, C.R., Smith, 
S.C., Smith, K.A., Smith, B.I., Sodt, A.J., Stewart, N.N., Stumpf, K.R., Sunkin, S.M., Sutram, M., Tam, A., 
Teemer, C.D., Thaller, C., Thompson, C.L., Varnam, L.R., Visel, A., Whitlock, R.M., Wohnoutka, P.E., 
Wolkey, C.K., Wong, V.Y., Wood, M., Yaylaoglu, M.B., Young, R.C., Youngstrom, B.L., Yuan, X.F., Zhang, 
B., Zwingman, T.A. and Jones, A.R. (2007) Genome-wide atlas of gene expression in the adult mouse brain. 
Nature, 445: 168-76 
 
Li, C.M., Margolin, A.A., Salas, M., Memeo, L., Mansukhani, M., Hibshoosh, H., Szabolcs, M., Klinakis, A. 
and Tycko, B. (2006) PEG10 is a c-MYC target gene in cancer cells. Cancer Res, 66: 665-72 
 
 183 
Li, E. and Zhang, Y. (2014) DNA methylation in mammals. Cold Spring Harb Perspect Biol, 6: a019133 
 
Li, J.Y., Lees-Murdock, D.J., Xu, G.L. and Walsh, C.P. (2004) Timing of establishment of paternal methylation 
imprints in the mouse. Genomics, 84: 952-60 
 
Li, L., Keverne, E.B., Aparicio, S.A., Ishino, F., Barton, S.C. and Surani, M.A. (1999) Regulation of maternal 
behavior and offspring growth by paternally expressed Peg3. Science, 284: 330-3 
 
Li, Y., Treffers, E.E., Napthine, S., Tas, A., Zhu, L., Sun, Z., Bell, S., Mark, B.L., van Veelen, P.A., van Hemert, 
M.J., Firth, A.E., Brierley, I., Snijder, E.J. and Fang, Y. (2014) Transactivation of programmed ribosomal 
frameshifting by a viral protein. Proc Natl Acad Sci U S A, 111: E2172-81 
 
Liao, P.Y., Choi, Y.S., Dinman, J.D. and Lee, K.H. (2011) The many paths to frameshifting: kinetic modelling 
and analysis of the effects of different elongation steps on programmed -1 ribosomal frameshifting. Nucleic 
Acids Res, 39: 300-12 
 
Lind, K.E., Du, Z., Fujinaga, K., Peterlin, B.M. and James, T.L. (2002) Structure-based computational database 
screening, in vitro assay, and NMR assessment of compounds that target TAR RNA. Chem Biol, 9: 185-93 
 
Liu, D.C., Yang, Z.L. and Jiang, S. (2011) Identification of PEG10 and TSG101 as carcinogenesis, progression, 
and poor-prognosis related biomarkers for gallbladder adenocarcinoma. Pathol Oncol Res, 17: 859-66 
 
Liu, R., Paxton, W.A., Choe, S., Ceradini, D., Martin, S.R., Horuk, R., MacDonald, M.E., Stuhlmann, H., Koup, 
R.A. and Landau, N.R. (1996) Homozygous defect in HIV-1 coreceptor accounts for resistance of some 
multiply-exposed individuals to HIV-1 infection. Cell, 86: 367-77 
 
Llorens, C., Munoz-Pomer, A., Bernad, L., Botella, H. and Moya, A. (2009) Network dynamics of eukaryotic 
LTR retroelements beyond phylogenetic trees. Biol Direct, 4: 41 
 
Lorenc, A., Linnenbrink, M., Montero, I., Schilhabel, M.B. and Tautz, D. (2014) Genetic differentiation of 
hypothalamus parentally biased transcripts in populations of the house mouse implicate the Prader-Willi 
syndrome imprinted region as a possible source of behavioral divergence. Mol Biol Evol, 31: 3240-9 
 
Lorgeoux, R.P., Pan, Q., Le Duff, Y. and Liang, C. (2013) DDX17 promotes the production of infectious HIV-1 
particles through modulating viral RNA packaging and translation frameshift. Virology, 443: 384-92 
 
Low, J.T., Garcia-Miranda, P., Mouzakis, K.D., Gorelick, R.J., Butcher, S.E. and Weeks, K.M. (2014) Structure 
and dynamics of the HIV-1 frameshift element RNA. Biochemistry, 53: 4282-91 
 
Ludovici, D.W., De Corte, B.L., Kukla, M.J., Ye, H., Ho, C.Y., Lichtenstein, M.A., Kavash, R.W., Andries, K., 
de Bethune, M.P., Azijn, H., Pauwels, R., Lewi, P.J., Heeres, J., Koymans, L.M., de Jonge, M.R., Van Aken, 
K.J., Daeyaert, F.F., Das, K., Arnold, E. and Janssen, P.A. (2001) Evolution of anti-HIV drug candidates. Part 3: 
Diarylpyrimidine (DAPY) analogues. Bioorg Med Chem Lett, 11: 2235-9 
 
Lux, A., Beil, C., Majety, M., Barron, S., Gallione, C.J., Kuhn, H.M., Berg, J.N., Kioschis, P., Marchuk, D.A. 
and Hafner, M. (2005) Human retroviral gag- and gag-pol-like proteins interact with the transforming growth 
factor-beta receptor activin receptor-like kinase 1. J Biol Chem, 280: 8482-93 
 
Lux, H., Flammann, H., Hafner, M. and Lux, A. (2010) Genetic and molecular analyses of PEG10 reveal new 
aspects of genomic organization, transcription and translation. PLoS One, 5: e8686 
 
MacDonald, H.R. and Wevrick, R. (1997) The necdin gene is deleted in Prader-Willi syndrome and is imprinted 
in human and mouse. Hum Mol Genet, 6: 1873-8 
 
Mager, J., Montgomery, N.D., de Villena, F.P. and Magnuson, T. (2003) Genome imprinting regulated by the 
mouse Polycomb group protein Eed. Nat Genet, 33: 502-7 
 
Maier, T., Guell, M. and Serrano, L. (2009) Correlation of mRNA and protein in complex biological samples. 
FEBS Lett, 583: 3966-73 
 
Manktelow, E., Shigemoto, K. and Brierley, I. (2005) Characterization of the frameshift signal of Edr, a 
mammalian example of programmed -1 ribosomal frameshifting. Nucleic Acids Res, 33: 1553-63 
 
 184 
Mann, J.R. and Lovell-Badge, R.H. (1984) Inviability of parthenogenones is determined by pronuclei, not egg 
cytoplasm. Nature, 310: 66-7 
 
Marcheschi, R.J., Mouzakis, K.D. and Butcher, S.E. (2009) Selection and characterization of small molecules 
that bind the HIV-1 frameshift site RNA. ACS Chem Biol, 4: 844-54 
 
Marcheschi, R.J., Tonelli, M., Kumar, A. and Butcher, S.E. (2011) Structure of the HIV-1 frameshift site RNA 
bound to a small molecule inhibitor of viral replication. ACS Chem Biol, 6: 857-64 
 
Marquez, V., Wilson, D.N., Tate, W.P., Triana-Alonso, F. and Nierhaus, K.H. (2004) Maintaining the ribosomal 
reading frame: the influence of the E site during translational regulation of release factor 2. Cell, 118: 45-55 
 
Mathew, S.F. (2008). Understanding genetic recoding in HIV-1: The mechanism of -1 frameshifting. Doctor of 
Philosophy, University of Otago, Dunedin. 
 
Mathew, S.F., Crowe-McAuliffe, C., Graves, R., Cardno, T.S., McKinney, C., Poole, E.S. and Tate, W.P. (2015) 
The Highly Conserved Codon following the Slippery Sequence Supports −1 Frameshift Efficiency at the HIV-1 
Frameshift Site. PLoS One, 10: e0122176 
 
Matsufuji, S., Matsufuji, T., Miyazaki, Y., Murakami, Y., Atkins, J.F., Gesteland, R.F. and Hayashi, S. (1995) 
Autoregulatory frameshifting in decoding mammalian ornithine decarboxylase antizyme. Cell, 80: 51-60 
 
Matsumoto, A., Susaki, E., Onoyama, I., Nakayama, K., Hoshino, M. and Nakayama, K.I. (2011) Deregulation 
of the p57-E2F1-p53 axis results in nonobstructive hydrocephalus and cerebellar malformation in mice. Mol Cell 
Biol, 31: 4176-92 
 
Matsuoka, S., Edwards, M.C., Bai, C., Parker, S., Zhang, P., Baldini, A., Harper, J.W. and Elledge, S.J. (1995) 
p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor 
gene. Genes Dev, 9: 650-62 
 
Matsuoka, S., Thompson, J.S., Edwards, M.C., Bartletta, J.M., Grundy, P., Kalikin, L.M., Harper, J.W., Elledge, 
S.J. and Feinberg, A.P. (1996) Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, 
p57KIP2, on chromosome 11p15. Proc Natl Acad Sci U S A, 93: 3026-30 
 
Matsuura, T., Sutcliffe, J.S., Fang, P., Galjaard, R.J., Jiang, Y.H., Benton, C.S., Rommens, J.M. and Beaudet, 
A.L. (1997) De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman 
syndrome. Nat Genet, 15: 74-7 
 
Matsuzawa, S.I. and Reed, J.C. (2001) Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin 
degradation linked to p53 responses. Mol Cell, 7: 915-26 
 
McGarry, K.G., Walker, S.E., Wang, H. and Fredrick, K. (2005) Destabilization of the P site codon-anticodon 
helix results from movement of tRNA into the P/E hybrid state within the ribosome. Mol Cell, 20: 613-22 
 
McGrath, J. and Solter, D. (1984) Completion of mouse embryogenesis requires both the maternal and paternal 
genomes. Cell, 37: 179-83 
 
McGuigan, C., Kinchington, D., Nicholls, S.R., Nickson, C. and O'Connor, T.J. (1993) Kinase bypass: A new 
strategy for anti-HIV drug design. Bioorganic and Medicinal Chemistry Letters, 3: 1207-1210 
 
McKinney, C. (2001). The mechanism of frameshifting at the HIV-1 site. Doctor of Philosophy, University of 
Otago, Dunedin. 
 
McNaughton, B.R., Gareiss, P.C. and Miller, B.L. (2007) Identification of a selective small-molecule ligand for 
HIV-1 frameshift-inducing stem-loop RNA from an 11,325 member resin bound dynamic combinatorial library. 
J Am Chem Soc, 129: 11306-7 
 
Mehellou, Y. and De Clercq, E. (2010) Twenty-six years of anti-HIV drug discovery: where do we stand and 
where do we go? J Med Chem, 53: 521-38 
 
Meister, B., Perez-Manso, M. and Daraio, T. (2013) Delta-like 1 homologue is a hypothalamus-enriched protein 




Meskauskas, A., Harger, J.W., Jacobs, K.L. and Dinman, J.D. (2003) Decreased peptidyltransferase activity 
correlates with increased programmed -1 ribosomal frameshifting and viral maintenance defects in the yeast 
Saccharomyces cerevisiae. RNA, 9: 982-92 
 
Miller, K., Lynch, C., Martin, J., Herniou, E. and Tristem, M. (1999) Identification of multiple Gypsy LTR-
retrotransposon lineages in vertebrate genomes. J Mol Evol, 49: 358-66 
 
Miller, N.L., Wevrick, R. and Mellon, P.L. (2009) Necdin, a Prader-Willi syndrome candidate gene, regulates 
gonadotropin-releasing hormone neurons during development. Hum Mol Genet, 18: 248-60 
 
Minakami, R., Kurose, K., Etoh, K., Furuhata, Y., Hattori, M. and Sakaki, Y. (1992) Identification of an internal 
cis-element essential for the human L1 transcription and a nuclear factor(s) binding to the element. Nucleic Acids 
Res, 20: 3139-45 
 
Mitchell, S.F. and Parker, R. (2014) Principles and properties of eukaryotic mRNPs. Mol Cell, 54: 547-58 
 
Mitsuya, H., Weinhold, K.J., Furman, P.A., St Clair, M.H., Lehrman, S.N., Gallo, R.C., Bolognesi, D., Barry, 
D.W. and Broder, S. (1985) 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the 
infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in 
vitro. Proc Natl Acad Sci U S A, 82: 7096-100 
 
Miyoshi, N., Kuroiwa, Y., Kohda, T., Shitara, H., Yonekawa, H., Kawabe, T., Hasegawa, H., Barton, S.C., 
Surani, M.A., Kaneko-Ishino, T. and Ishino, F. (1998) Identification of the Meg1/Grb10 imprinted gene on 
mouse proximal chromosome 11, a candidate for the Silver-Russell syndrome gene. Proc Natl Acad Sci U S A, 
95: 1102-7 
 
Monk, D., Arnaud, P., Frost, J., Hills, F.A., Stanier, P., Feil, R. and Moore, G.E. (2009) Reciprocal imprinting of 
human GRB10 in placental trophoblast and brain: evolutionary conservation of reversed allelic expression. Hum 
Mol Genet, 18: 3066-74 
 
Moon, H.E., Ahn, M.Y., Park, J.A., Min, K.J., Kwon, Y.W. and Kim, K.W. (2005) Negative regulation of 
hypoxia inducible factor-1alpha by necdin. FEBS Lett, 579: 3797-801 
 
Moon, Y.S., Smas, C.M., Lee, K., Villena, J.A., Kim, K.H., Yun, E.J. and Sul, H.S. (2002) Mice lacking 
paternally expressed Pref-1/Dlk1 display growth retardation and accelerated adiposity. Mol Cell Biol, 22: 5585-
92 
 
Moore, T. and Haig, D. (1991) Genomic imprinting in mammalian development: a parental tug-of-war. Trends 
Genet, 7: 45-9 
 
Morison, I.M., Ramsay, J.P. and Spencer, H.G. (2005) A census of mammalian imprinting. Trends Genet, 21: 
457-65 
 
Morrione, A., Valentinis, B., Resnicoff, M., Xu, S. and Baserga, R. (1997) The role of mGrb10alpha in insulin-
like growth factor I-mediated growth. J Biol Chem, 272: 26382-7 
 
Mouzakis, K.D., Lang, A.L., Vander Meulen, K.A., Easterday, P.D. and Butcher, S.E. (2013) HIV-1 frameshift 
efficiency is primarily determined by the stability of base pairs positioned at the mRNA entrance channel of the 
ribosome. Nucleic Acids Res, 41: 1901-13 
 
Mukhopadhyay, R., Yu, W., Whitehead, J., Xu, J., Lezcano, M., Pack, S., Kanduri, C., Kanduri, M., Ginjala, V., 
Vostrov, A., Quitschke, W., Chernukhin, I., Klenova, E., Lobanenkov, V. and Ohlsson, R. (2004) The binding 
sites for the chromatin insulator protein CTCF map to DNA methylation-free domains genome-wide. Genome 
Res, 14: 1594-602 
 
Murakami, K., Oshimura, M. and Kugoh, H. (2007) Suggestive evidence for chromosomal localization of non-
coding RNA from imprinted LIT1. J Hum Genet, 52: 926-33 
 
Muscatelli, F., Abrous, D.N., Massacrier, A., Boccaccio, I., Le Moal, M., Cau, P. and Cremer, H. (2000) 
Disruption of the mouse Necdin gene results in hypothalamic and behavioral alterations reminiscent of the 




Nagano, T., Mitchell, J.A., Sanz, L.A., Pauler, F.M., Ferguson-Smith, A.C., Feil, R. and Fraser, P. (2008) The 
Air noncoding RNA epigenetically silences transcription by targeting G9a to chromatin. Science, 322: 1717-20 
 
Nakayama, K., Frew, I.J., Hagensen, M., Skals, M., Habelhah, H., Bhoumik, A., Kadoya, T., Erdjument-
Bromage, H., Tempst, P., Frappell, P.B., Bowtell, D.D. and Ronai, Z. (2004) Siah2 regulates stability of prolyl-
hydroxylases, controls HIF1alpha abundance, and modulates physiological responses to hypoxia. Cell, 117: 941-
52 
 
Namy, O., Moran, S.J., Stuart, D.I., Gilbert, R.J. and Brierley, I. (2006) A mechanical explanation of RNA 
pseudoknot function in programmed ribosomal frameshifting. Nature, 441: 244-7 
 
Nijhuis, M., Deeks, S. and Boucher, C. (2001) Implications of antiretroviral resistance on viral fitness. Curr 
Opin Infect Dis, 14: 23-8 
 
O'Neill, M.J. (2005) The influence of non-coding RNAs on allele-specific gene expression in mammals. Hum 
Mol Genet, 14 Spec No 1: R113-20 
 
O'Neill, T.J., Rose, D.W., Pillay, T.S., Hotta, K., Olefsky, J.M. and Gustafson, T.A. (1996) Interaction of a 
GRB-IR splice variant (a human GRB10 homolog) with the insulin and insulin-like growth factor I receptors. 
Evidence for a role in mitogenic signaling. J Biol Chem, 271: 22506-13 
 
Ofori, L.O., Hilimire, T.A., Bennett, R.P., Brown, N.W., Jr., Smith, H.C. and Miller, B.L. (2014) High-affinity 
recognition of HIV-1 frameshift-stimulating RNA alters frameshifting in vitro and interferes with HIV-1 
infectivity. J Med Chem, 57: 723-32 
 
Ogle, J.M., Brodersen, D.E., Clemons, W.M., Jr., Tarry, M.J., Carter, A.P. and Ramakrishnan, V. (2001) 
Recognition of cognate transfer RNA by the 30S ribosomal subunit. Science, 292: 897-902 
 
Okabe, H., Satoh, S., Furukawa, Y., Kato, T., Hasegawa, S., Nakajima, Y., Yamaoka, Y. and Nakamura, Y. 
(2003) Involvement of PEG10 in human hepatocellular carcinogenesis through interaction with SIAH1. Cancer 
Res, 63: 3043-8 
 
Oldham, M.C., Horvath, S. and Geschwind, D.H. (2006) Conservation and evolution of gene coexpression 
networks in human and chimpanzee brains. Proc Natl Acad Sci U S A, 103: 17973-8 
 
Ono, R., Kobayashi, S., Wagatsuma, H., Aisaka, K., Kohda, T., Kaneko-Ishino, T. and Ishino, F. (2001) A 
retrotransposon-derived gene, PEG10, is a novel imprinted gene located on human chromosome 7q21. 
Genomics, 73: 232-7 
 
Ono, R., Nakamura, K., Inoue, K., Naruse, M., Usami, T., Wakisaka-Saito, N., Hino, T., Suzuki-Migishima, R., 
Ogonuki, N., Miki, H., Kohda, T., Ogura, A., Yokoyama, M., Kaneko-Ishino, T. and Ishino, F. (2006) Deletion 
of Peg10, an imprinted gene acquired from a retrotransposon, causes early embryonic lethality. Nat Genet, 38: 
101-6 
 
Ortiz, P.A., Ulloque, R., Kihara, G.K., Zheng, H. and Kinzy, T.G. (2006) Translation elongation factor 2 
anticodon mimicry domain mutants affect fidelity and diphtheria toxin resistance. J Biol Chem, 281: 32639-48 
 
Palde, P.B., Ofori, L.O., Gareiss, P.C., Lerea, J. and Miller, B.L. (2010) Strategies for recognition of stem-loop 
RNA structures by synthetic ligands: application to the HIV-1 frameshift stimulatory sequence. J Med Chem, 53: 
6018-27 
 
Park, S.J., Kim, Y.G. and Park, H.J. (2011) Identification of RNA pseudoknot-binding ligand that inhibits the -1 
ribosomal frameshifting of SARS-coronavirus by structure-based virtual screening. J Am Chem Soc, 133: 10094-
100 
 
Pask, A.J., Papenfuss, A.T., Ager, E.I., McColl, K.A., Speed, T.P. and Renfree, M.B. (2009) Analysis of the 
platypus genome suggests a transposon origin for mammalian imprinting. Genome Biol, 10: R1 
 
Pasquinelli, A.E. (2012) MicroRNAs and their targets: recognition, regulation and an emerging reciprocal 






Persson-Augner, D., Lee, Y.W., Tovar, S., Dieguez, C. and Meister, B. (2014) Delta-Like 1 Homologue (DLK1) 
Protein in Neurons of the Arcuate Nucleus That Control Weight Homeostasis and Effect of Fasting on 
Hypothalamic DLK1 mRNA. Neuroendocrinology, 100: 209-20 
 
Piras, G., El Kharroubi, A., Kozlov, S., Escalante-Alcalde, D., Hernandez, L., Copeland, N.G., Gilbert, D.J., 
Jenkins, N.A. and Stewart, C.L. (2000) Zac1 (Lot1), a potential tumor suppressor gene, and the gene for epsilon-
sarcoglycan are maternally imprinted genes: identification by a subtractive screen of novel uniparental fibroblast 
lines. Mol Cell Biol, 20: 3308-15 
 
Plant, E.P. and Dinman, J.D. (2006) Comparative study of the effects of heptameric slippery site composition on 
-1 frameshifting among different eukaryotic systems. RNA, 12: 666-73 
 
Plant, E.P., Jacobs, K.L., Harger, J.W., Meskauskas, A., Jacobs, J.L., Baxter, J.L., Petrov, A.N. and Dinman, 
J.D. (2003) The 9-A solution: how mRNA pseudoknots promote efficient programmed -1 ribosomal 
frameshifting. RNA, 9: 168-74 
 
Poliseno, L., Salmena, L., Zhang, J., Carver, B., Haveman, W.J. and Pandolfi, P.P. (2010) A coding-independent 
function of gene and pseudogene mRNAs regulates tumour biology. Nature, 465: 1033-8 
 
Poole, E.S., Major, L.L., Cridge, A.G. and Tate, W.P. (2004). The Mechanism of Recoding in Pro- and 
Eukaryotes. In: Nierhaus KH and Wilson DN (eds). Protein Synthesis and Ribosome Structure: Translating the 
Genome. Wiley-VCH Verlag GmbH&Co. KGaA: Weinheim. pp 397–428. 
 
Poulter, R. and Butler, M. (1998) A retrotransposon family from the pufferfish (fugu) Fugu rubripes. Gene, 215: 
241-9 
 
Puertas-Avendano, R.A., Gonzalez-Gomez, M.J., Ruvira, M.D., Ruiz-Hidalgo, M.J., Morales-Delgado, N., 
Laborda, J., Diaz, C. and Bello, A.R. (2011) Role of the non-canonical notch ligand delta-like protein 1 in 
hormone-producing cells of the adult male mouse pituitary. J Neuroendocrinol, 23: 849-59 
 
Qi, J., Nakayama, K., Cardiff, R.D., Borowsky, A.D., Kaul, K., Williams, R., Krajewski, S., Mercola, D., 
Carpenter, P.M., Bowtell, D. and Ronai, Z.A. (2010) Siah2-dependent concerted activity of HIF and FoxA2 
regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell, 18: 23-38 
 
Quan, Y., Gu, Z., Li, X., Li, Z., Morrow, C.D. and Wainberg, M.A. (1996) Endogenous reverse transcription 
assays reveal high-level resistance to the triphosphate of (-)2'-dideoxy-3'-thiacytidine by mutated M184V human 
immunodeficiency virus type 1. J Virol, 70: 5642-5 
 
Radonic, A., Thulke, S., Mackay, I.M., Landt, O., Siegert, W. and Nitsche, A. (2004) Guideline to reference 
gene selection for quantitative real-time PCR. Biochem Biophys Res Commun, 313: 856-62 
 
Rakauskaite, R., Liao, P.Y., Rhodin, M.H., Lee, K. and Dinman, J.D. (2011) A rapid, inexpensive yeast-based 
dual-fluorescence assay of programmed--1 ribosomal frameshifting for high-throughput screening. Nucleic Acids 
Res, 39: e97 
 
Ramakers, C., Ruijter, J.M., Deprez, R.H. and Moorman, A.F. (2003) Assumption-free analysis of quantitative 
real-time polymerase chain reaction (PCR) data. Neurosci Lett, 339: 62-6 
 
Ramanathan, C.S. and Taylor, E.W. (1997) Computational genomic analysis of hemorrhagic fever viruses. Biol 
Trace Elem Res, 56: 93-106 
 
Ramsay, J.P., Tester, L.G., Major, A.S., Sullivan, J.T., Edgar, C.D., Kleffmann, T., Patterson-House, J.R., Hall, 
D.A., Tate, W.P., Hynes, M.P. and Ronson, C.W. (2015) Ribosomal frameshifting and dual-target antiactivation 
restrict quorum-sensing-activated transfer of a mobile genetic element. Proc Natl Acad Sci U S A in press, 
 
Raport, C.J., Gosling, J., Schweickart, V.L., Gray, P.W. and Charo, I.F. (1996) Molecular cloning and functional 
characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha. J 
Biol Chem, 271: 17161-6 
 
Rawn, S.M. and Cross, J.C. (2008) The evolution, regulation, and function of placenta-specific genes. Annu Rev 




Reeves, J.D., Lee, F.H., Miamidian, J.L., Jabara, C.B., Juntilla, M.M. and Doms, R.W. (2005) Enfuvirtide 
resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, 
and virus neutralization. J Virol, 79: 4991-9 
 
Reik, W. (1989) Genomic imprinting and genetic disorders in man. Trends Genet, 5: 331-6 
 
Reik, W., Howlett, S.K. and Surani, M.A. (1990) Imprinting by DNA methylation: from transgenes to 
endogenous gene sequences. Dev Suppl: 99-106 
 
Relaix, F., Wei, X., Li, W., Pan, J., Lin, Y., Bowtell, D.D., Sassoon, D.A. and Wu, X. (2000) Pw1/Peg3 is a 
potential cell death mediator and cooperates with Siah1a in p53-mediated apoptosis. Proc Natl Acad Sci U S A, 
97: 2105-10 
 
Relaix, F., Weng, X., Marazzi, G., Yang, E., Copeland, N., Jenkins, N., Spence, S.E. and Sassoon, D. (1996) 
Pw1, a novel zinc finger gene implicated in the myogenic and neuronal lineages. Dev Biol, 177: 383-96 
 
Renfree, M.B., Hore, T.A., Shaw, G., Graves, J.A. and Pask, A.J. (2009) Evolution of genomic imprinting: 
insights from marsupials and monotremes. Annu Rev Genomics Hum Genet, 10: 241-62 
 
Ritchie, D.B., Foster, D.A. and Woodside, M.T. (2012) Programmed -1 frameshifting efficiency correlates with 
RNA pseudoknot conformational plasticity, not resistance to mechanical unfolding. Proc Natl Acad Sci U S A, 
109: 16167-72 
 
Ritchie, D.B., Soong, J., Sikkema, W.K. and Woodside, M.T. (2014) Anti-frameshifting ligand reduces the 
conformational plasticity of the SARS virus pseudoknot. J Am Chem Soc, 136: 2196-9 
 
Rougeulle, C., Glatt, H. and Lalande, M. (1997) The Angelman syndrome candidate gene, UBE3A/E6-AP, is 
imprinted in brain. Nat Genet, 17: 14-5 
 
Sa-Pereira, P., Duarte, J. and Costa-Ferreira, M. (2000) Electroelution as a simple and fast protein purification 
method: isolation of an extracellular xylanase from Bacillus sp. CCMI 966. Enzyme Microb Technol, 27: 95-99 
 
Sahoo, T., del Gaudio, D., German, J.R., Shinawi, M., Peters, S.U., Person, R.E., Garnica, A., Cheung, S.W. and 
Beaudet, A.L. (2008) Prader-Willi phenotype caused by paternal deficiency for the HBII-85 C/D box small 
nucleolar RNA cluster. Nat Genet, 40: 719-21 
 
Samson, M., Stordeur, P., Labbe, O., Soularue, P., Vassart, G. and Parmentier, M. (1996) Molecular cloning and 
chromosomal mapping of a novel human gene, ChemR1, expressed in T lymphocytes and polymorphonuclear 
cells and encoding a putative chemokine receptor. Eur J Immunol, 26: 3021-8 
 
Sanchez-Solana, B., Nueda, M.L., Ruvira, M.D., Ruiz-Hidalgo, M.J., Monsalve, E.M., Rivero, S., Garcia-
Ramirez, J.J., Diaz-Guerra, M.J., Baladron, V. and Laborda, J. (2011) The EGF-like proteins DLK1 and DLK2 
function as inhibitory non-canonical ligands of NOTCH1 receptor that modulate each other's activities. Biochim 
Biophys Acta, 1813: 1153-64 
 
Saurat, N. (2009). Is the retroelement-derived human gene PEG10 regulated by microRNAs? BSc (Hons), 
University of Otago, Dunedin. 
 
Schmidt, J.V., Matteson, P.G., Jones, B.K., Guan, X.J. and Tilghman, S.M. (2000) The Dlk1 and Gtl2 genes are 
linked and reciprocally imprinted. Genes Dev, 14: 1997-2002 
 
Schmidt-Edelkraut, U., Daniel, G., Hoffmann, A. and Spengler, D. (2014) Zac1 regulates cell cycle arrest in 
neuronal progenitors via Tcf4. Mol Cell Biol, 34: 1020-30 
 
Schmittgen, T.D. and Livak, K.J. (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat 
Protoc, 3: 1101-8 
 
Schmittgen, T.D. and Zakrajsek, B.A. (2000) Effect of experimental treatment on housekeeping gene expression: 
validation by real-time, quantitative RT-PCR. J Biochem Biophys Methods, 46: 69-81 
 
Schols, D., Struyf, S., Van Damme, J., Este, J.A., Henson, G. and De Clercq, E. (1997) Inhibition of T-tropic 




Schroeder, A., Mueller, O., Stocker, S., Salowsky, R., Leiber, M., Gassmann, M., Lightfoot, S., Menzel, W., 
Granzow, M. and Ragg, T. (2006) The RIN: an RNA integrity number for assigning integrity values to RNA 
measurements. BMC Mol Biol, 7: 3 
 
Schuller, M., Jenne, D. and Voltz, R. (2005) The human PNMA family: novel neuronal proteins implicated in 
paraneoplastic neurological disease. J Neuroimmunol, 169: 172-6 
 
Schwanhausser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W. and Selbach, M. (2011) 
Global quantification of mammalian gene expression control. Nature, 473: 337-42 
 
Searle, A.G. and Beechey, C.V. (1990) Genome imprinting phenomena on mouse chromosome 7. Genet Res, 56: 
237-44 
 
Sekita, Y., Wagatsuma, H., Nakamura, K., Ono, R., Kagami, M., Wakisaka, N., Hino, T., Suzuki-Migishima, R., 
Kohda, T., Ogura, A., Ogata, T., Yokoyama, M., Kaneko-Ishino, T. and Ishino, F. (2008) Role of 
retrotransposon-derived imprinted gene, Rtl1, in the feto-maternal interface of mouse placenta. Nat Genet, 40: 
243-8 
 
Seto, M., Aikawa, K., Miyamoto, N., Aramaki, Y., Kanzaki, N., Takashima, K., Kuze, Y., Iizawa, Y., Baba, M. 
and Shiraishi, M. (2006) Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and 
biological activities of 1-benzazocine derivatives containing a sulfoxide moiety. J Med Chem, 49: 2037-48 
 
Sharma, V., Prere, M.F., Canal, I., Firth, A.E., Atkins, J.F., Baranov, P.V. and Fayet, O. (2014) Analysis of tetra- 
and hepta-nucleotides motifs promoting -1 ribosomal frameshifting in Escherichia coli. Nucleic Acids Res, 42: 
7210-25 
 
Shehu-Xhilaga, M., Crowe, S.M. and Mak, J. (2001) Maintenance of the Gag/Gag-Pol ratio is important for 
human immunodeficiency virus type 1 RNA dimerization and viral infectivity. J Virol, 75: 1834-41 
 
Shigemoto, K., Brennan, J., Walls, E., Watson, C.J., Stott, D., Rigby, P.W. and Reith, A.D. (2001) Identification 
and characterisation of a developmentally regulated mammalian gene that utilises -1 programmed ribosomal 
frameshifting. Nucleic Acids Res, 29: 4079-88 
 
Shimaki, Y. (2008). Is PEG10 a retroelement that has undergone molecular domestication to become a 
functional mammalian gene? Bachelor of Science with Honours, University of Otago, Dunedin. 
 
Sibley, C.P., Coan, P.M., Ferguson-Smith, A.C., Dean, W., Hughes, J., Smith, P., Reik, W., Burton, G.J., 
Fowden, A.L. and Constancia, M. (2004) Placental-specific insulin-like growth factor 2 (Igf2) regulates the 
diffusional exchange characteristics of the mouse placenta. Proc Natl Acad Sci U S A, 101: 8204-8 
 
Silverman, M.N., Pearce, B.D., Biron, C.A. and Miller, A.H. (2005) Immune modulation of the hypothalamic-
pituitary-adrenal (HPA) axis during viral infection. Viral Immunol, 18: 41-78 
 
Simmons, D.G. and Cross, J.C. (2005) Determinants of trophoblast lineage and cell subtype specification in the 
mouse placenta. Dev Biol, 284: 12-24 
 
Simmons, D.G., Fortier, A.L. and Cross, J.C. (2007) Diverse subtypes and developmental origins of trophoblast 
giant cells in the mouse placenta. Dev Biol, 304: 567-78 
 
Sleutels, F., Zwart, R. and Barlow, D.P. (2002) The non-coding Air RNA is required for silencing autosomal 
imprinted genes. Nature, 415: 810-3 
 
Smallwood, A., Papageorghiou, A., Nicolaides, K., Alley, M.K., Jim, A., Nargund, G., Ojha, K., Campbell, S. 
and Banerjee, S. (2003) Temporal regulation of the expression of syncytin (HERV-W), maternally imprinted 
PEG10, and SGCE in human placenta. Biol Reprod, 69: 286-93 
 
Smas, C.M. and Sul, H.S. (1993) Pref-1, a protein containing EGF-like repeats, inhibits adipocyte 
differentiation. Cell, 73: 725-34 
 
Smith, F.M., Holt, L.J., Garfield, A.S., Charalambous, M., Koumanov, F., Perry, M., Bazzani, R., Sheardown, 
S.A., Hegarty, B.D., Lyons, R.J., Cooney, G.J., Daly, R.J. and Ward, A. (2007) Mice with a disruption of the 
imprinted Grb10 gene exhibit altered body composition, glucose homeostasis, and insulin signaling during 
postnatal life. Mol Cell Biol, 27: 5871-86 
 190 
Spada, F., Haemmer, A., Kuch, D., Rothbauer, U., Schermelleh, L., Kremmer, E., Carell, T., Langst, G. and 
Leonhardt, H. (2007) DNMT1 but not its interaction with the replication machinery is required for maintenance 
of DNA methylation in human cells. J Cell Biol, 176: 565-71 
 
Spengler, D., Villalba, M., Hoffmann, A., Pantaloni, C., Houssami, S., Bockaert, J. and Journot, L. (1997) 
Regulation of apoptosis and cell cycle arrest by Zac1, a novel zinc finger protein expressed in the pituitary gland 
and the brain. EMBO J, 16: 2814-25 
 
Spiegel, P.C., Ermolenko, D.N. and Noller, H.F. (2007) Elongation factor G stabilizes the hybrid-state 
conformation of the 70S ribosome. RNA, 13: 1473-82 
 
Stahl, G., McCarty, G.P. and Farabaugh, P.J. (2002) Ribosome structure: revisiting the connection between 
translational accuracy and unconventional decoding. Trends Biochem Sci, 27: 178-83 
 
Staple, D.W. and Butcher, S.E. (2005) Solution structure and thermodynamic investigation of the HIV-1 
frameshift inducing element. J Mol Biol, 349: 1011-23 
 
Steplewski, A., Krynska, B., Tretiakova, A., Haas, S., Khalili, K. and Amini, S. (1998) MyEF-3, a 
developmentally controlled brain-derived nuclear protein which specifically interacts with myelin basic protein 
proximal regulatory sequences. Biochem Biophys Res Commun, 243: 295-301 
 
Straub, R.H. (2014) Interaction of the endocrine system with inflammation: a function of energy and volume 
regulation. Arthritis Res Ther, 16: 203 
 
Surani, M.A., Barton, S.C. and Norris, M.L. (1984) Development of reconstituted mouse eggs suggests 
imprinting of the genome during gametogenesis. Nature, 308: 548-50 
 
Surmacz, B., Noisa, P., Risner-Janiczek, J.R., Hui, K., Ungless, M., Cui, W. and Li, M. (2012) DLK1 promotes 
neurogenesis of human and mouse pluripotent stem cell-derived neural progenitors via modulating Notch and 
BMP signalling. Stem Cell Rev, 8: 459-71 
 
Suzuki, S., Ono, R., Narita, T., Pask, A.J., Shaw, G., Wang, C., Kohda, T., Alsop, A.E., Marshall Graves, J.A., 
Kohara, Y., Ishino, F., Renfree, M.B. and Kaneko-Ishino, T. (2007) Retrotransposon silencing by DNA 
methylation can drive mammalian genomic imprinting. PLoS Genet, 3: e55 
 
Swaney, W.T., Curley, J.P., Champagne, F.A. and Keverne, E.B. (2007) Genomic imprinting mediates sexual 
experience-dependent olfactory learning in male mice. Proc Natl Acad Sci U S A, 104: 6084-9 
 
Takahashi, K. and Nakayama, K. (2000) Mice lacking a CDK inhibitor, p57Kip2, exhibit skeletal abnormalities 
and growth retardation. J Biochem, 127: 73-83 
 
Tanaka, M., Gertsenstein, M., Rossant, J. and Nagy, A. (1997) Mash2 acts cell autonomously in mouse 
spongiotrophoblast development. Dev Biol, 190: 55-65 
 
Taniura, H., Matsumoto, K. and Yoshikawa, K. (1999) Physical and functional interactions of neuronal growth 
suppressor necdin with p53. J Biol Chem, 274: 16242-8 
 
Taniura, H., Taniguchi, N., Hara, M. and Yoshikawa, K. (1998) Necdin, a postmitotic neuron-specific growth 
suppressor, interacts with viral transforming proteins and cellular transcription factor E2F1. J Biol Chem, 273: 
720-8 
 
Tavangar, K., Hoffman, A.R. and Kraemer, F.B. (1990) A micromethod for the isolation of total RNA from 
adipose tissue. Anal Biochem, 186: 60-3 
 
Taylor, E.W. and Ramanathan, C.S. (1995) Theoretical Evidence that the Ebola Virus Zaire Strain May Be 
Selenium-Dependent: A Factor in Pathogenesis and Viral Outbreak? J Orthomol Med, 10: 131-8 
 
Tebit, D.M., Lobritz, M., Lalonde, M., Immonen, T., Singh, K., Sarafianos, S., Herchenroder, O., Krausslich, 
H.G. and Arts, E.J. (2010) Divergent evolution in reverse transcriptase (RT) of HIV-1 group O and M lineages: 






Telenti, A., Martinez, R., Munoz, M., Bleiber, G., Greub, G., Sanglard, D. and Peters, S. (2002) Analysis of 
natural variants of the human immunodeficiency virus type 1 gag-pol frameshift stem-loop structure. J Virol, 76: 
7868-73 
 
Thellin, O., Zorzi, W., Lakaye, B., De Borman, B., Coumans, B., Hennen, G., Grisar, T., Igout, A. and Heinen, 
E. (1999) Housekeeping genes as internal standards: use and limits. J Biotechnol, 75: 291-5 
 
ThyagaRajan, S. and Priyanka, H.P. (2012) Bidirectional communication between the neuroendocrine system 
and the immune system: relevance to health and diseases. Ann Neurosci, 19: 40-6 
 
Trkola, A., Kuhmann, S.E., Strizki, J.M., Maxwell, E., Ketas, T., Morgan, T., Pugach, P., Xu, S., Wojcik, L., 
Tagat, J., Palani, A., Shapiro, S., Clader, J.W., McCombie, S., Reyes, G.R., Baroudy, B.M. and Moore, J.P. 
(2002) HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc 
Natl Acad Sci U S A, 99: 395-400 
 
Tsamis, F., Gavrilov, S., Kajumo, F., Seibert, C., Kuhmann, S., Ketas, T., Trkola, A., Palani, A., Clader, J.W., 
Tagat, J.R., McCombie, S., Baroudy, B., Moore, J.P., Sakmar, T.P. and Dragic, T. (2003) Analysis of the 
mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human 
immunodeficiency virus type 1 entry. J Virol, 77: 5201-8 
 
Tsibris, A.M., Sagar, M., Gulick, R.M., Su, Z., Hughes, M., Greaves, W., Subramanian, M., Flexner, C., Giguel, 
F., Leopold, K.E., Coakley, E. and Kuritzkes, D.R. (2008) In vivo emergence of vicriviroc resistance in a human 
immunodeficiency virus type 1 subtype C-infected subject. J Virol, 82: 8210-4 
 
Tsou, A.P., Chuang, Y.C., Su, J.Y., Yang, C.W., Liao, Y.L., Liu, W.K., Chiu, J.H. and Chou, C.K. (2003) 
Overexpression of a novel imprinted gene, PEG10, in human hepatocellular carcinoma and in regenerating 
mouse livers. J Biomed Sci, 10: 625-35 
 
Tsuchihashi, Z. and Kornberg, A. (1990) Translational frameshifting generates the gamma subunit of DNA 
polymerase III holoenzyme. Proc Natl Acad Sci U S A, 87: 2516-20 
 
Tsuji, K., Yasui, K., Gen, Y., Endo, M., Dohi, O., Zen, K., Mitsuyoshi, H., Minami, M., Itoh, Y., Taniwaki, M., 
Tanaka, S., Arii, S., Okanoue, T. and Yoshikawa, T. (2010) PEG10 is a probable target for the amplification at 
7q21 detected in hepatocellular carcinoma. Cancer Genet Cytogenet, 198: 118-25 
 
Tunster, S.J., Van de Pette, M. and John, R.M. (2011) Fetal overgrowth in the Cdkn1c mouse model of 
Beckwith-Wiedemann syndrome. Dis Model Mech, 4: 814-21 
 
Udier-Blagovic, M., Tirado-Rives, J. and Jorgensen, W.L. (2003) Validation of a model for the complex of HIV-
1 reverse transcriptase with nonnucleoside inhibitor TMC125. J Am Chem Soc, 125: 6016-7 
 
Uhlen, M., Fagerberg, L., Hallstrom, B.M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, A., Kampf, 
C., Sjostedt, E., Asplund, A., Olsson, I., Edlund, K., Lundberg, E., Navani, S., Szigyarto, C.A., Odeberg, J., 
Djureinovic, D., Takanen, J.O., Hober, S., Alm, T., Edqvist, P.H., Berling, H., Tegel, H., Mulder, J., Rockberg, 
J., Nilsson, P., Schwenk, J.M., Hamsten, M., von Feilitzen, K., Forsberg, M., Persson, L., Johansson, F., 
Zwahlen, M., von Heijne, G., Nielsen, J. and Ponten, F. (2015) Tissue-based map of the human proteome. 
Science, 347: 1260419 
 
Valente, T., Junyent, F. and Auladell, C. (2005) Zac1 is expressed in progenitor/stem cells of the neuroectoderm 
and mesoderm during embryogenesis: differential phenotype of the Zac1-expressing cells during development. 
Dev Dyn, 233: 667-79 
 
Van Buggenhout, G. and Fryns, J.P. (2009) Angelman syndrome (AS, MIM 105830). Eur J Hum Genet, 17: 
1367-73 
 
van der Horst, P.H., Wang, Y., Vandenput, I., Kuhne, L.C., Ewing, P.C., van Ijcken, W.F., van der Zee, M., 
Amant, F., Burger, C.W. and Blok, L.J. (2012) Progesterone inhibits epithelial-to-mesenchymal transition in 
endometrial cancer. PLoS One, 7: e30840 
 
Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A. and Speleman, F. (2002) 
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal 
control genes. Genome Biol, 3: RESEARCH0034 
 
 192 
Varmuza, S. and Mann, M. (1994) Genomic imprinting--defusing the ovarian time bomb. Trends Genet, 10: 
118-23 
 
Varrault, A., Ciani, E., Apiou, F., Bilanges, B., Hoffmann, A., Pantaloni, C., Bockaert, J., Spengler, D. and 
Journot, L. (1998) hZAC encodes a zinc finger protein with antiproliferative properties and maps to a 
chromosomal region frequently lost in cancer. Proc Natl Acad Sci U S A, 95: 8835-40 
 
Varrault, A., Gueydan, C., Delalbre, A., Bellmann, A., Houssami, S., Aknin, C., Severac, D., Chotard, L., Kahli, 
M., Le Digarcher, A., Pavlidis, P. and Journot, L. (2006) Zac1 regulates an imprinted gene network critically 
involved in the control of embryonic growth. Dev Cell, 11: 711-22 
 
Villanueva, C., Jacquier, S. and de Roux, N. (2012) DLK1 is a somato-dendritic protein expressed in 
hypothalamic arginine-vasopressin and oxytocin neurons. PLoS One, 7: e36134 
 
Vogel, C., Abreu Rde, S., Ko, D., Le, S.Y., Shapiro, B.A., Burns, S.C., Sandhu, D., Boutz, D.R., Marcotte, E.M. 
and Penalva, L.O. (2010) Sequence signatures and mRNA concentration can explain two-thirds of protein 
abundance variation in a human cell line. Mol Syst Biol, 6: 400 
 
Vogel, C. and Marcotte, E.M. (2012) Insights into the regulation of protein abundance from proteomic and 
transcriptomic analyses. Nat Rev Genet, 13: 227-32 
 
Volff, J., Korting, C. and Schartl, M. (2001) Ty3/Gypsy retrotransposon fossils in mammalian genomes: did they 
evolve into new cellular functions? Mol Biol Evol, 18: 266-70 
 
Wan, L.B. and Bartolomei, M.S. (2008) Regulation of imprinting in clusters: noncoding RNAs versus insulators. 
Adv Genet, 61: 207-23 
 
Wang, C., Xiao, Y., Hu, Z., Chen, Y., Liu, N. and Hu, G. (2008) PEG10 directly regulated by E2Fs might have a 
role in the development of hepatocellular carcinoma. FEBS Lett, 582: 2793-8 
 
Wang, X., Miller, D.C., Harman, R., Antczak, D.F. and Clark, A.G. (2013) Paternally expressed genes 
predominate in the placenta. Proc Natl Acad Sci U S A, 110: 10705-10 
 
Wang, X., Soloway, P.D. and Clark, A.G. (2011) A survey for novel imprinted genes in the mouse placenta by 
mRNA-seq. Genetics, 189: 109-22 
 
Wang, Y. and Sul, H.S. (2006) Ectodomain shedding of preadipocyte factor 1 (Pref-1) by tumor necrosis factor 
alpha converting enzyme (TACE) and inhibition of adipocyte differentiation. Mol Cell Biol, 26: 5421-35 
 
Wang, Y. and Sul, H.S. (2009) Pref-1 regulates mesenchymal cell commitment and differentiation through Sox9. 
Cell Metab, 9: 287-302 
 
Wei, X., Decker, J.M., Liu, H., Zhang, Z., Arani, R.B., Kilby, J.M., Saag, M.S., Wu, X., Shaw, G.M. and 
Kappes, J.C. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion 
inhibitor (T-20) monotherapy. Antimicrob Agents Chemother, 46: 1896-905 
 
Weiss, R.B., Dunn, D.M., Shuh, M., Atkins, J.F. and Gesteland, R.F. (1989) E. coli ribosomes re-phase on 
retroviral frameshift signals at rates ranging from 2 to 50 percent. New Biol, 1: 159-69 
 
Westby, M., Lewis, M., Whitcomb, J., Youle, M., Pozniak, A.L., James, I.T., Jenkins, T.M., Perros, M. and van 
der Ryst, E. (2006) Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a 
minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a 
pretreatment CXCR4-using virus reservoir. J Virol, 80: 4909-20 
 
White, K.H., Orzechowski, M., Fourmy, D. and Visscher, K. (2011) Mechanical unfolding of the beet western 
yellow virus -1 frameshift signal. J Am Chem Soc, 133: 9775-82 
 
Wild, C., Oas, T., McDanal, C., Bolognesi, D. and Matthews, T. (1992) A synthetic peptide inhibitor of human 
immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad 






Wild, C.T., Shugars, D.C., Greenwell, T.K., McDanal, C.B. and Matthews, T.J. (1994) Peptides corresponding 
to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus 
infection. Proc Natl Acad Sci U S A, 91: 9770-4 
 
Wilhelm, M., Schlegl, J., Hahne, H., Moghaddas Gholami, A., Lieberenz, M., Savitski, M.M., Ziegler, E., 
Butzmann, L., Gessulat, S., Marx, H., Mathieson, T., Lemeer, S., Schnatbaum, K., Reimer, U., Wenschuh, H., 
Mollenhauer, M., Slotta-Huspenina, J., Boese, J.H., Bantscheff, M., Gerstmair, A., Faerber, F. and Kuster, B. 
(2014) Mass-spectrometry-based draft of the human proteome. Nature, 509: 582-7 
 
Wilkinson, L.S., Davies, W. and Isles, A.R. (2007) Genomic imprinting effects on brain development and 
function. Nat Rev Neurosci, 8: 832-43 
 
Wills, N.M., Moore, B., Hammer, A., Gesteland, R.F. and Atkins, J.F. (2006) A functional -1 ribosomal 
frameshift signal in the human paraneoplastic Ma3 gene. J Biol Chem, 281: 7082-8 
 
Wilson, W., Braddock, M., Adams, S.E., Rathjen, P.D., Kingsman, S.M. and Kingsman, A.J. (1988) HIV 
expression strategies: ribosomal frameshifting is directed by a short sequence in both mammalian and yeast 
systems. Cell, 55: 1159-69 
 
Wood, A. and Armour, D. (2005) The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for 
the treatment of HIV infection and AIDS. Prog Med Chem, 43: 239-71 
 
Wood, A.J. and Oakey, R.J. (2006) Genomic imprinting in mammals: emerging themes and established theories. 
PLoS Genet, 2: e147 
 
Wood, A.J., Schulz, R., Woodfine, K., Koltowska, K., Beechey, C.V., Peters, J., Bourc'his, D. and Oakey, R.J. 
(2008) Regulation of alternative polyadenylation by genomic imprinting. Genes Dev, 22: 1141-6 
 
Woringer, M., Darzacq, X. and Izeddin, I. (2014) Geometry of the nucleus: a perspective on gene expression 
regulation. Curr Opin Chem Biol, 20: 112-9 
 
Xie, F., Sun, G., Stiller, J.W. and Zhang, B. (2011) Genome-wide functional analysis of the cotton transcriptome 
by creating an integrated EST database. PLoS One, 6: e26980 
 
Xiong, J., Qin, J., Zheng, Y., Peng, X., Luo, Y. and Meng, X. (2012) PEG10 promotes the migration of human 
Burkitt's lymphoma cells by up-regulating the expression of matrix metalloproteinase-2 and -9. Clin Invest Med, 
35: E117-25 
 
Yan, S., Wen, J.D., Bustamante, C. and Tinoco, I., Jr. (2015) Ribosome Excursions during mRNA Translocation 
Mediate Broad Branching of Frameshift Pathways. Cell, 160: 870-81 
 
Yan, Y., Frisen, J., Lee, M.H., Massague, J. and Barbacid, M. (1997) Ablation of the CDK inhibitor p57Kip2 
results in increased apoptosis and delayed differentiation during mouse development. Genes Dev, 11: 973-83 
 
Ye, W., Mairet-Coello, G., Pasoreck, E. and Dicicco-Bloom, E. (2009) Patterns of p57Kip2 expression in 
embryonic rat brain suggest roles in progenitor cell cycle exit and neuronal differentiation. Dev Neurobiol, 69: 1-
21 
 
Yevtodiyenko, A. and Schmidt, J.V. (2006) Dlk1 expression marks developing endothelium and sites of 
branching morphogenesis in the mouse embryo and placenta. Dev Dyn, 235: 1115-23 
 
Yoon, B., Herman, H., Hu, B., Park, Y.J., Lindroth, A., Bell, A., West, A.G., Chang, Y., Stablewski, A., Piel, 
J.C., Loukinov, D.I., Lobanenkov, V.V. and Soloway, P.D. (2005) Rasgrf1 imprinting is regulated by a CTCF-
dependent methylation-sensitive enhancer blocker. Mol Cell Biol, 25: 11184-90 
 
Youngson, N.A., Kocialkowski, S., Peel, N. and Ferguson-Smith, A.C. (2005) A small family of sushi-class 
retrotransposon-derived genes in mammals and their relation to genomic imprinting. J Mol Evol, 61: 481-90 
 
Zemel, S., Bartolomei, M.S. and Tilghman, S.M. (1992) Physical linkage of two mammalian imprinted genes, 
H19 and insulin-like growth factor 2. Nat Genet, 2: 61-5 
 
Zhang, P., Wong, C., DePinho, R.A., Harper, J.W. and Elledge, S.J. (1998) Cooperation between the Cdk 
inhibitors p27(KIP1) and p57(KIP2) in the control of tissue growth and development. Genes Dev, 12: 3162-7 
 194 
Zhao, C., Putnik, M., Gustafsson, J.A. and Dahlman-Wright, K. (2009) Microarray analysis of altered gene 
expression in ERbeta-overexpressing HEK293 cells. Endocrine, 36: 224-32 
 
Zhu, X., Zhang, J., Tollkuhn, J., Ohsawa, R., Bresnick, E.H., Guillemot, F., Kageyama, R. and Rosenfeld, M.G. 
(2006) Sustained Notch signaling in progenitors is required for sequential emergence of distinct cell lineages 













Ammonium persulphate, chloroform,  






Agar, agarose, DEPC, EGTA, glycine, 
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BDH Laboratory Supplies 
CaCl2, formamide, MgSO4, Triton™ X-
100, ZnCl2 
 
Bio-Rad Laboratories Inc. 
30% (w/v) acrylamide/bis solution 















37% (v/v) formaldehyde, imidazole, 
NaOAc, tryptone, yeast extract 
 







Passive Lysis Buffer (5×) 
 
Roche Diagnostics 
DTT, D(−)-Luciferin, λ DNA 
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Scharlab S.L. 
HOAc, acetone, (NH4)2SO4, boric acid, 
EDTA, H2O2, HCl, KCl, K2HPO4, 




4-iodiphenylboronic acid (4-IPBA), 
NH4HCO3, ampicillin, ATP disodium salt 
grade 1, β-mercaptoethanol, Brilliant Blue 
R-250, Coenzyme A, ethanolamine-HCl, 
luminol, MnCl2, PIPES, reduced 
glutathione, tricine, Tween® 20 
 
Thermo Fisher Scientific 
Protease inhibitor tablets (EDTA-free), 









All solutions were prepared using ddH2O (Milli-Q, Thermo Fisher Scientific). Solutions were 




Acidic elution buffer 
100 mM glycine 
150 mM NaCl 
Adjusted to pH 2.4 with HCl 
 
Acid wash solution 
0.1 M NaOAc 
0.5 M NaCl 
Adjusted to pH 4.5 with HCl 
 
 
Alkaline washe solution 
0.1 M Tris 
0.5 M NaCl 
Adjusted to pH 8.5 with HCl 
 
Chemiluminescent reagent stock 
62.5 mM luminol 
100 mM 4-IPBA 






100 mM Tris-HCl (pH 8.8) 
2% (v/v) chemiluminescent reagent stock 
5.3 mM H2O2 
 
Coelenterazine stock 
50 µM Coelenterazine 
98% (v/v) methanol 
2% (v/v) 1 M HCl 
 
Coomassie stain 
0.25% (w/v) Brilliant Blue R-250 
45% (v/v) methanol 
10% (v/v) HOAc 
Filter through Whatman No.1 filter paper 
 
Coupling buffer 
100 mM HEPES 
Adjusted to pH 7.5 with NaOH 
 
Coupling termination buffer 
1 M ethanolamine-HCl 
Adjusted to pH 8.0 with HCl 
 
Destain 
5% (v/v) methanol 




DNA loading buffer 
7 M urea 
50% (w/v) sucrose 
0.1 mM EDTA (pH 7.0) 
0.1% (w/v) bromophenol blue 
 
Electroelution buffer 
50 mM NH4HCO3  
0.1% (w/v) SDS 
Prepared fresh immediately before use 
 
FA gel buffer, 10× 
200 mM MOPS 
50 mM NaOAc 
10 mM EDTA 
Adjusted to pH 7.0 with NaOH 
 
FA gel running buffer 
1× FA gel buffer 
1.95% (v/v) formaldehyde 
0.1 µg/mL ethidium bromide 
 
Fixing solution 
45% (v/v) methanol 
10% (v/v) HOAc 
 
Freezing medium 
90% (v/v) FBS 
10% (v/v) DMSO 
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Luc+ assay buffer 
500 µM Luciferin stock 
20 mM tricine 
2.67 mM MgSO4 
0.1 mM EDTA 
33.3 mM DTT 
270 µM Coenzyme A 
500 µM ATP 
Aliquoted and stored at −80 °C 
 
Luciferin stock 
2 mM D(−)-Luciferin 
20 mM tricine 
10 mM DTT 
Aliquoted and stored at −80 °C 
 
Luria-Bertani medium 
1% (w/v) tryptone 
0.5% (w/v) yeast extract 
1% (w/v) NaCl 





2 mM DTT 
0.5% (v/v) Triton™ X-100 
 
Neutralising buffer 
1 M Tris-HCl 
Adjusted to pH 8.0 with HCl 
 
PBS 
Dissolved 1 tablet in 100 mL ddH2O 
 
PBS, 10× 
1.4 M NaCl 
27 mM KCl 
102 mM Na2HPO4 




0.53 mM EDTA (pH 8.0)  
 
Ponceau S stain 
0.5% (w/v) Ponceau S 
1% (v/v) HOAc 
 
Protein extraction buffer 
50 mM Tris-HCl (pH 8.0) 
50 mM NaCl 
1 mM EDTA (pH 8.0) 
10 mM EGTA (pH 8.0) 
0.01% (v/v) Triton™ X-100 
1 M urea 
Pierce Protease inhibitor tablet 
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Protein loading buffer 
250 mM Tris-HCl (pH 6.8) 
30% (v/v) glycerol 
10% (w/v) SDS 
10% (v/v) β-mercaptoethanol 
 
RLuc assay buffer 
0.5 µM Coelenterazine stock 
0.5 M NaCl 
0.1 M KH2PO4/K2HPO4 (pH 6.7) 
1 mM EDTA 
Flushed with nitrogen for >60 s, aliquoted 
and stored at −80 °C 
 
RNA loading dye, 10× 
7 M urea 
50% (w/v) sucrose 
0.1% (w/v) bromophenol blue 
0.1 mM EDTA 
 
RNA loading buffer 
11.4% (v/v) 10× FA gel buffer 
56.8% (v/v) deionised formamide 
20.5% (v/v) formaldehyde 
11.4% (v/v) 10× RNA loading dye 




SDS-PAGE inner running buffer 
25 mM Tris 
192 mM glycine 
0.2% (w/v) SDS 
 
SDS-PAGE outer running buffer 
25 mM Tris 
192 mM glycine 
 
Separating gel buffer, 4× 
3 M Tris 
Adjusted to pH 8.8 with HCl 
 
Separating gel, 12.5% 
1× separating gel buffer 
12.5% (v/v) acrylamide/bis solution 
(37.5:1) 
0.09% (w/v) ammonium persulphate 
0.075% (v/v) TEMED 
 
Stacking gel buffer, 4× 
0.5 M Tris 
Adjusted to pH 6.8 with HCl 
 
Stacking gel, 4% 
1× separating gel buffer 
4% (v/v) acrylamide/bis solution (37.5:1) 
0.1% (w/v) ammonium persulphate 
0.1% (v/v) TEMED 
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TB buffer 
10 mM PIPES 
15 mM CaCl2 
125 mM KCl 
55 mM MnCl2 




45 mM Tris 
1 mM EDTA 
45 mM boric acid 
 
TBST, 10× 
400 mM Tris 
1.5 M NaCl 
0.5% (v/v) Tween®20 
Adjusted to pH 7.4 with HCl 
Transfer buffer 
25 mM Tris 
192 mM glycine 
10% (v/v) methanol 
 
Zinc stain solution 1 
0.2 M imidazole 
0.1% (w/v) SDS 
 
Zinc stain solution 2 






















This was adapted from Hellemans et al. (2007) under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/2.0/). Formulae 1–6 were removed because they were not used, and 












Appendix III  Purity and concentration of RNA samples 
 
 
Appendix III.a: Summary of RNA purity assessments of male mouse tissues. 
Male 260/280 260/230 ng/µL  Male 260/280 260/230 ng/µL 
Brain 2.16 2.17 674.3  Kidney 2.15 2.26 1246.8 
 2.16 2.15 639.8   2.14 2.00 1703.0 
 2.12 1.63 477.9   2.15 2.27 1482.8 
 2.10 1.69 327.2   2.14 2.04 905.9 
 2.15 2.12 507.2   2.15 2.25 1100.3 
 2.11 1.88 388.8   2.14 2.24 887.5 
Thyroid 2.15 2.20 857.2  Stomach 2.15 1.94 591.7 
 2.15 2.22 1385.1   2.15 2.20 796.1 
 2.15 2.17 1513.1   2.15 2.17 653.7 
 2.21 2.21 930.7   2.16 2.24 552.7 
 2.16 2.10 1211.6   2.14 2.05 517.3 
 2.17 2.21 1121.3   2.17 2.10 662.1 
Heart 2.15 1.84 159.9  Intestine 2.16 2.21 911.9 
 2.15 1.90 166.1   2.17 2.21 1066.7 
 2.09 1.70 124.4   2.16 2.21 1368.2 
 2.12 1.66 124.5   2.16 2.19 1411.0 
 2.13 1.75 131.9   2.15 2.20 1063.2 
 2.13 1.85 146.6   2.16 2.21 1309.9 
Lung 2.13 1.41 464.0  Muscle 2.11 1.82 181.3 
 2.15 2.18 414.1   2.11 1.78 124.3 
 2.13 2.14 428.1   2.04 1.47 79.0 
 2.09 2.18 411.0   2.06 1.66 123.4 
 2.15 2.22 851.6   2.05 1.56 97.7 
 2.17 2.17 450.5   2.10 1.76 185.8 
Liver 2.14 2.10 1514.5  Adipose 2.12 1.75 116.7 
 2.15 2.10 1440.7   2.16 2.04 198.0 
 2.14 2.04 1089.2   2.09 1.91 154.3 
 2.16 2.08 1230.0   2.12 1.94 195.3 
 2.16 2.14 1215.9   2.22 2.07 189.8 
 2.14 2.17 2174.8   2.15 2.00 206.1 
Spleen 2.10 1.56 590.4  Testis 2.15 2.21 724.2 
 2.10 2.15 645.8   2.13 2.18 688.3 
 2.11 2.18 672.7   2.16 2.19 583.1 
 2.09 2.17 900.1   2.12 1.80 408.7 
 2.11 2.12 734.6   2.13 1.61 509.2 
 2.08 2.19 974.2    2.21 1.87 329.4 






Appendix III.b: Summary of RNA purity assessments of female mouse tissues. 
Female 260/280 260/230 ng/µL  Female 260/280 260/230 ng/µL 
Brain 2.14 2.04 422.4  Kidney 2.16 2.17 561.5 
 2.14 2.10 416.2   2.15 2.18 774.8 
 2.19 2.18 487.6   2.16 2.18 560.0 
 2.15 2.14 414.9   2.15 2.19 471.1 
 2.13 2.10 418.5   2.15 2.10 708.3 
 2.13 1.80 481.9   2.14 2.16 511.3 
Thyroid 2.16 2.23 1224.3  Stomach 2.17 2.23 848.6 
 2.01 1.03 25.7   2.16 2.21 560.9 
 2.17 2.20 886.5   2.14 2.06 816.6 
 2.16 2.23 897.4   2.17 2.27 835.1 
 2.16 2.13 883.9   2.14 2.13 475.4 
 2.17 2.19 697.3   2.14 2.13 419.2 
Heart 2.19 1.85 155.2  Intestine 2.18 2.28 1339.6 
 2.19 1.74 141.7   2.16 2.21 712.7 
 2.17 1.77 115.0   2.17 2.24 1231.9 
 2.24 1.61 65.7   2.18 2.20 831.7 
 2.22 1.61 76.5   2.18 2.23 993.8 
 2.17 1.77 99.5   2.18 2.24 890.0 
Lung 2.16 2.04 285.5  Muscle 2.10 1.82 135.6 
 2.15 2.06 340.5   2.08 1.15 55.5 
 2.13 2.05 311.1   2.13 1.80 133.9 
 2.13 2.01 260.1   2.06 1.44 97.8 
 2.13 2.03 257.2   2.10 1.59 80.7 
 2.12 1.01 177.8   1.96 1.33 48.8 
Liver 2.15 2.12 1661.2  Adipose 2.12 1.54 130.3 
 2.14 2.03 843.8   2.11 1.36 43.9 
 2.15 1.83 961.0   2.10 1.67 88.4 
 2.12 1.98 789.3   2.16 1.70 127.7 
 2.14 2.07 773.0   2.07 1.23 35.2 
 2.13 1.96 760.8   2.13 1.80 124.1 
Spleen 2.13 2.08 420.5  Uterus 2.12 1.93 302.3 
 2.12 2.10 574.1   2.12 2.05 465.7 
 2.10 2.16 550.8   2.17 2.01 458.4 
 2.13 2.12 600.1   2.03 1.42 83.5 
 2.14 2.18 874.7   2.18 2.11 692.1 
 2.14 2.11 693.5   2.13 1.78 236.7 
     Ovary 2.11 1.95 409.0 









Appendix III.c: Summary of RNA purity assessments of pregnant female tissues. 
PF 260/280 260/230 ng/µL  PF 260/280 260/230 ng/µL 
Brain 2.13 1.98 232.0  Stomach 2.15 1.87 505.6 
 2.17 2.09 433.0   2.18 2.34 712.9 
 2.13 2.08 317.6   2.17 2.28 720.8 
 2.13 1.93 476.1   2.19 2.34 892.3 
 2.13 1.99 390.0   2.18 2.27 783.1 
 2.13 2.08 311.8   2.17 2.28 637.9 
Thyroid 2.15 2.05 869.5  Intestine 2.16 2.13 720.0 
 2.15 2.12 686.4   2.15 2.24 1285.1 
 2.15 2.19 893.1   2.15 2.22 1323.9 
 2.14 2.08 761.5   2.15 2.23 1660.1 
 2.13 2.19 840.3   2.15 2.24 1446.9 
 2.12 2.19 1120.3   2.15 2.25 1404.5 
Heart 2.14 2.06 246.2  Muscle 2.08 1.84 149.0 
 2.14 2.04 249.2   2.12 1.80 103.4 
 2.15 2.03 254.6   2.11 1.98 185.8 
 2.12 1.86 125.7   2.07 1.22 103.3 
 2.14 1.90 187.5   2.11 1.77 97.2 
 2.12 1.74 140.3   2.09 1.88 127.8 
Lung 2.10 1.46 220.0  Adipose 2.11 1.81 119.4 
 2.10 2.05 212.6   2.14 1.68 91.3 
 2.13 2.16 366.7   2.10 1.75 94.7 
 2.12 2.13 259.5   2.13 1.80 156.3 
 2.12 2.14 289.7   2.11 1.91 149.8 
 2.13 2.07 189.6   2.10 1.74 102.2 
Liver 2.13 2.04 723.1  Amnion 2.16 2.19 722.9 
 2.13 2.07 1805.6   2.16 2.13 498.2 
 2.13 2.12 1696.7   2.16 2.18 727.0 
 2.14 2.11 1160.6   2.12 1.86 471.7 
 2.13 2.07 1432.3   2.14 2.13 518.1 
 2.13 2.14 2075.4   2.08 1.10 192.2 
Spleen 2.16 2.19 971.4  Embryo 2.10 1.81 280.0 
 2.16 2.17 914.6   2.17 2.21 874.6 
 2.14 2.16 892.8   2.16 2.22 979.5 
 2.16 2.19 961.9   2.17 1.77 1004.2 
 2.15 2.16 304.0   2.16 2.24 1023.7 
 2.15 2.19 913.7   2.12 2.11 384.3 
Kidney 2.15 1.99 490.6  Placenta 2.16 2.14 1057.6 
 2.15 2.17 522.7   2.14 2.17 1276.5 
 2.12 2.13 499.8   2.14 2.16 1540.9 
 2.18 2.19 702.1   2.15 2.19 1702.2 
 2.17 2.19 649.4   2.13 2.11 927.9 
 2.17 2.23 833.8   2.16 2.12 1225.2 
Pancreas 2.14 2.10 1688.8  PF: pregnant female 
 2.13 2.20 1553.2      
  2.13 2.18 2224.2   
Values were obtained using a Nanodrop ND-1000 Spectrophotometer. 
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Appendix III.d: Summary of RNA purity assessments of rat tissues. 
Male 260/280 260/230 ng/µL  LF 260/280 260/230 ng/µL 
CB 1.97 2.22 2322.2  CB 2.05 2.08 1135.6 
 2.01 2.28 1340.9   2.04 2.13 1377.7 
 1.82 1.67 530.3   1.98 2.07 1361.8 
CTX 1.97 1.98 759.5  CTX 2.05 2.07 1117.0 
 2.00 2.21 1893.4   2.05 2.16 1218.9 
 1.84 1.71 529.0   2.03 1.92 1468.2 
HPC 1.87 2.00 234.2  HPC 2.04 2.11 1038.3 
 1.98 2.29 674.2   2.04 2.01 922.3 
 1.83 1.71 539.0   2.01 2.12 1051.0 
HYP 1.90 1.97 512.1  HYP 1.87 1.88 280.6 
 1.91 2.32 289.9   1.89 1.84 281.4 
 1.83 1.77 527.9   1.89 1.79 392.9 
TH 1.91 2.02 415.8  TH 1.89 1.58 195.4 
 1.91 2.07 190.4   1.93 1.77 421.3 
 1.84 1.79 537.2   1.90 1.81 408.6 
         
Female 260/280 260/230 ng/µL  PF 260/280 260/230 ng/µL 
CB 2.03 2.23 1304.1  Placenta 2.12 2.02 534.2 
 2.03 2.28 1312.3   2.14 2.17 1225.8 
 2.00 1.90 1958.9   2.13 2.16 1045.0 
CTX 2.02 2.24 1295.8      
 2.02 2.07 1123.3      
 2.04 2.03 1808.9      
HPC 2.00 2.22 879.5      
 2.02 1.78 825.7      
 2.03 1.75 1118.8      
HYP 1.99 2.23 695.1      
 1.92 2.18 306.5      
 1.97 1.72 626.0      
TH 2.03 2.23 1546.7      
 1.95 2.24 418.6      
 1.99 1.72 744.3      
Values were obtained using a Nanodrop ND-1000 Spectrophotometer. CB: cerebellum, CTX: cortex, HPC: 


















Appendix IV.a: Mouse RNA integrity analysed by formaldehyde gel electrophoresis. 
Total RNA (1 µg) was loaded onto each lane. The positions of 28S, 18S rRNA and small RNA species are 
indicated. The numbers above each lane indicate biological replicates 1–6. 
1 3 4 5 62 1 3 4 5 62 1 3 4 5 62
Male kidney Male testisMale brain
1 3 4 5 62 1 3 4 5 62 1 3 4 5 62
Male intestine Male LiverMale lung
1 3 4 5 62 1 3 4 5 62 1 3 4 5 62





















Appendix IV.b: Mouse RNA integrity analysed by formaldehyde gel electrophoresis. 
Total RNA (1 µg) was loaded onto each lane. The positions of 28S, 18S rRNA and small RNA species are 
indicated. The numbers above each lane indicate biological replicates 1–6. Asterisks (*) indicate prokaryotic 
rRNAs. 
1 3 4 5 62 1 3 4 5 62 1 3 4 5 62
Female Liver Female brainFemale intestine
1 3 4 5 62 1 3 4 5 62 1 3 4 5 62
Female lung Female kidneyFemale stomach
1 3 4 5 6 1 3 4 5 62 1 3 5 62
























Appendix IV.c: Mouse RNA integrity analysed by formaldehyde gel electrophoresis. 
Total RNA (1 µg) was loaded onto each lane. The positions of 28S, 18S rRNA and small RNA species are 
indicated. The numbers above each lane indicate biological replicates 1–6. Asterisks (*) indicate prokaryotic 
rRNAs. 
1 3 4 5 62 1 3 4 5 62 1 3 4 5 62
Pregnant female lung Pregnant female brainPregnant female spleen
1 3 4 5 62 1 3 4 5 62 1 3 4 5 62
Pregnant female intestine Pregnant female thyroidPregnant female liver
1
Pregnant female Embryo Pregnant female pancreasPregnant female amnion
3 4 5 62 1 3 4 5 62 1 4 6
1
Pregnant female placenta Pregnant female kidneyPregnant female stomach

















































Appendix IV.d: Rat RNA integrity analysed by formaldehyde gel electrophoresis. 
Total RNA (1 µg) was loaded onto each lane. The positions of 28S, 18S rRNA and small RNA species are 
indicated. The numbers (1–3) under placenta represents biological replicates 1–3. CB: cerebellum, CTX: cortex, 































CB CTX HPC HYP TH CB CTX HPC HYP TH CB CTX HPC HYP TH
Female #1 Female #3Female #2
CB CTX HPC HYP THCB CTX HPCHYPTH CB CTX HPC HYP TH
Lactating female #1 Lactating female #3Lactating female #2








Appendix V.a: RNA integrity assessed using a Bioanalyzer. 
Total RNAs (1 µL of 25–200 ng/µL RNA concentration) from tissues of male and female mice were used for 
analysis. The numbers above each lane indicate biological replicates 1–6. Positions of 28S, 18S rRNA and small 
RNA species are indicated. RIN: RNA integrity number, M: marker and N/A: not applicable. 
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Female adiposeM
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Male heartM
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Appendix V.b: RNA integrity assessed using a Bioanalyzer. 
Total RNAs (1 µL of 25–200 ng/µL RNA concentration) from female and pregnant female mice were used for 
analysis. The numbers above each lane indicate biological replicates 1–6. Positions of 28S, 18S rRNA and small 
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Appendix VI  Biological replicates used for qPCR 
 
 
Appendix VI: Number of biological samples used for qPCR and causes of their loss. 
 Tissue Biological sample number Causes of loss of biological samples 
Male Stomach 4 Unsuccessful qPCR reaction 
Female Thyroid 5 Insufficient RNA concentration 
 Adipose 4 Insufficient RNA concentration 
 Ovary 1 Pooled together due to very small sample size 
PF Spleen 5 Unsuccessful qPCR reaction 
 Stomach 5 Unsuccessful qPCR reaction 
 Intestine 5 Unsuccessful qPCR reaction 
 Pancreas 1 Only 3 biological samples collected and unsuccessful qPCR reaction 
Female Thyroid 5 Insufficient RNA concentration 
 Adipose 4 Insufficient RNA concentration 
 Ovary 1 Pooled together due to very small sample size 
PF Pancreas 3 Only 3 biological samples collected 
The upper table is for qPCR using Peg10CDS primers while the lower is for Peg103´UTR primers. The data 
were collected from six biological replicates for other tissue samples. PF, pregnant female. 
 
 




Appendix VII: Melting curve analysis of qPCR samples showing two peaks. 
After the completion of thermal cycles, samples were subjected to melting curve analysis. Samples in green 
show two distinct peaks, indicating amplification of two products. A red line represents a sample with a specific 




Appendix VIII  Quality controls of qPCR data 
 
 
Appendix VIII.a: Coefficient of variation for the mouse reference genes. 
Male Run 1 Run 2 Run 3 Run 4  
Hsp90ab1 23.20 14.77 14.51 48.77  
Bet1l 21.79 14.19 30.58 24.22  
Wdr33 14.89 18.07 23.16 50.79  
Run average 19.96 15.67 22.75 41.26  
Overall average 24.91  
Female Run 1 Run 2 Run 3 Run 4 Run 4 of PF 
Hsp90ab1 26.43 12.73 12.72 12.70 19.46 
Bet1l 26.31 13.54 13.31 9.81 26.22 
Wdr33 18.41 18.25 17.37 14.03 16.67 
Run average 23.72 14.84 14.47 12.18 20.78 
Overall average 17.20 
Pregnant female Run 1 Run 2 Run 3 Run 4 Run 5 
Hsp90ab1 23.45 20.46 14.84 19.46 27.97 
Bet1l 22.85 30.96 11.95 26.22 29.76 
Wdr33 16.48 33.42 16.17 16.67 19.85 
Run average 20.93 28.28 14.32 20.78 25.86 
Overall average 22.03 




Appendix VIII.b: Mouse reference gene stability parameter (Mgene). 
Male Run 1 Run 2 Run 3 Run 4  
Hsp90ab1 0.526 0.376 0.483 1.335  
Bet1l 0.486 0.367 0.636 0.872  
Wdr33 0.409 0.411 0.574 1.037  
Average Mgene 0.474 0.384 0.564 1.081  
Overall average 0.626  
Female Run 1 Run 2 Run 3 Run 4 Run 4 of PF 
Hsp90ab1 0.646 0.347 0.339 0.315 0.508 
Bet1l 0.564 0.351 0.346 0.274 0.574 
Wdr33 0.476 0.420 0.412 0.309 0.460 
Average Mgene 0.562 0.372 0.366 0.299 0.514 
Overall average 0.423 
Pregnant female Run 1 Run 2 Run 3 Run 4 Run 5 
Hsp90ab1 0.545 0.618 0.348 0.508 0.624 
Bet1l 0.506 0.766 0.327 0.574 0.814 
Wdr33 0.427 0.780 0.367 0.460 0.554 
Average Mgene 0.493 0.721 0.347 0.514 0.664 
Overall average 0.548 
Reference gene stability parameter was calculated using the formulae 21–25 shown in Appendix II. 
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Appendix VIII.c: Inter-run calibrator stability parameter (Mirc) for mouse samples. 
Male Hsp90ab1 Bet1l Wdr33 Peg10 CDS Peg10 3´UTR 
Calibrator 1 0.033 0.071 0.041 0.241 0.231 
Calibrator 2 0.034 0.059 0.027 0.243 0.390 
Calibrator 3 0.063 0.097 0.035 0.192 0.259 
Average Mirc 0.044 0.076 0.035 0.225 0.293 
Overall Mirc 0.134 
Female Hsp90ab1 Bet1l Wdr33 Peg10 CDS Peg10 3´UTR 
Calibrator 1 0.059 0.096 0.085 0.237 0.078 
Calibrator 2 0.059 0.080 0.065 0.233 0.093 
Calibrator 3 0.077 0.126 0.082 0.190 0.125 
Average Mirc 0.065 0.101 0.078 0.220 0.098 
Overall Mirc 0.112 
Pregnant female Hsp90ab1 Bet1l Wdr33 Peg10 CDS Peg10 3´UTR 
Calibrator 1 0.072 0.140 0.089 0.354 0.129 
Calibrator 2 0.095 0.159 0.081 0.321 0.152 
Calibrator 3 0.100 0.210 0.122 0.352 0.215 
Average Mirc 0.089 0.170 0.097 0.343 0.166 
Overall Mirc 0.173 
Inter-run calibrator stability parameter was calculated using the formulae 21´–25´ shown in Appendix II. 
 
 
Appendix VIII.d: Coefficient of variation (CV) and stability parameters (Mgene) for the 
rat reference genes. 
 
 Male  Female  Lactating female 
 CV (%) Mgene  CV (%) Mgene  CV (%) Mgene 
Hprt1 17.84 0.465  10.81 0.361  17.48 0.457 
Hsp90ab1 15.60 0.440  18.43 0.432  20.78 0.491 
Cyc-1 22.97 0.553  19.92 0.482  17.96 0.477 
Average 18.80 0.486  16.39 0.425  18.74 0.475 
Coefficient of variation and rat reference gene stability parameters were calculated using the formulae 17–20 and 









Appendix IX.a: Immunoblotting results of brain, thyroid and heart samples. 
Total protein extracts (200 µg) were acetone precipitated, fractionated on a polyacrylamide gel, and then 
transferred to a membrane. The membrane was probed with anti-mPeg10ORF1 and exposed for 5 min. M, 
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Appendix IX.b: Immunoblotting results of lung, liver and spleen. 
Total protein extracts (200 µg) were acetone precipitated, fractionated on a polyacrylamide gel, and then 
transferred to a membrane. The membrane was probed with anti-mPeg10ORF1 and exposed for 1, 2 and 5 min 













M M M1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6kDa + + +
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M M M1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6kDa + + +
Male lung Female lung Pregnant female lung
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Appendix IX.c: Immunoblotting results of kidney, stomach and intestine. 
Total protein extracts (200 µg) were acetone precipitated, fractionated on a polyacrylamide gel, and then 
transferred to a membrane. The membrane was probed with anti-mPeg10ORF1 and exposed for 1 min for kidney 
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Appendix IX.d: Immunoblotting results of muscle, adipose, testis, uterus and pancreas. 
Total protein extracts (200 µg) were acetone precipitated, fractionated on a polyacrylamide gel, and then 
transferred to a membrane. The membrane was probed with anti-mPeg10ORF1 and exposed for 3 min for 
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Male muscle Female muscle Pregnant female muscle
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Appendix IX.e: Immunoblotting results of amnion, embryo and placenta. 
Total protein extracts (200 µg) were acetone precipitated, fractionated on a polyacrylamide gel, and then 
transferred to a membrane. The membrane was probed with anti-mPeg10ORF1 and exposed for 1 min for 
amnion and placenta, and 3 min for embryo. M, marker; 1–6, biological replicates 1–6 and +, positive control 










M M M1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6kDa + + +
Pregnant female amnion Pregnant female embryo Pregnant female placenta
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Appendix X.a: Extracted ion chromatographs for placenta. 
Top row (black) represents the total mass spectra. Other rows represent peaks within a certain molecular weight 
range shown on the right. The peptides identified as mPeg10 are shown in the table, and these peptides were 
used as reference to search mPeg10 expression in other tissues. Amino acid position is based on the NCBI 
reference (NP_570947.2). 
RT: 13.00 - 48.64
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Base Peak  MS 
13128_P_1
NL: 2.09E6
Base Peak m/z= 
592.29500-
592.30500  MS 
13128_P_1
NL: 6.29E6
Base Peak m/z= 
1026.99900-
1027.01200  MS 
13128_P_1
NL: 5.83E6
Base Peak m/z= 
613.68900-
613.69600  MS 
13128_P_1
NL: 1.04E6
Base Peak m/z= 
1139.62800-
1139.63600  MS 
13128_P_1
NL: 1.20E5
Base Peak m/z= 
1513.36500-
1513.37500  MS 
13128_P_1




















Appendix X.b: Extracted ion chromatograph for adipose tissue. 
Top row (black) represents the total mass spectra. Other rows represent peaks within a certain molecular weight 
range shown on the right. None of the mPeg10 peptides were identified from adipose tissue. 
 
RT: 11.50 - 51.16
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Base Peak  MS 
13128_A_1
NL: 2.67E5
Base Peak m/z= 
592.29500-
592.30500  MS 
13128_A_1
NL: 7.72E4
Base Peak m/z= 
1026.99900-
1027.01200  MS 
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NL: 8.77E4
Base Peak m/z= 
613.68900-
613.69600  MS 
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NL: 2.70E4
Base Peak m/z= 
1139.62800-
1139.63600  MS 
13128_A_1
NL: 1.82E4
Base Peak m/z= 
1513.36500-





Appendix X.c: Extracted ion chromatograph for muscle. 
Top row (black) represents the total mass spectra. Other rows represent peaks within a certain molecular weight 









RT: 11.76 - 47.56




























































Base Peak  MS 
13128_M_1
NL: 4.93E6
Base Peak m/z= 
592.29500-
592.30500  MS 
13128_M_1
NL: 1.21E5
Base Peak m/z= 
1026.99900-
1027.01200  MS 
13128_M_1
NL: 2.92E6
Base Peak m/z= 
613.68900-
613.69600  MS 
13128_M_1
NL: 2.37E4
Base Peak m/z= 
1139.62800-
1139.63600  MS 
13128_M_1
NL: 1.85E4
Base Peak m/z= 
1513.36500-
1513.37500  MS 
13128_M_1
